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Introduction and aims: The strong association between obesity and cardiovascular 
diseases (CVD) stresses the necessity of elucidating the underlying molecular 
mechanisms linking these pathologies. Evidence suggests that Epac (exchange 
protein directly activated by cAMP) could be a new therapeutic target for obesity and 
CVD. This study aimed to elucidate the role of Epac in (i) myocardial I/R injury of ex 
vivo hearts from normal weight; and diet-induced obese rats; (ii) vascular reactivity of 
ex vivo aortas from diet-induced obese rats and (iii) free fatty acid (FFA)-induced 
endothelial dysfunction in rat aortic endothelial cells (RAECs).  
Methods: Male Wistar rats of normal weight (250 to 350 g) or receiving a high-calorie 
diet (HC) for 16 weeks or age-matched controls (CD), were used. Mechanical function 
of isolated perfused working rat hearts were evaluated. Regional ischaemia (35 
minutes) was followed by 60 minutes reperfusion and infarct size determination. 
Hearts were perfused with a selective Epac1 agonist (8-CPT-2’-O-Me-cAMP, CPT, 2 
µM) or antagonist (ESI-09, 5 µM) for 10 minutes before (pre-treatment) or after (post-
treatment) regional ischaemia and also post-treated with MEK-ERK inhibitor 
(PD98059, 10 µM) or PKB inhibitor (A6730, 2.5 µM). Thoracic aortas were isolated 
from rats fed either the HC or CD diet. Aortas were pre-incubated for 15 min with CPT, 
ESI-09 or nitric oxide synthase (NOS) inhibitor (L-NAME, 100 µM). Vascular reactivity 
was evaluated by phenylephrine-precontraction followed by acetylcholine-induced 
relaxation.  Cardiac and aortic signalling proteins were detected with Western blotting. 
Cultured RAECs were supplemented with FFAs (Palmitic acid and Oleic acid) to 
induce endothelial injury. The effects of FFAs, CPT and ESI-09 on intracellular levels 
of NO, superoxide (ROS) and cell viability were determined with fluorescence-based 
assays.  
Results: After 16 weeks the HC animals presented with significantly increased body 
weight and visceral fat. In hearts, HC diet had no deleterious effects on post-ischaemic 
cardiac function and infarct size. Post-treatment with CPT (2 µM) reduced infarct size 
and improved cardiac recovery. This protection was abolished by post-treatment with 
A6730 in HC hearts, but not with PD98059. Furthermore, CPT increased CaMKII 
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activation but reduced eNOS phosphorylation. Epac inhibitor (ESI-09, 5 µM) was 
detrimental to cardiac function.  This was associated with: decreased phosphorylated 
ERK1/2 and GSK-3b; increased phosphorylated AMPK, ULK-1 and PARP cleavage. 
HC diet did not adversely affect vascular reactivity. CPT significantly improved 
vasorelaxation in both diets which were abolished by ESI-09. CPT induced 
vasorelaxation in a dose-dependent manner in both diets via NOS. ESI-09 reduced 
PKB phosphorylation in CD aortas and increased AMPK phosphorylation in both diets. 
In normal RAECs CPT improved NO production and reduced intracellular ROS. CPT 
could not reverse the detrimental effect of FFAs on RAECs. 
Conclusion: Post-ischaemic Epac activation is cardioprotective against I/R injury in 
ex vivo isolated rat hearts from HC, partially via the PKB pathway. Epac activation 
improved vasorelaxation via NOS in ex vivo aortas from both diets.  In addition, Epac 
activation increased NO production and reduced ROS generation in normal RAECs. 





Inleiding en doelstellings:  Die sterk verband tussen vetsug en kardiovaskulêre 
siektes (KVS) beklemtoon die noodsaaklikheid om die onderliggende molekulêre 
meganismes wat hierdie patologieë verbind, te verklaar. Bewyse dui daarop dat Epac 
(‘n uitruil-proteïen wat direk deur cAMP geaktiveer word) 'n nuwe terapeutiese teiken 
vir vetsug en KVS kan wees. Hierdie studie het ten doel gehad om die rol van Epac in 
(i) miokardiale isgemie-herperfusie (I/R)-besering van ex vivo-harte van óf normale 
gewig óf dieet-geïnduseerde vetsugtige rotte; (ii) vaskulêre reaktiwiteit van ex vivo 
aortas van dieet-geïnduseerde vetsugtige rotte en (iii) vrye vetsuur (VVS) 
geïnduseerde endoteel disfunksie in rot aorta endoteelselle (RAEC), te ondersoek. 
 
Metodes: Manlike Wistar-rotte van 'n normale gewig (250 tot 350 g) of 'n hoë-kalorie-
dieet (HC) vir 16 weke of 'n ouderdomskontrole (CD), is gebruik. Meganiese funksie 
van geïsoleerde geperfuseerde werkende rot harte is geëvalueer. Streeks-isgemie (35 
minute) is gevolg deur herperfusie (60 minute) en infarkt-grootte bepaling. Harte is 
behandel met 'n selektiewe Epac1-agonis (8-CPT-2'-O-Me-cAMP, CPT, 2 µM) of 'n 
antagonis (ESI-09, 5 µM) vir 10 minute voor (pre-behandeling) of na (post-
behandeling) streeks-isgemie en ook post-behandeling met MEK-ERK-inhibitor 
(PD98059, 10 µM) of PKB-inhibitor (A6730, 2.5 µM). Torakale aortas is geïsoleer van 
rotte wat óf die HC- óf CD-dieet gevoer is. Aortas is 15 minute vooraf geïnkubeer met 
CPT, ESI-09 of stikstofoksied sintase (NOS) inhibitor (L-NAME, 100 µM). Vaskulêre 
reaktiwiteit is geëvalueer deur fenielefrien-prekontraksie gevolg deur asetielkolien-
geïnduseerde ontspanning. Met Western blot analise is hart- en aorta-seineproteïene 
bepaal. Gekultuurde RAEC is gesupplementeer met VVSe (Palmitaat en Oleaat) om 
endoteelbesering te veroorsaak. Die effekte van VVSe, CPT en ESI-09 op 
intrasellulêre vlakke van NO, superoksied (ROS) en sel-oorlewing is bepaal met 
behulp van fluoressensie-gebaseerde toetse. 
 
Resultate: Na 16 weke het die HC-diere se liggaamsgewig en viserale vet aansienlik 
vermeerder. In die harte het HC-dieet geen nadelige gevolge gehad op post-
isgemiese hartfunksie en infarkt-grootte nie. Post-behandeling met CPT (2 µM) het 
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infarkt-grootte verminder en die funksionele herstel verbeter. Hierdie beskerming is 
opgehef deur post-behandeling met A6730 in HC-harte, maar nie met PD98059 nie. 
Verder het CPT die aktivering van CaMKII verhoog, maar eNOS-fosforilering 
verminder. Epac-antagonis (ESI-09, 5 µM) was nadelig vir die hartfunksie. Dit was 
geassosieer met: verminderde gefosforileerde ERK1/2 en GSK-3b; verhoogde 
gefosforileerde AMPK, ULK-1 en PARP splitsing. HC-dieet het nie die vaskulêre 
reaktiwiteit benadeel nie. CPT het in beide diëte vaso-verslapping aansienlik verbeter, 
wat deur ESI-09 opgehef is. CPT het vaso-verslapping op 'n dosis-afhanklike manier 
in beide diëte via NOS, veroorsaak. ESI-09 verminder PKB-fosforilering in CD-aortas 
en verhoog AMPK-fosforilering in beide diëte. In normale RAEC's het CPT die NO 
produksie verbeter en die intrasellulêre ROS verminder. CPT kon nie die nadelige 
uitwerking van VVSe op RAEC's omkeer nie. 
Gevolgtrekking: Post-iskemiese Epac-aktivering is kardiobeskermend teen I/R-
beserings in ex vivo geïsoleerde rotteharte van HC, gedeeltelik via die PKB-pad. Epac-
aktivering het vaso-verslapping, via NOS in ex vivo aortas van beide diëte, verbeter. 
Boonop het Epac-aktivering NO produksie verhoog en ROS-ontwikkeling in RAEC's 
verminder. Daarom kan Epac 'n potensiële terapeutiese teiken in die beskerming teen 
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 Literature Review  
 
1. Cardiovascular disease (CVD) 
1.1 General introduction and epidemiology  
 
Cardiovascular disease (CVD) is a broad term used to describe  a range of disorders 
that affect the heart and the circulatory system; such disorders include coronary artery 
disease (CAD), cardiac dysrhythmias, hypertension, congenital heart defects and 
cerebrovascular disease (British Heart Foundation, 2019; Sanchis-Gomar et al., 
2016). 
 
CVD is the most common causes of death worldwide. In the year 2016, the World 
Health Organisation (WHO) estimated about 17.9 million people died from CVDs each 
year, which contributed to 31% of all deaths globally (WHO, 2018a). Of these deaths, 
CAD and stroke were the major contributors with an estimated 7.4 million deaths due 
to CAD and 6.7 million deaths due to stroke respectively (WHO, 2018a). In 2015, an 
estimated 82% of premature deaths in underdeveloped (low income) and developing 
(middle income) countries were due to non-communicable diseases (NCDs), and 37% 
were caused by CVDs (WHO, 2018a).  
 
In Africa, the challenges of communicable diseases such as malaria, HIV/AIDS, and 
tuberculosis are well known (Kandala et al., 2014). However, the rapid increase in 
chronic NCDs such as CAD and stroke, due to risk factors like obesity, hypertension, 
and type 2 diabetes mellitus (T2D) are becoming a major public health problem, 
especially in Sub-Saharan Africa (Kandala et al., 2014). Epidemiological transition 
driven by urbanisation, globalization and social changes is the major contributor to the 





South Africa is the most urbanised developing country with an estimated 62% of the 
country’s population living in the cities (Oni et al., 2015; Prados-Torres et al., 2014) 
and that number has increased to 65.78% in 2017 (Statista, 2017). This rapid and 
unplanned demographic shift can affect lifestyle choices such as unhealthy dietary 
patterns due to the high cost of living in the cities (Kandala et al., 2014; Mathers and 
Loncar, 2006).  
 
Therefore in South Africa, NCDs particular CVD are already among the top causes of 
death (Nojilana et al., 2016). In 2010, NCDs accounted for 39% of total deaths in the 
country and more than a third (36%) of these deaths occurred before the age of 60 
years (Nojilana et al., 2016). In addition, the number of deaths due to NCDs was 
similar to the number from HIV/AIDS and tuberculosis combined (Nojilana et al., 2016).  
 
Recently, NCDs were estimated to account for more than 50% of all deaths in South 
Africa and CVD (19%) as the major contributor (WHO, 2018b). Furthermore, the major 
risk factors for NCDs in South Africa include excessive use of alcohol, physical 
inactivity, increased salt/sodium intake, tobacco use, high blood pressure and obesity 
(WHO, 2018b).  
 
 
1.2 Risk factors of CVD  
 
There are two types of CVD risk factors: non-modifiable and modifiable. The “non-
modifiable” risk factors cannot be changed and they include age, gender and family 
history. Other risk factors can be changed (“modifiable’’), which include dyslipidaemia 
(altered levels of blood cholesterol and raised triglycerides with low HDL-cholesterol), 
hypertension/high blood pressure, diabetes, excessive stress, sedentary lifestyle, 
smoking, excessive alcohol consumption and being overweight/ obesity (Díaz-Vegas 
et al., 2018; Grundy, 2012; Mandini et al., 2018; Puddey et al., 1999). For the purpose 





1.3 Obesity as a CVD risk factor  
 
Obesity is persistently increasing worldwide, and it affects all age groups. Obesity is 
defined by or classified using an anthropometric measurement, the body mass index 
(BMI). An individual is classified overweight with a BMI of 25–29.9 kg/m2 and obese 
with a BMI of ≥ 30 kg/m2 or waist to hip ratio of >0.9 (male) or >0.85 (females) (Lanktree 
and Hegele, 2017; Poirier et al., 2009). However, it has been reported that BMI is not 
the gold standard measure of body fat and there is no clear association between body 
weight, mortality and cardiovascular events (Romero-Corral et al., 2006). Generally, 
excess body fat is closely associated with cardiovascular abnormalities (Wormser et 
al., 2011). Therefore, although BMI influences cardiovascular risk, one should argue 
that other adiposity indices should be taken into consideration such as the waist 
circumference and waist-to-hip ratio (Bastien et al., 2014). These adiposity indices 
may further influence the intermediate risk factors (high blood pressure, diabetes, 
dyslipidaemia, insulin resistance and inflammation) which may lead to increased 
cardiovascular events (Bastien et al., 2014; Poirier, 2007; Romero-Corral et al., 2007, 
2006). It has been reported that among patients with CVDs, the overweight and obese 
patients often counterintuitively show an improvement in cardiovascular events and 
mortality, and this controversy is called the “obesity paradox” (Bastien et al., 2014; 
Carbone et al., 2019). Therefore, despite the influence of obesity on cardiovascular 
health, normal-weight patients can also develop metabolic abnormalities that may 
increase cardiovascular events and mortality.  
 
1.3.1 Excessive visceral adiposity and CVD 
 
Visceral fat or abdominal fat is located within the abdominal cavity and it surrounds 
the major organs e.g. stomach, liver, kidneys and intestines. Regardless of BMI, 
excess abdominal fat is strongly associated with a number of diabetogenic and 
atherogenic abnormalities such as an increase in peripheral tissue insulin resistance, 
plasma free fatty acid (FFA) release, inflammatory cytokines, decrease in adiponectin, 
a decrease in cardiac output and a decrease in endothelium-dependent 
vasorelaxation (Bastien et al., 2014). In the vasculature, an excess in perivascular 
adipose tissue (PVAT) can cause local inflammation, impaired vascular function, 
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vascular remodelling and an increase in macrophage infiltration into atherosclerotic 
lesions (Horimatsu et al., 2017; Lastra and Manrique, 2015; Ozen. et al., 2015) 
 
 
1.3.2 Cardiac remodelling and obesity 
 
Cardiac remodelling also known as the ventricular remodelling is defined as a change 
in size, shape and function of the heart. This can occur due to exercise or after an 
injury to the heart muscle (pathological remodelling). Obesity is associated with 
increased myocardial fat and impair myocardial metabolism which can induce cardiac 
remodelling whereby the heart is trying to adapt to the new environment as well as to 
maintain the whole body’s blood supply (Bastien et al., 2014). Therefore, the heart 
maintains this adaptive state by increasing the cardiac output and decreasing 
peripheral resistance (Bastien et al., 2014; Kaltman and Goldring, 1976; Messerli et 
al., 1987). Furthermore, excess myocardial fat can lead to impaired myocardial 
metabolism and reduced metabolic activity. This could lead to heart failure (with a 
decreased diastolic chamber compliance, an increase in the left ventricular (LV) mass, 
a concentric LV remodelling and fatty infiltration of the right ventricle (Iacobellis et al., 
2014; Iacobellis and Sharma, 2007).  
  
In obese patients, an increased cardiac output can be a determinant of the amount of 
blood pumped out in each ventricle due to contraction (Bastien et al., 2014). Excessive 
blood volume contributes to an increase in heart preload and if this happens for a 
longer duration it can cause left ventricular wall thickening (ventricular remodelling) 
and subsequently left ventricular hypertrophy (LVH) (Ku et al., 1994). LVH, muscle 
degeneration, systolic and diastolic dysfunction are major factors that contribute to 
heart failure in obese patients (Alpert et al., 1995; Lauer et al., 2010). Furthermore, 
increased epicardial fat is associated with obesity and atherosclerosis (Shimabukuro 
et al., 2013; Vela et al., 2007). Epicardial fat is closely associated with the amount of 
visceral fat deposits which may produce proinflammatory cytokines and macrophages 




1.4 Ischaemic heart disease (IHD) 
 
The term ischaemia refers to an inadequate blood supply to organs (such as the heart, 
brain, liver, kidney and intestine) due to narrowing or obstruction of the arterial flow as 
a result of atherosclerotic plaque development (NIH, 2019). Myocardial ischaemia is 
defined as a narrowing of the coronary arteries, which is also known as coronary artery 
disease (CAD) (NIH, 2019). Therefore, a reduction in blood supply causes an 
insufficient supply of oxygen and reduces the availability of nutrients to the 
myocardium (see “Ischaemic phase” in section 1.4.3.1).  
 
1.4.1 Process of atherosclerosis  
 
1.4.1.1 Endothelial cells in the heart  
 
The heart is a complex organ and is made up of different cell types, including 
cardiomyocytes, endothelial cells, inflammatory cells, stem cells, and fibroblasts 
(Kamo et al., 2015; Perin and Silva, 2004). These cells are highly organised in the 
myocardium and secrete autocrine, juxtacrine, and paracrine factors that modulate the 
function of neighbouring cells (Segers et al., 2018). Intercellular communication is 
pivotal in cardiac development, normal cardiac function and in pathophysiology of 
cardiac remodelling and heart failure development (Segers et al., 2018). In particular, 
cardiac microvascular endothelial cells (CMEC), which are part of cardiac 
endothelium, secrete factors that play a vital role in normal cardiac function and during 
cardiac remodelling (Segers, Brutsaert and De Keulenaer, 2018). 
 
The myocardium is a highly metabolic tissue and it receives blood supply from a dense 
vascular and capillary network (Duncker and Bache, 2008). The CMECs line these 
capillaries and serve as a barrier between blood and the myocardial tissue. But they 
also communicate with adjacent cardiomyocytes by exchanging small molecules, 
peptides, proteins, microvesicles, and microRNAs (Brutsaert, 2015). Similar to cardiac 
endothelium, the endothelial cells are located in the pericardial coronary arteries, 
which are part of coronary vascular endothelium, that plays a crucial role in modulating 
vascular smooth muscle function (Brutsaert, 2015). Endothelial cells in the 
microcirculation of the heart produce paracrine factors which can regulate 
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cardiomyocyte contractility, growth and survival (Segers et al., 2018). These paracrine 
factors include prostacyclin, angiotensin II, endothelin 1 and nitric oxide (NO) 
(Brutsaert, 2015).  
 




NO and endothelium function 
NO is a soluble gas synthesised from the amino acid L-arginine in endothelial cells by 
the constitutive Ca2+-calmodulin-dependent enzyme and endothelial nitric oxide 
synthase (eNOS) (Behrendt and Ganz, 2002; Palmer et al., 1988). Endothelial nitric 
oxide is one of the three distinct isoforms of NOS, including neuronal NOS (nNOS) 
and inducible NOS (iNOS). Endothelial NOS is constitutively expressed and it is 
referred to as Ca2+-dependent enzyme even though eNOS can be activated in a Ca2+-
independent manner (Behrendt and Ganz, 2002; Förstermann and Kleinert, 1995). 
Endothelium shear stress (blood flow) is the main trigger of NO production under 
physiological conditions in a Ca2+-independent manner (Figure 1.1) (Behrendt and 
Ganz, 2002; Zhao et al., 2015). On the other hand, agonists including acetylcholine 
(ACh), serotonin, thrombin and bradykinin act on specific receptors on the endothelial 
cell membrane to increase the intracellular concentration of Ca2+, which binds to 
calmodulin (CaM) and leads to the activation of calmodulin-binding domain of eNOS 
to produce NO (Figure1.1 Behrendt and Ganz, 2002; Zhao et al., 2015). The 
vasodilatory effect of NO on vascular smooth muscle is through activation of guanylate 
cyclase, an enzyme that catalyses the synthesis of cyclic guanosine monophosphate 
(cGMP) from guanosine-5'-triphosphate (GTP) in response to low intracellular Ca2+ 
levels (Behrendt and Ganz, 2002; Förstermann and Kleinert, 1995). 
 
Subsequently, it was discovered that endocardial endothelial cells produce NO which 
modulates growth, contractility and rhythmicity of cardiomyocytes (Brutsaert, 2015). 
NO has a positive inotropic effect in smaller concentration, however, in higher 
concentrations, it has negative inotropic effects (Balligand et al., 2009; Brutsaert, 





Figure 1. 1 Endothelial nitric oxide synthase (eNOS). 
Endothelial NOS can be activated in Ca2+-dependent or- independent ways. The Ca2+-dependent 
pathway involves agonist such Ach, bradykinin and histamine which act on receptors (R) to increase 
intracellular Ca2+, which binds to CaM and leads to activation of calmodulin-binding domain of eNOS to 
produce NO. On the other hand, phosphorylation of eNOS independently of the calcium concentration 
is also important for the activation of the enzyme. Thr495 is an inhibitory site but Ser635 and Ser1179 
are activation sites. The responses to hemodynamic shear stress and hormones are mediated mainly 
through this calcium-independent pathway. Taken from (Zhao et al., 2015). 
 
 
1.4.1.3 Endothelial dysfunction  
 
Endothelial dysfunction (ED) is a major pathophysiological phenomenon that leads to 
coronary artery disease, and other atherosclerotic diseases (Higashi, 2015). A 
reduction in the bioavailability of pro-vasodilatory factors, predominantly NO, is a key 
indicator of endothelial dysfunction. (Grover-Páez and Zavalza-Gómez, 2009; Lerman 
and Zeiher, 2005). Thus, ED is mainly an imbalance in between factors with pro-
vasodilatory, anti-mitogenic and anti-thrombogenic properties (endothelium-derived 
relaxing factors such as NO) and factors with pro-vasoconstrictory, pro-thrombotic and 
proliferative characteristics (endothelium-derived contracting factors such as 





1.4.1.4 The role of endothelial cells in the process of atherosclerosis  
 
Atherosclerosis is a disease characterised by thickening of the intimal layer of arteries, 
accumulation of fat (due to hyperlipidaemia), lipid oxidation, inflammation and other 
factors (Rafieian-Kopaei et al., 2014). It is a vascular disease that can affect the aorta 
and coronary arteries (Baradaran, 2012). Several studies have demonstrated that fatty 
streaks are the first indicators of atherosclerosis (Skålén et al., 2002; Tavafi, 2013).  
Increased accumulation of lipoprotein particles (proteins, phospholipids, cholesterol 
and triglycerides) in the vascular intimal layer of arteries initiates an atherosclerotic 
lesion (Rafieian-Kopaei et al., 2014). Low-density lipoprotein (LDL) is also known for 
its major role in the development of atherosclerotic lesions (Figure 1.2) (Diaz et al., 
2002). LDL can easily infiltrate the endothelium or adhere to extracellular matrix 
components such as proteoglycans and be trapped in the vascular intima (Hajjar and 
Gotto, 2013; Leitinger, 2003). This leads to the activation of endothelial cells, which 
causes an increase in the expression of leukocyte adhesion molecules and 
inflammatory genes (Leitinger, 2003). This causes the blood cells to migrate to the 
area of activation. Monocytes infiltrate the area of activation and differentiate 
macrophages leading to plaque development. This activates the immune system, 
followed by T-cell, antigen-presenting dendritic cell, monocyte, macrophage, and mast 
cell infiltration (Hansson, 2001). Macrophages secrete meta proteases that contribute 
to lysis of the extracellular matrix. T-cells (T-lymphocytes) produce a pro-inflammatory 
cytokine, tumour necrosis factor-alpha (TNF-α), which prevents collagen synthesis in 
the smooth muscle cells (Rafieian-Kopaei et al., 2014). This process weakens the 
fibrous cap of the plaque resulting in plaque rupture, which leads to blood clot 
formation in the arteries and blockage of blood flow (Rafieian-Kopaei et al., 2014). 
This results in an inadequate blood supply (ischaemia) to the vital organs such as 
heart, brain and kidneys. Furthermore, lipolysis in visceral adipose tissues increases 
nonesterified fatty acids (NEFA), which in turn increase insulin resistance and 
eventually an increase in oxidative stress (Hajjar and Gotto, 2013). Oxidative stress 
and adipokines further exacerbate the vascular pro-oxidant and pro-inflammatory 





Figure 1. 2 Mechanisms of disease in atherosclerosis and obesity. 
Taken from (Hajjar and Gotto, 2013).  
 
1.4.2 Pathophysiology of myocardial infarction  
 
The acute occlusion of coronary arteries through a build-up of atherosclerotic plaque 
causes a reduction in oxygen and nutrient supply to the myocardium (Ambrose and 
Singh, 2015). Cardiomyocytes are very sensitive to changes in intracellular oxygen as 
they rely on oxidative metabolism and therefore a slight reduction in oxygen can result 
in ischaemic injury to cardiomyocytes (Ardehali et al., 2012). Therefore, myocardial 
infarction can be defined be as myocardial cell death due to prolonged ischaemia 






1.4.3 Ischaemia-reperfusion (I/R) injury  
 
1.4.3.1 Ischaemic phase  
 
The oxygen tension in cells decreases during ischaemia. There is a decrease in 
mitochondrial energy production (adenosine triphosphate, ATP, synthesis) due to a 
loss of oxidative phosphorylation (de Groot and Rauen, 2007). ATP depletion impairs 
cellular ion homeostasis, resulting in the activation of hydrolases, and increasing the 
permeability of cellular membranes (de Groot and Rauen, 2007). In addition, ATP 
depletion induces cellular acidosis which alters the activity of the sodium 
(Na+)/potassium (K+) adenosine triphosphatase (ATPase) pump, which favours an 
increase in exchange of Ca2+ for Na+ by the antiporter (Buja, 2005; de Groot and 
Rauen, 2007; Turer and Hill, 2010). An increase in intracellular Ca2+ activates 
phospholipases and hydrolases which disrupt the cellular structure by degrading their 
substrates and eventually leading to cell death (Turer and Hill, 2010). Furthermore, an 
increase in intercellular Ca2+ causes osmotic swelling and further disruption of the 
cellular structures. This type of injury would result in necrotic cell death (Buja, 2005).  
 
1.4.3.2 Reperfusion phase: 
 
This may start from macrophages, neutrophils and endothelial cells which are 
activated by cell debris (constituents of damaged cells) and reoxygenation. The 
restoration of oxygen supply to the ischaemic area generates the release of several 
factors including reactive oxygen species (ROS), TNF-α, Ca2+ overload and high 
concentrations of nitric oxide (Lejay et al., 2016; Li and Jackson, 2013; Turer and Hill, 
2010; Zweier and Talukder, 2006). These factors contribute to cytotoxicity, the 
opening of the mitochondrial permeability transition pore (mPTP), disruption of cellular 
structure and eventually cell death (Buja, 2005; Turer and Hill, 2010).  
 
 
1.4.3.3 Mechanisms of myocardial cell death  
 
Apoptosis 
Apoptosis or programmed cell death is characterized by cell shrinking, chromatin 
condensation and nuclear fragmentation, and eventual phagocytosis of the cells by 
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macrophages (Zitvogel et al., 2010). Apoptosis is induced by a death ligand tumour 
TNF-α, the same TNF-α may induce both apoptosis and necrosis (Galluzzi et al., 
2012). The binding of the ligand to a death receptor is called an extrinsic apoptotic 
pathway (Galluzzi et al., 2012). The intrinsic or mitochondrial apoptotic pathway is 
induced by various stimuli including oxidative stress, growth factor deprivation and 
hypoxia. In response to the stimuli, the members of the Bcl-2 family proteins 
(antiapoptotic: Bcl-2, Bcl-xl and proapoptotic: Bax, Bak and Bad) are recruited to the 
mitochondria and sarcoplasmic reticulum to trigger apoptotic proteins (Chipuk et al., 
2010). Furthermore, Cytochrome C initiates the assembly of the so-called apoptosome 
in which procaspase-9 is cleaved and caspase-9 activates the downstream caspase-
3 which leads to apoptosis (Acehan et al., 2004).  
 
In vivo studies have demonstrated that cardiac overexpression of Bcl-2 reduces both 
infarct size (a small localized area of dead tissue resulting from the failure of blood 
supply) and cardiac dysfunction following I/R injury (Brocheriou et al., 2000; Chen et 
al., 2001). On the other hand, deletion of Bax reduced infarct size in isolated hearts 
subjected to an I/R injury (Hochhauser et al., 2015) and reported to induce a moderate 
reduction in the infarct size after a permanent coronary artery occlusion (Hochhauser 
et al., 2007). Therefore, the members of the Bcl-2 family modulate infarct size.  
 
Necrosis  
Necrosis is a form of premature cell death due to injury and is characterized 
morphologically by cell and organelle swelling, and eventually, plasma membrane 
rupture resulting in a loss of intracellular contents. Unlike apoptosis, this process of 
cell death is considered merely accidental, however, evidence suggests that necrosis 
may also be programmed or tightly regulated (Degterev et al., 2005; Marín-García, 
2016; Vandenabeele et al., 2010).  
 
Several studies have demonstrated that regulated or programmed necrosis plays a 
role in myocardial necrosis. For example, in vivo, the inhibition of  Receptor-interacting 
protein 1 (RIP1), a kinase that regulates inflammation and cell death, showed a 
reduction in infarct size in hearts subjected to I/R (Lim et al., 2007; Ofengeim and 
Yuan, 2013). It has been suggested that the RIP1 cardioprotective role is depended 
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on the presence of cyclophilin D, a positive regulator of mPTP (Lim et al., 2007). In 
addition, cyclophilin D knock out mice, as well pharmacological inhibition of cyclophilin 
D, showed a significant reduction in infarct size in hearts subjected to I/R injury 
(Argaud et al., 2005; Baines et al., 2005; Clarke et al., 2002; Nakagawa et al., 2005). 
Furthermore, Bax and Bak have been demonstrated to play a role in necrosis, and the 
silencing of Bax and Bak showed a reduction in the degree of necrosis in mice 
subjected to I/R (Whelan et al., 2012). Therefore, RIP1, Bax and Bak play a major role 
in regulated myocardial necrosis. Altogether, both apoptosis and necrosis contribute 
to the pathogenesis of myocardial infarction.  
 
Autophagy 
Autophagy or “self-eating” is a physiological process in which the cell destroys its own 
damaged organelles to generate new ones. Under stressful conditions such as 
starvation or mild ischaemia, the cell digests its own proteins and lipids to provide 
energy for cell survival (Mizushima et al., 2008). Cardiomyocyte autophagy is induced 
in both I/R as well as in permanent occlusion of the coronary artery.  
Adenosine monophosphate-activated protein kinase (AMPK) is a kinase that plays a 
role in energy homeostasis. During ischaemia, AMPK is activated and inhibits 
mammalian target of rapamycin (mTOR), a potent inhibitor of autophagy (Matsui et 
al., 2007). However, inhibition of AMPK suppresses autophagy and increases infarct 
size (Matsui et al., 2007). Similar results were found when autophagy was decreased 
through overexpression of Ras homolog enriched in brain (Rheb) (Sciarretta et al., 
2012) and deletion of one allele of glycogen synthase kinase 3 beta (GSK3β) (Zhai et 
al., 2011). However, other studies suggest that autophagy protects the myocardium 
against I/R (Hamacher-Brady et al., 2007, 2006). On the other hand, prolonged 
ischaemia may induce too much autophagy that may be detrimental to the 
myocardium (Gustafsson and Gottlieb, 2009; Zhu et al., 2007).  
 
1.4.4 I/R and cardioprotective mechanisms 
 
Time is a very important factor in cardioprotection. The shorter the time of thrombotic 
coronary artery occlusion, the less severe the myocardial infarction and the better the 
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outcome for the patient (Gersh et al., 2005; Heusch and Gersh, 2017). Although 
restoration of oxygen to the myocardium (myocardial reperfusion) is essential to 
protect and rescue the viable myocardium, it comes at a high price that causes more 
damage to the myocardium and it is called I/R injury (Vinten-Johansen et al., 2013). 
Several animal and human studies have demonstrated the significant contribution of 
I/R injury on myocardial infarct size. Therefore, current cardioprotective studies are 
looking at the mechanisms of I/R injury to develop new therapies (Rossello and Yellon, 
2016). 
 
1.4.4.1 Ischaemic conditioning (IC) 
 
It has been over 20 years since Murry and colleagues demonstrated that repeated 
short cycles of non-injurious I/R significantly protects the myocardium from 
subsequent prolonged ischaemia (Murry et al., 1986). Therefore, myocardial IC is the 
is a powerful form of endogenous protection against myocardial infarction. This 
phenomenon has been widely studied in organs, different animal species as well as 
in humans (Wever et al., 2015, 2012; Yellon et al., 1993). The IC cardioprotective 
strategies are further divided into ischaemic preconditioning (IPreC) and 
ischaemic postconditioning (IPosC). IPreC is a cardioprotective strategy that 
includes repeated short episodes of I/R just before a sustained period of I/R 
(Ferdinandy et al., 2014).  
 
There are two forms of postconditioning: IPosC and remote ischaemic 
postconditioning (RPosC) (Ferdinandy et al., 2014). IPosC is defined as brief 
episodes of ischaemia after a sustained ischaemia insult. RPosC is also subdivided 
in the forms of pre (before), per (during evolving infarction), and post (after) 
conditioning (Heusch, 2015).  
 
Cardioprotection by IPosC is mediated through a delayed reversed acidosis and it 
involves activation of signalling transduction cascades such as adenosine and 
mediation of protein kinases. This intervention has been shown to reduce infarct size 
significantly, most likely through the activation of pro-survival kinases and the final 
step of ischaemic postconditioning is the inhibition of the mPTP. The applicability of 
IPosC is limited clinically, therefore, activation of pro-survival kinases with 
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pharmacologic agents/drugs at reperfusion to mimic IPosC could be beneficial. Figure 
1.3 illustrates the potential targets for pharmacological interventions during early 
reperfusion (Hausenloy and Yellon, 2007).  
 
 
Figure 1. 3 The common signalling mechanisms and signalling cascades though to be 
involved in cardioprotection at the time of reperfusion 
Adapted from (Hausenloy and Yellon, 2007).  
 
 
1.4.4.2 Reperfusion Injury Salvage Kinase (RISK) pathway 
 
Earlier studies on cardioprotection against I/R injury were targeting pro-apoptotic 
signalling cascades. This was based on the hypothesis that antagonising these pro-
apoptotic signalling cascades could save the cardiomyocytes that were already 
committed to undergo cell death through apoptosis. It was, therefore, demonstrated 
that by inhibiting caspases, at the time of reperfusion, the infarct size could be reduced 
in animal models (Mocanu et al., 2000). Furthermore, the apoptotic processes were 
not only inhibited through antagonising of pro-apoptotic caspases but also through 
activation of pro-survival protein kinases such as phosphoinositide-dependent kinase 
(PI3K), protein kinase B (PKB) and extracellular signal-regulated kinase 1/2 (ERK 1/2) 
– mitogen-activated protein kinase (MAPK), also called the RISK pathway (Baxter et 
al., 2001; Yellon and Baxter, 1999). Schulman and colleagues, further demonstrated 
that the administration of urocortin (a growth factor) at reperfusion, protects the heart 
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from I/R injury through upregulation of the ERK 1/2 signalling pathway (Schulman et 
al., 2015). Co-administration of PD98059 (ERK 1/2 inhibitor) and urocortin at 
reperfusion abolished protection (increased infarct size), thus confirming the 
cardioprotective role of ERK 1/2. Furthermore, insulin and transforming growth factor-
beta 1 (TGF-β1) was also found to protect against myocardial infarction and apoptotic 
cell death through activation of the RISK pathway at reperfusion (Baxter et al., 2001; 
Jonassen et al., 2001).  
 
Activation of both PI3K-PKB and ERK1/2, using growth factors and cytokines, could 
mediate cell survival through activation of anti-apoptotic mechanisms (Schulman et 
al., 2015). This led to more investigations on these pro-survival protein kinases during 
reperfusion, using pharmacological agents/drugs (Heusch, 2015). The proposed main 
end effector of myocardial protection against I/R injury is the mPTP which opens within 
the first 15 minutes of reperfusion (Hausenloy et al., 2003). The RISK pathway 
cardioprotective mechanism has been linked to the closure of the mPTP in rat 
myocytes (Davidson et al., 2006). In addition, in IPreC, PI3K-PKB phosphorylation 
inhibits GSK3!	 activity thus inhibiting mPTP opening during reperfusion (Heusch, 
2015; Juhaszova et al., 2004; Tong et al., 2002).  
 
1.4.4.3 Survivor activating factor enhancement (SAFE) pathway 
 
The RISK pathway is considered the universal signalling pathway for cardioprotection, 
however, there are other cardioprotective signalling cascades including the survivor 
activating factor enhancement (SAFE) pathway (Heusch, 2015). Lecour and co-
workers discovered that pharmacological preconditioning (PPreC) with TNF-α was 
cardioprotective without involving the RISK pathway (Lecour, 2009). The same group 
further investigated the effects of administering TNF-α at reperfusion and discovered 
that TNF-α recruited an alternative signalling cascade, called the SAFE pathway 
(Lacerda et al., 2010). The SAFE pathway is also known to be involved in the trigger 
phase of ischaemic preconditioning which involves dual activation of signal transducer 
and activator of transcription 3 (STAT-3) and PKB (Boengler et al., 2010). In the clinical 
setting, it seems that the signal transducer and activator of transcription 5 (STAT-5) 





1.4.4.4 Second messengers in cardioprotection 
 
Second messengers are small lipid or water-soluble molecules that are produced in 
response to stimuli ( i.e. protein hormones, growth factors) and transmit signals from 
a membrane receptors to downstream effectors (i.e. signalling proteins). Second 
messengers amplify the signal strength received by the receptors to target receptors 
in the cytosol and/or nucleus. Cyclic adenosine 3',5' monophosphate (cAMP) and 
cyclic guanosine 3',5' monophosphate (cGMP) are cyclic nucleotides which are two of 
the major second messengers.  
 
In the cGMP signalling pathway, phosphorylated PI3K and PKB can phosphorylate 
eNOS to produce NO (Dimmeler et al., 1999). NO activates a soluble guanylate 
cyclase to form cGMP, which then activates PKG (Cohen and Downey, 2007). PKG 
targets mitochondrial ATP-dependent potassium channels (mKATP)  and redox 
signalling (Oldenburg et al., 2004; Penna et al., 2007). In addition, mKATP channel 
dysfunction leads to a loss of cardioprotection (Lejay et al., 2016).   
 
The b-adrenoceptors, on the other hand, play a crucial role in the regulation of cardiac 
function in both the normal and diseased state (Port and Bristow, 2001). Stimulation 
of these receptors activates adenyl cyclase to form cAMP from ATP. It has been 
demonstrated that the !-adrenergic-cAMP signalling pathway is involved in several 
cardioprotective events including IPreC (Khaliulin et al., 2014, 2010; Lochner et al., 
1999). An increase in tissue cAMP during preconditioning is cardioprotective against 
I/R injury (Lochner et al., 1999).  
 
 
1.5. Cyclic adenosine 3',5' monophosphate (cAMP) 
 
As early as in 1958, cAMP was the first second messenger to be identified and to play 
a crucial role in cellular responses to hormone signalling and neurotransmitters 
(Sutherland and Rall, 1958). cAMP plays a vital role in cardiovascular processes such 
as the regulation of cardiac contractility, cardiac relaxation, endothelial barrier function 
and vasodilation (Patterson et al., 2000; Roberts and Dart, 2014). Cellular levels of 
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cAMP are controlled and regulated by changes in the activity of a  transmembrane 
enzyme, adenylate cyclase (AC), as well as cyclic nucleotide phosphodiesterase 
(PDE). AC activity is controlled through stimulation or inhibition of G-protein-coupled 
receptors (GPCR) such as the b adrenoceptor by interactions with the a subunit of the 
Gs protein (as - stimulating activity) or a b adrenoceptor by interactions with the a 
subunit of the Gi protein (ai - inhibiting it) (Sassone-Corsi, 2012). Binding of an agonist 
ligand (e.g. epinephrine in the case of b adrenoceptors) to GPCR complexes causes 
a release of an a subunit of the Gs protein (as) from the GPCR complexes to bind and 
activate AC (Sassone-Corsi, 2012). Therefore, cAMP production depends not only on 
the AC activation or inhibition by ligands from GPCR-as to GPCR-aI, but also on its 
degradation by PDEs, which catalyse the hydrolysis of cAMP to adenosine 
monophosphate (5’-AMP) (Lezoualc’H et al., 2016; Mika et al., 2012). ACs catalyses 
the conversion of adenosine triphosphate (ATP) (a substrate) in the presence of 
magnesium as a co-factor to produce cAMP and pyrophosphate. The cAMP generated 
through AC activation can serve as a regulatory signal via protein kinase A (PKA) 
which is one of the most studied cAMP-dependent proteins (Pierce et al., 2002). Over 
the years, all cAMP-mediated effects were attributed to the activation of PKA 
(Patterson et al., 2000; Vossler et al., 1997), however cAMP-induced activation of the 
small GTPase, Rap1, was unresponsive to PKA inhibitors. This led to the discovery of 
a new cAMP effector protein, namely exchange protein directly activated by cAMP 
(Epac) (De Rooij et al., 1998; Kawasaki et al., 1998). 
 
 
1.6 Exchange protein directly activated by cAMP (Epac) 
1.6.1 Epac structure and the mechanism of activation  
 
Recent evidence suggests that Epac, independent of PKA, plays an important role in 
many cellular functions, including in the cardiovascular system. Epac proteins are a 
family of cAMP guanine nucleotide exchange factors (GEFs) for the small GTPases, 
Rap1 and Rap2. There are two Epac isoforms namely, cAMP-GEF-1 (Epac1) and 
cAMP-GEF-2 (Epac2), which are GEFs for Rap1 and Rap2, respectively (Bos, 2006; 
De Rooij et al., 1998; Kawasaki et al., 1998). Epac proteins are encoded differently by 
Rapgef3 (Epac1) and Rapgef4 (Epac2) genes although they display a similar genetic 




Epac1 and Epac2 are multi-domain proteins that contain an N-terminal regulatory 
region and a C-terminal catalytic region. These proteins have a cyclic-nucleotide-
binding domain (CNBD) at the N-terminal regulatory region that is homogenous to that 
of PKA R-subunit (see Figure 1.4) (Cheng et al., 2008). The CNBD is a high-affinity 
cAMP-binding domain (Epac activation) and activates the Ras superfamily of small 
GTPases Rap1 and Rap2. Epac1 has one N-terminal CNBD whereas Epac2 is further 
subdivided into three isoforms: (i) Epac2A (brain/b-cell type) which has an additional 
N-terminal CNBD acting as a low affinity cAMP-binding domain, (ii) Epac2B (adrenal 
type) which is similar to Epac1 in domain structure and (iii) Epac2C (De Rooij et al., 
2000; Lewis et al., 2016; Niimura et al., 2009). The regulatory region of Epac also 
contains a Dishevelled, Egl-10, Pleckstrin (DEP) domain which is involved in Epac 
localization. A cytosolic localization was observed with Epac1 through deletion of the 
DEP domain but that did affect the regulation of Epac by cAMP (Ponsioen et al., 2004). 
The catalytic region of Epac contains a Ras-exchange motif domain, RAS association 
domain and a CDC25 homology domain which controls the nucleotide exchange 
activity (Cheng et al., 2008).   
Binding of a ligand (extracellular signal) to the GPCR complexes leads to activation of 
AC, which catalyses the conversion of ATP to cAMP (Figure 1.4). The binding of cAMP 
to Epac’s CNBD allows the regulatory region to rotate and expose the CDC25 
homology domain for Rap to bind. The active Epac complex catalyses the exchange 
of inactive Rap- guanosine diphosphate (GDP) to an active Rap-guanosine 








Figure 1. 4 Mechanisms of Epac activation and its associated biological functions. 
Intracellular cAMP is produced from ATP by the enzyme adenyl cyclase (AC) in response to binding of 
the ligand (e.g. norepinephrine) to the Gas -coupled G-protein-couples receptors. cAMP can bind to the 
cyclic-nucleotide-binding domain (CNBD) of Epac (alternative PKA CNBD) and this allows the 
regulatory region to rotate and expose the catalytic CDC25 homology domain for Rap to bind. The 
active Epac complex catalyses the exchange of inactive Rap-guanosine diphosphate (GDP) to an active 
Rap-guanosine triphosphate (GTP) and controls Rap-mediated biological functions. Adapted from 
(Lezoualc’H et al., 2016; Métrich et al., 2010; Schmidt et al., 2013). 
 
 
1.6.2 Epac protein tissue expression 
 
Epac1 messenger RNA (mRNA) is expressed in relatively high levels in the heart, 
thyroid gland, ovary, blood vessels, proximal tubules of the kidney and in some parts 
of the brain (De Rooij et al., 1998; Honegger et al., 2006; Kawasaki et al., 1998; Li et 
al., 2008). Previous studies suggest that the regulation of Epac1 and Epac2 mRNA 
expression depends on developmental stages and pathophysiological conditions. In 
foetal organs (heart, brain, kidney, and lungs), Epac1 and Epac2 mRNA can be 
detected at an early stage of development, suggesting that both proteins play a major 
role in organ development and function (Ulucan et al., 2007). Both isoforms have 
shown to be highly expressed in adulthood in these organs, with only renal Epac2 
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showing a decline in mRNA expression in adulthood (Ulucan et al., 2007). In the heart, 
Epac1 and Epac2 mRNA expression have shown to be upregulated in isoproterenol-
induced left ventricular hypertrophy whereas only Epac1 mRNA was expressed in 
pressure overload-induced hypertrophy (Ulucan et al., 2007).  
 
1.6.3 Pharmacological modulators of Epac 
 




Figure 1. 5 Development of exchange protein activated by cAMP (EPAC)-selective cAMP 
analogues. 
 (A) cAMP. (B) cAMP methylated at the ribose 2′oxygen (2′O) yields 2′-O-Me-cAMP. (C) Addition of 
parachlorophenylthio (pCPT) to carbon 8 of the base yields 8-pCPT-2′O-Me-cAMP (007) (CPT) 
(Enserink et al., 2002). (D) Masking the phosphate group of 007 with an acetoxymethyl ester (8-pCPT-
2′O-Me-cAMP-AM) improves membrane permeability (intracellular esterases remove this to allow 
binding to cAMP-binding domains) (Vliem et al., 2008). From (Parnell et al., 2015). 
 
The discovery of Epac-selective agonist and antagonists for both Epac1 and/or 
Epac2 have enhanced the study of Epac signalling in different cell types, including 















Table 1.1: Epac’s agonists and antagonists  
Adapted from: (Lezoualc’H et al., 2016; Parnell et al., 2015) 
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1.7 Epac and vascular function  
 
The integrity of blood vessels is critical to vascular homeostasis (Murakami and 
Simons, 2009). Vascular smooth muscle cells (VSMCs) and vascular endothelial cells 
(VECs) play a crucial role in regulation of vascular tone, blood pressure and 
maintenance of blood vascular integrity (Lezoualc’H et al., 2016). In pathological 
conditions, the abnormal regulation of VSMCs and VECs can lead to development 
cells with migratory and proliferative phenotypes that can result in the progression of 
cardiovascular diseases, such as atherosclerosis and restenosis (Gimbrone and 
García-Cardeña, 2016; Lezoualc’H et al., 2016). 
  
1.7.1 Role of Epac on vascular tone  
 
Vascular tone is determined by the balance between cellular signalling pathways that 
mediate the generation of force (vasoconstriction) and release of force (vasodilation) 
respectively in the blood vessel (Morgado et al., 2012). Vascular tone can be 
influenced by either extrinsic factors such as sympathetic nerves and circulating 
angiotensin II or intrinsic factors such as myogenic mechanisms (which increases 
tone), endothelial factors (e.g. NO, which modulate vascular tone) and metabolic by-
products or hypoxia (which modulate vascular tone).  
cAMP and cGMP are considered as the main second messengers that are involved in 
the regulation of vascular tone through various signalling pathways (Morgado et al., 
2012). Therefore since the effects of cAMP were previously mainly attributed to PKA, 
current studies have shifted the focus to the role of Epac.  
 
Current studies have demonstrated that Epac activation could be a potential 
therapeutic target in vascular diseases (Barker et al., 2017; Parnell et al., 2015). 
Pharmacological activation of Epac with its selective agonists such as 8- pCPT [8-(4-
chlorophenylthio)-2′ -O-methyladenosine 3′,5′ - cyclic monophosphate] has shown 
promising results about role of Epac in the regulation of vasorelaxation. In primary 
human tracheal smooth muscle cells, Epac1 via Rap1 relaxes airway smooth muscles 
by inhibiting Ras homolog gene family member A (RhoA) activity, leading to 
dephosphorylation of myosin light chain (MLC) thereby inducing vasorelaxation 
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(Roscioni et al., 2011). Zieba et al. (2011) have demonstrated that in both intact and 
permeabilized vascular, gut, and airway smooth muscle cells, 8- pCPT significantly 
reduced agonist-induced contractile force and MLC phosphatase phosphorylation 
independent of PKA and PKG (Zieba et al., 2011). Furthermore, silencing Epac1 in rat 
aortic smooth muscle cells leads to the inhibition of isoproterenol-induced Rap1 
activity, which further confirms that cAMP-medicated signalling mechanism through 
Epac activation is independent of PKA (Zieba et al., 2011). Rap1b knockout mice 
presented with cardiac hypertrophy, elevated blood pressure and endothelial 
dysfunction (reduced eNOS activity) suggesting that Epac1/Rap1b is required for 
maintenance of vascular tone and normal blood pressure (Lakshmikanthan et al., 
2014).  
 
Epac1/Rap1b activation with CPT in vascular endothelial cells stimulates ryanodine 
receptor (RyR) in sarcoplasmic reticulum to release Ca2+. Ca2+ release activates BKCa 
(Ca2+ -sensitive large-conductance K+) channels causing membrane hyperpolarization 
and eventually closure of voltage gated Ca2+ channels, this leads to a decrease in 
intracellular Ca2+ which induces vasorelaxation (Roberts et al., 2013).  
In addition, Epac activation through eNOS activity seems to be involved in 
endothelium-dependent Epac-mediated vasorelaxation (Lakshmikanthan et al., 2014; 
Roberts et al., 2013). However, PKA cannot be excluded in Epac’s role in 
vasorelaxation. Some studies suggested that in smooth muscle the inhibition of RhoA 
activity is mediated by activation of both Epac and PKA (Zieba et al., 2011).  
 
Overall, Epac1/Rap1b activation with its agonist CPT directly induces vasorelaxation 
in different types of vascular smooth muscle cells through inhibition of RhoA activity 
and independent of PKA. In addition, Epac induced vasorelaxation in vascular smooth 
muscle cells may be via the activation of endothelial nitric oxide synthase (eNOS).  
 
1.7.2 Role of Epac in the regulation of VSMC proliferation and migration 
 
Cell proliferation in vascular tissue can be defined by excessive growth of VSMC which 
can contribute to the development of atherosclerosis and restenosis. Cell proliferation 
can be controlled by different signalling molecules and cell proliferation is increased 
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in tumours. The well-known factor influencing VSMC proliferation is the platelet-
derived growth factor (PDGF) and its receptor (PDGFR) via downstream signalling 
effectors (including the Ras/ MAPK-, Src-, PI3K/PKB-, phospholipase C-γ- and 
JAK/STAT pathways) (Wang et al., 2018; Yu et al., 2018). Adenosine A₂(B) receptors 
have been reported to facilitate an early induction of genes which lead to a decrease 
in arterial smooth muscle cell proliferation (Mayer et al., 2011). On the other hand, 
Epac activation with CPT and PKA synergistically inhibits VSMC proliferation via a 
Rap1 independent mechanism (Hewer et al., 2011). 
 
Cell migration is a central process in embryogenesis, bone remodelling and wound 
healing, it requires all immune responses and other cellular signals for the cells to 
migrate to the place of injury (Lauffenburger and Horwitz, 1996; Stossel, 1993). cAMP 
has been implicated in promoting wound healing in VSMC after injury (Palmer et al., 
1998). Epac1 is upregulated during neointimal thickening and increases VSMC 
migration. Thus Epac may play a crucial role in vascular remodelling and restenosis 
upon injury (Yokoyama et al., 2008b, 2008a). Furthermore, Yokoyama at al. 
suggested that both Epac and PKA take part in vascular remodelling (Yokoyama et 
al., 2010). In rat aortas, cAMP-mediated inhibition of VSMC migration is associated 
with the activity of phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4) 
(Palmer et al., 1998).  
 
PDE4 inhibition reduced the thickening of arterial walls following vascular injury in an 
Epac-dependent manner (Lehrke et al., 2015). McKean and co-workers have 
demonstrated that the cAMP producing agonist, beraprost, inhibited migration in 
human VSMC through Epac and the proposed mechanism was via Rap1 and with 
subsequent inhibition of RhoA (McKean et al., 2015, 2013). Recently, Epac1 
deficiency, possible via PKB-GSK3β pathway, inhibited the basic fibroblast growth 
factor (bFGF)-mediated VSMC migration (Kato et al., 2019). Therefore,  these studies 
suggest that Epac may play a crucial role in the regulation of VSMC proliferation and 











Figure 1. 6 An overview of Epac’s role in vascular function. 
In endothelial cells, the complex Epac1-PDE4D VE-cadherin-bearing cell to cell contacts and the 
interaction of Epac1 with ERM molecules stabilize endothelial barrier function. Furthermore, Epac1-
Rap1 via c-Jun and C/ERB promotes suppressor of cytokine signalling 3 (SOCS-3) in the nucleus, 
which blocks proinflammatory cytokine interleukin 6 (IL6). In VSMC, Epac1-Rap1b decreases smooth 
muscle cells proliferation through inhibition of early growth response protein 1 (Erg1), Cycline D and s-
phase kinase-associated protein 2 (Skp2). Epac1 activation also inhibits RhoA which lead to 
dephosphorylation of MLC and vasorelaxation. Epac1 also stimulates RyR in the sarcoplasmic 
reticulum and a release of Ca2+ which activates BKca causing membrane hyperpolarization and 
eventually closure of voltage gated Ca2+ channels, this leads to a decrease in intracellular Ca2+ 
concentration which induces VSMC relaxation. In addition, Epac1 induces endothelial-dependent 
VSMC relaxation via eNOS and NO release.  Adapted from (Métrich et al., 2010; Roberts and Dart, 





Vascular endothelial cells  
Vascular smooth muscle cells   
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1.7.3 Role of Epac in vascular endothelial barrier function  
 
The endothelium is defined as a simple squamous layer of vascular endothelial cells 
which separates all tissues from the blood in the vasculature. The primary function of 
the endothelium is to control vascular tone and permeability (which allows a selective 
transport of fluids, ions, macromolecules, and leukocytes across the vessel wall), also 
to regulate vascular inflammation, prevention of thrombosis and maintenance of 
vascular integrity (Chavez et al., 2011). Inflammation, diabetes, oxidative stress, 
dyslipidaemia and invasion of pathogens can initiate loss of vascular endothelial 
function (endothelial dysfunction) which can lead to the development of cardiovascular 
diseases such as atherosclerosis (Svensjö and Bouskela, 2018). The vascular 
endothelial barrier function and vascular integrity are highly supported by two major 
intracellular junctions which join the adjacent endothelial cells (Vestweber, 2012). The 
adherens junctions composed of mainly vascular endothelial (VE)-cadherin and the 
membrane proteins (p120, β-catenin, and plakoglobin/γ-catenin) (Dejana and 
Orsenigo, 2013; Hirase and Node, 2011). The tight junctions are formed by junctional 
adhesion molecules and membrane proteins (occludin and claudins) and they are 
involved in the control movement of solutes between adjacent cells (Hirase and Node, 
2011; Runkle and Mu, 2013).  
 
Over the years, cAMP/PKA has been known to regulate endothelial cell barrier 
function. Both in vivo and in vitro studies have shown cAMP elevation with PDE 
inhibitors and AC activators can decrease inflammation-induced basal permeability 
and reverse vascular leakage in endothelial cells. 
 
However, studies with PKA inhibitors generated inconsistent results with regard to the 
regulation of vascular endothelial cell barrier function. The direct activation of 
Epac1/Rap1 with its agonist CPT has been shown to regulate endothelial cell barrier 
function through RhoA inhibition at junctions which induces redistribution of VE-
cadherin and tight junctions molecules enhancing barrier function (Figure 1.6) (Cullere 
et al., 2005). However, Birukova et al., (2007) have demonstrated that both PKA and 
Epac/Rap, through activation of Rac1, lead to the enhancement of peripheral actin 
cytoskeleton and adherens junctions (Birukova et al., 2010, 2008, 2007). Furthermore, 
the vascular endothelial cell barrier permeability depends on the integrity of cell to cell 
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junctions stability VE-cadherin and tight junctions (Figure 1.6) (Dejana and Orsenigo, 
2013; Hirase and Node, 2011; Runkle and Mu, 2013). Therefore, PKA and Epac1 
agonists have been shown to reduce vascular endothelial cell barrier permeability and 
vascular leakage through increased cell to cell junction stability. Both PKA and Epac1, 
through inhibition of Rho and activation of Rac1, lead to accumulation of intercellular 
junctional proteins which regulate and stabilize the adherens and tight junction (Aslam 
et al., 2014). Furthermore, phosphodiesterase 4D (PDE4D) enzymes integrate Epac1 
to VE-cadherin-signalling complex and control the effects of cAMP on vascular 
endothelial cell permeability (Figure 1.6) (Rampersad et al., 2010).  
 
1.8 Epac in the heart  
 
The cAMP is a known second messenger that modulates several physiological 
processes in the heart, including cardiac contractility and relaxation. The β-adrenergic 
receptors belong to the GPCR superfamily and are known to play a crucial role in 
cardiac function. There are three β-adrenergic receptor subtypes that are expressed 
in the mammalian heart namely β1-, β2 - and β3-adrenergic receptor subtypes, with 
only β1- and β2 adrenergic receptor subtypes known to regulate cardiac performance 
in response to stress or exercise (Berthouze et al., 2011). Cardiac function is 
controlled by the sympathetic nervous system. Catecholamines (nor-epinephrine and 
epinephrine) serves as primary agonists of all β-adrenergic receptors. Therefore,  
binding of catecholamines to β-adrenergic receptors activates AC which increases 
intracellular cAMP (Sassone-Corsi, 2012). The cAMP produced serves as a regulatory 
signal that activates PKA, which further phosphorylates the key excitation-contraction 
coupling proteins including troponin I, cardiac ryanodine receptors (RyR), or 
phospholamban (PLB) (Aasakiran, 2007; Berthouze et al., 2011; Freedman and 
Lefkowitz, 2004).	 
 
1.8.1 Role of Epac in Ca2+ handling and cardiac excitation-contraction  
 
Ca2+ is a universal intracellular second messenger and it plays a central role in cardiac 
contraction and relaxation (Bers, 2007). PKA phosphorylates the L-type Ca2+ channels 
located at the sarcolemma, which allows Ca2+ to enter the cardiomyocyte, and this 
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triggers more Ca2+ from the sarcoplasmic reticulum to induce myofilament contraction. 
PKA also phosphorylates RyR resulting in Ca2+ leakage from the sarcoplasmic 
reticulum, thus providing the Ca2+ necessary to activate the contraction of the 
myofibrils (Lezoualc’H et al., 2016). After contraction, PLB phosphorylation by PKA at 
Ser16 relieves its tonic inhibition on sarcoplasmic reticulum Ca2+ ATPase activity, 
allowing Ca2+ uptake in the sarcoplasmic reticulum, thus favouring relaxation (Bers, 
2007; Lezoualc’H et al., 2016). In addition, the a subunit of the inhibitory G protein 
(Gai), which inhibits AC, activates cytosolic effector molecule phospholipase A2 
(cPLA2) leading to a reduced cardiac contractility independent of cAMP (Aasakiran, 
2007).  
 
Since Ca2+ is a key element that modulates cardiac excitation-contraction, several 
studies have shown that Epac regulated intracellular  Ca2+ handling in cardiomyocytes 
(Cazorla et al., 2009; Domínguez-Rodríguez et al., 2015; Kaur et al., 2016; Morel et 
al., 2005; Oestreich et al., 2009, 2007; Pereira et al., 2017, 2012; Ruiz-Hurtado et al., 
2013, 2012). Initial evidence demonstrated that selective activation of Epac with its 
analogue CPT increases spontaneous Ca2+ transients in cultured rat neonatal 
ventricular myocytes (Figure 1.7) (Morel et al., 2005). Similarly, CPT increased the 
frequency of Ca2+ sparks via Ca2+/calmodulin kinase II (CaMKII)-dependent and 
independent of PKA in adult rat cardiomyocytes, thus confirming a role of Epac in Ca2+ 
handling (Figure 1.7) (Pereira et al., 2007). Like PKA, Epac phosphorylates RyR which 
results in Ca2+ leakage from the sarcoplasmic reticulum independent of PKA but rather 
require involvement of phospholipase Cε (PLCε) and Ca2+/calmodulin kinase II 
(CaMKII) activation (Cazorla et al., 2009; Oestreich et al., 2007; Pereira et al., 2012, 
2007). Epac activation in rat cardiac muscle increased myofilament Ca2+ sensitivity via 
CaMKII, an effect which was abolished by a CaMKII inhibitor KN-93 (Cazorla et al., 
2009; Kaur et al., 2016). Moreover, Epac activation with CPT showed a positive 
inotropic effect by boosting extracellular Ca2+ influx via L-type Ca2+ channels (Ruiz-
Hurtado et al., 2012). In summary, Epac activates the enzyme PLCε which catalyses 
the conversion of phosphatidylinositol 4,5-bisphosphate (PIP2) to produce inositol 
trisphosphate (IP3) and diacylglycerol (DAG) leading to the activation of PKC and 
CaMKII. PKC and CaMKII are involved in contractile protein phosphorylation and 




1.8.2 Epac and arrhythmias and hypertrophy  
 
In the heart, Epac1 and Epac2 mRNA expression have shown to be upregulated in 
isoproterenol-induced left ventricular hypertrophy whereas only Epac1 mRNA was 
expressed in pressure overload-induced hypertrophy (Ulucan et al., 2007).  In 
addition, Metrich and co-workers (2008) reported that Epac1 is expressed in the 
human heart and that it’s level increases during heart failure (Métrich et al., 2008). 
However, Epac proteins may exert both anti- and pro-hypertrophic properties in 





Figure 1. 7 An overview of Epac signalling and cardiac remodelling. 
In cardiomyocytes, beta-arrestin (β-arr) and PDE regulate EPAC1 hypertrophic signalling, which also 
involves calcineurin (CaN) and nuclear factor of activated T-cells (NFAT). Eapc1-Rap2 pathway 
phosphorylates RyR via activation of CaMKII and PLCɛ / PKC ɛ, this results in Ca2+ leakage from the 
sarcoplasmic reticulum which may trigger arrhythmia. Further, Epac1 increases phosphorylation of PLB 
which inhibits sarcoplasmic reticulum Ca2+ ATPase (SERCA) activity and may contribute to the 
development of arrhythmia and heart failure. Adapted from:  (Laudette et al., 2018; Métrich et al., 2010) 
 




Several animal and human studies have investigated the role of Epac in 
cardiomyocytes, providing evidence that Epac plays a crucial role in modulating 
intracellular Ca2+ signalling (Cazorla et al., 2009; Domínguez-Rodríguez et al., 2015; 
Kaur et al., 2016; Morel et al., 2005; Oestreich et al., 2009, 2007; Pereira et al., 2017, 
2012; Ruiz-Hurtado et al., 2013, 2012). In cardiomyocytes, Epac is involved cardiac 
contraction by forming gap junctions and enhancing intracellular Ca2+ release by 
activating CaMKII (Pereira et al., 2007). A sustained Epac activation with its selective 
agonist CPT increases a spontaneous Ca2+ release as Ca2+ waves and extra Ca2+ 
transients, suggesting proarrhythmic effects (Figure 1.7) (Ruiz-Hurtado et al., 2012). 
Furthermore, CPT critically regulates action potential by reducing potassium current 
thus prolonging repolarizing in rat adult ventricle, which may explain why Epac is 
upregulated in conditions such as cardiac hypertrophy (Brette et al., 2013). Some 
studies have demonstrated that inhibition of both Epac and PKA downregulates the 
expression and function of the gap junction protein connexin 43 in rats with myocardial 
infarction, which prevented ventricular arrhythmias (Lee et al., 2013). Cardiac 
arrhythmias are associated with increased late sodium current (INaL), β-adrenergic 
receptor regulates INaL via PKA and CaMKII pathways, however, the mechanism is 
unclear. Recently, Yang and co-workers (2016) demonstrated that in vivo inhibition of 
Epac2-Rap1 in rats induced ventricular fibrillation followed by sudden death and the 
possible mechanism was through an increase in mitochondrial ROS and activation of 
INaL (Yang et al., 2016). Another study confirmed that β-adrenergic receptor stimulation 
regulates INaL via both PKA and CaMKII and suggest that ROS and NO may contribute 
to this effect (Hegyi et al., 2018). Pereira and colleagues (2017) proposed two possible 
pathways, the β-adrenergic- cAMP-Epac- PI3K-PKB-NOS1-CaMKII pathway to 
mediate Ca2+ leak and the β-adrenergic-cAMP-PKA pathway which plays a role in 
inotropic and lusitropic effects through regulation of Ca2+ current and sarcoplasmic 
reticulum Ca2+ ATPase (Pereira et al., 2017). Thus, suggesting that studying these 








1.9 Epac, metabolic syndrome and cardiovascular disease  
 
The evidence collected over the years indicates that Epac plays a critical role in 
integrating and transducing multiple signalling pathways in the cardiovascular system, 
including some reports suggesting detrimental effects, such as cardiac remodelling 
and arrythmias (Lee et al., 2013; Okumura et al., 2014; Pereira et al., 2017; Yang et 
al., 2016). Several studies have been published on Epac1, Epac2 or Epac1/2 knockout 
mice (Table 1.2). The knockout mice models have revealed diverse functions of Epac 
in different organs. In the brain (hypothalamus), Epac1 deletion mice fed with a high-
fat diet (HFD) was associated with an improved leptin signalling, reduced food intake 
and reduced adiposity (Yan et al., 2013). Interestingly, Kai and colleagues (2013) 
reported that Epac1 deficient mice developed pancreatic !-cell dysfunction and 
metabolic syndrome (Kai et al., 2013). Furthermore, Epac2 deletion in mice impaired 
hypothalamic leptin signalling (Hwang et al., 2017). In addition, Rap1 knockout mice 
presented with signs of metabolic syndrome and developed hepatic steatosis 
(Martínez et al., 2013).  
 
In the cardiovascular system,  Epac1 deletion was shown to be cardioprotective but 
not Epac2 deletion (Okumura et al., 2014). However, Epac1 deletion was detrimental 
on infarct size in mice fed with a HFD; furthermore, the HFD “paradoxically reduced” 
infarct size in both HFD wild type and HFD Epac2 knockout mice (Edland et al., 2016). 
In rats fed with a standard chow, a pharmacological activation of Epac1/2 with CPT 
did not affect infarct size. However, co-treatment with a PKA activator (6-Bnz) and 
CPT reduce the infarct size (Khaliulin et al., 2017). Clinically,  dysfunctional epicardial 
adipose tissue (EAT) may promote maladaptive cardiac remodelling through Epac2 
and ST2 (cardiac biomarker) expression, which inhibits an interleukin 33 (IL-33)-




















Model Organ  Proposed mechanism  Reference  
Epac1 Mice: in vivo and in 




- Epac1 induced leptin 
resistance. 
- HFD increased Rap1 
expression after 4 weeks. 
- Epac1 blunted leptin signalling 
pathway (PKB-STAT3, mTOR-
S6K, ERK, and AMPK) 
(Fukuda et 
al., 2011) 
Epac 1 Rap1 knock out 
mice 
Liver and 
visceral fat  
- Accumulation of abdominal fat 
- Developed hepatic steatosis 
- High-fasting plasma levels of 
insulin 
- High glucose concentration 





Epac1 knock out 




- Reduced food intake 
- Reduced adiposity  
- Reduced plasma leptin 
- pSTAT3 was enhanced 
(Yan et al., 
2013) 
Epac1 Epac1 knock out 
mice: in vivo study 
(HFD induced)  
Pancreas:  
!-cells   
- Elevated plasma triglycerides  
- Severe diet-induced obesity 
- Developed insulin resistance  
- !-cells dysfunction 
- Reduced GLUT2 and PDX-1 
expression    
(Kai et al., 
2013) 
Epac1/2 Epac1/ and Epac2 
knockout mice 
Heart - Epac1 deletion protects the 
hearts from various stresses 








Epac1 and Epac2  
knock out mice 






- HFD “paradoxically reduced” 
infarct size in both HFDwt and 
HFD Epac2 knockout  




Epac1/2 Rats (normal diet) Heart  - Only co-treatment of PKA (6-
Bnz) and Epac (CPT) led to 
infarct size reduction via PKC 
inhibition  
 (Khaliulin et 
al., 2017) 













- Dysfunctional EAT, Epac2 and 
ST2 expression inhibits IL-33 





Given the above, it is evident that Epac plays a critical role in different systems or 
organs as shown in Epac knockout experiments. However, some of the data are 
inconclusive and contradictory. In addition, Lochner and colleagues (1999) have 
demonstrated that an increase in tissue cAMP during preconditioning is 
cardioprotective against I/R injury (Lochner et al., 1999). PKA and Epac are the 
downstream signalling cascade targets of cAMP. Therefore, this warrants more 
investigation on the role of Epac in myocardial I/R, obesity and insulin resistance. 
Furthermore, it is relevant to investigate Epac’s role on the RISK pathway, which is 
one of the best described cardioprotective pathways.   
 
1.10 Problem statement and study aims   
 
1.10.1 Problem statement  
 
Despite intense research over decades on the prevalence, treatment, and 
management of CVD, it still remains the number one cause of death globally, and it 
affects both men and women. NCDs, particularly CVDs, are already among the top 
causes of death in South Africa (Nojilana et al., 2016). In 2010, NCDs accounted for 
39% of total deaths in the country. More than a third (36%) of these deaths occurred 
before the age of 60 years. In 2010, the number of deaths due to NCDs was similar to 
the number from HIV/AIDS and tuberculosis (TB) combined (Nojilana et al., 2016). In 
2006, with almost two-thirds of the patients enrolled in the Heart of Soweto study 
cohort presented with multiple cardiovascular risk factors such as hypertension and 
obesity (Pretorius et al., 2017; Tibazarwa et al., 2009).  
 
Obesity could increase the risk of CAD and heart failure (Kenchaiah et al., 2002) and 
could worsen the sequelae of a myocardial infarction (Aronson et al., 2010; Clavijo et 
al., 2006). These adverse effects are consistent with experimental evidence of 
ischaemic intolerance and suppressed cardioprotection in hearts from obese, insulin-
resistant animals (du Toit et al., 2008, 2005; Essop et al., 2009; Huisamen et al., 2012; 
Maarman et al., 2012). Conversely, obesity with insulin resistance could decrease 
myocardial tolerance to I/R but the mechanisms for this decreased tolerance remains 
unclear (Donner et al., 2012). Therefore, the strong association between obesity and 
CVDs stresses the necessity of elucidating the underlying molecular mechanisms 
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linking these pathologies. Thus, detailed knowledge of intracellular events at a 
molecular level is a prerequisite for the development of therapeutic regimens aimed at 
protection of the vascular system and the heart. One such candidate mechanism is 
the cAMP-Epac pathway.  
 
 
1.10.2 Study aim, hypothesis and obejectives  
 
1.10.2.1 Study aim 
 
We aimed to investigate use a selective Epac agonist (CPT) and a newly discovered 
Epac1 selective antagonist (ESI-09) may provide a new path for the development of 
novel therapeutics for the treatment of CVDs.  
 
1.10.2.2 Hypothesis:  
 
We hypothesise that Epac activation with CPT is specifically involved in mediating 
cardioprotection during I/R injury and that Epac activation is an effective means of pre- 
and possible post- ischaemic treatment.   
 
1.10.2.3 Objectives:  
 
 
i. To elucidate the role of Epac in myocardial I/R of ex vivo hearts of a healthy rat 
model (Chapter 2)  
 
ii. To elucidate the role of Epac in  myocardial I/R of ex vivo hearts from a rat 
model of high-calorie diet-induced obesity (Chapter 3)  
 
iii. To investigate the role of Epac signalling in ex vivo thoracic aortas from a rat 
model of high-calorie diet-induced obesity (Chapter 4) 
 
iv. To investigate the role of Epac signalling in palmitic and oleic acid-induced 





The role of Epac in myocardial I/R of ex vivo hearts of a 




b-adrenoceptors play a crucial role in the regulation of cardiac function in both normal 
and disease state (Port and Bristow, 2001). Stimulation of these receptors activates 
adenyl cyclase to form cAMP from ATP. It has been demonstrated that the !-
adrenergic	 -cAMP signalling pathway is involved in several cardioprotective events 
including ischaemic preconditioning (Khaliulin et al., 2014, 2010; Lochner et al., 1999). 
The latter is short cycles of non-injurious I/R that protect the myocardium from 
subsequent long periods of ischaemia (Ferdinandy et al., 2014; Murry et al., 1986). A 
moderate pre-ischaemic stimulation of b-adrenoceptors before a sustained I/R has a 
cardioprotective affect (Lochner et al., 1999) while overstimulation of these receptors 
can have detrimental effects which may lead to heart failure (Port and Bristow, 2001). 
In heart failure, b-adrenoceptors are desensitized/downregulated due to hyperactivity 
of the sympathetic nervous system (de Lucia et al., 2018). Therefore, by targeting 
cAMP and its downstream effectors without stimulating the b-adrenoceptors could be 
an advantage in cardioprotection. However, cAMP via the PKA pathway did not yield 
a conclusive mechanism on cardioprotection, suggesting that an alternative cAMP 
effector might be involved (Makaula et al., 2005). Epac proteins are an additional class 
of cAMP effectors and the availability of pharmacological agents such as CPT (Epac 
selective agonist) and ESI-09 (Epac selective antagonist) has made it possible to 
discriminate between the role of Epac and PKA in cardioprotection against I/R injury. 
In this study we aimed to evaluate the role of Epac in myocardial I/R injury of a normal 
body weight rat model. To achieve this, Epac was activated with CPT or inhibited with 
ESI-09 respectively in ex vivo hearts using an isolated rat heart perfusion model. 
Cardiac functional recovery, infarct size and selected signalling pathways (using 
western blots) were measured as endpoints.  
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2.2 Methods and materials  
 
2.2.1 General materials used  
 
Cell Signaling Technologies (Beverly, MA, USA)  
1. Total ERKp44/p42 (catalogue number:  #9102) 
2. Phopho-ERKp44/p42 (Thr202/Tyr204) (ERK1/2) (catalogue number:  #9101) 
3. Total PKB (catalogue number:  #4691) 
4. Phospho-PKB/ (Ser473) (catalogue number:  #4058) 
5. Total CREB (catalogue number:  #4820) 
6. Phospho-CREB (Ser133) (catalogue number:  #9198) 
7. Cleaved-caspase-3 (catalogue number:  #9664)   
8. Horseradish peroxidise-linked anti-rabbit IgG (catalogue number:  #7074) 
 
Bio-Rad Laboratories, USA 
1. Enhanced chemiluminescence (ECL) detection reagent (catalogue number: 
#1705060)  
 
Millipore (Billerica, MA, USA) 
1. Polyvinylidene difluoride (PVDF) membrane (Immobilon™-P) (catalogue 
number: #IPVH00010) 
2. Rap1 Activation Assay Kit (catalogue number: #17-321) 
 
Sigma-Aldrich (St Louis, Mo, USA) 
1. MEK-ERKp44/p42/ ERK1/2 inhibitor (PD98059) (catalogue number: #P215-5M 
2. PKB kinase inhibitor (A6730-5mg) (catalogue number: #A6730) 
3. 8-pCPT-2'-O-Me-cAMP (CPT):  Epac agonist. (catalogue number: #C8988) 
4.  
Biolog Life Science Institute (Bremen, Germany) 
1. 3- [5- (tert.-Butyl)isoxazol- 3- yl]- 2- [2- (3- chlorophenyl)hydrazono]- 3- 
oxopropanenitrile (ESI-09):  Epac antagonist (catalogue number: #B133-05) 
 
All other chemicals were of Analar grade and were purchased from Merck (including 
methanol, standard salts for solutions and buffers, and dimethyl sulfoxide (DMSO)). 
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2.2.2 Animals  
 
The study was approved by the University of Stellenbosch animal ethics committee 
(SU-ACUD14-00020) appendix (Figure A. 6). Animals used were housed at the 
University of Stellenbosch Central Research Facility (Tygerberg Campus). The 
animals were treated in accordance with the South African National Standard (SANS) 
guidelines for animal care and usage. The rats had free access to food and water and 
house in a temperature of (22°C), the humidity of (40%) and a 12 hour light/dark cycle. 
The rats were fed standard rat laboratory chow. Male Wistar rats (6 weeks old) 
weighing between 250 to 300g were used in this study. 
 
2.2.3 Rat Heart Perfusion Technique 
 
The isolated working heart model was used, using the well-characterized perfusion 
technique (not electrically stimulated; preload 15 cm H2O; afterload 100 cm H2O) as 
described previously (Figure 2.1) (Lochner et al., 1999; Salie et al., 2019).  
 
Rats were anaesthetized by lethal intraperitoneal injection of pentobarbital (160 
mg/kg) for sacrifice. Immediately after removal, hearts were arrested with ice-cold 
(4°C) Krebs-Henseleit buffer (with composition in mmol/L: NaCl 119, KCl 4.74, CaCl2 
1.25, MgSO4 0.6, Na2SO4 0.59, KH2PO4 1.79, NaHCO3 24.9, Glucose 10) (Salie et al., 
2019). The hearts were immediately mounted onto an aortic cannula and perfused 
retrogradely with the Krebs-Henseleit buffer that was pre-warmed (37°C) and gassed 
(95% O2, 5% CO2) before and during the perfusion protocol. Retrograde perfusion was 
in a non-recirculating manner at a pressure of 100 cm H2O for 30 minutes (stabilization 
period). During this time, the left atrium was cannulated to allow for working heart 
perfusion at the preload of 15 cm H2O. After the stabilization period, the mode of 
perfusion was changed to a working heart mode for 10 minutes, the left ventricle 
ejecting against a hydrostatic pressure of 100 cm H2O (afterload) (not electrically 
stimulated). The temperature was monitored and maintained at 37°C throughout the 










Figure 2. 1 A schematic overview of the perfusion circuit. 
1. Electronic cardiogram     8., 9., 10., Bubble traps  
2. Temperature water bath    11. Aortic flow (AF) 
3. Carbogen tank      12. Reservoir  
4. Perfusion pump     13. Heart heat exchanger  
5. Filter 
6. Coronary flow (CF) 





2.2.4 Regional ischemia  
 
Thirty minutes stabilization was allowed before the induction of ischaemia. Regional 
myocardial ischaemia was induced by inserting silk suture around the left anterior 
descending (LAD) coronary artery. Thereafter, coronary artery occlusion was 
maintained for 35 minutes at a myocardial temperature of 36,5°C. The myocardial 
temperature was measured by inserting a temperature probe in the coronary sinus. 
After 35 minutes of regional ischaemia, the silk suture was released and the 
myocardium was reperfused for 65 minutes. Reperfusion included 10 minutes of 
retrograde perfusion, followed by 20 minutes of working heart perfusion and again by 
retrograde perfusion for another 30 minutes.  
 
2.2.5 Experimental protocols 
 
2.2.5 (a) Pre-treatment  
 
The hearts were perfused with an Epac selective-agonist, 8-pCPT-2'-O-Me-cAMP 
(CPT, 2 µM) or novel Epac inhibitor, ESI-09 (5 µM) or beta-adrenergic agonist, 
isoproterenol (ISO, 0.1 µM). The concentrations of CPT (Vliem et al., 2008) and ESI-
09 (Almahariq et al., 2012; Rehmann, 2013; Tsalkova et al., 2012) were obtained from 
the literature and for CPT dose-response see (Appendix A, Figure A. 2A).  
 
Drug administration was through an aortic cannula and perfused retrogradely (at a 
pressure of 100 cm H2O) 15 minutes before regional ischaemia (for protocol see 
Figure. 2.2).   
 
 
Figure 2. 2 The general experimental protocol for hearts pre-treated before I/R (see detailled 
protociols  with results). 
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2.2.5 (b) Post-treatment  
 
For post-treatment, drug administration was through an aortic cannula and perfused 
retrogradely in the first 10 minutes of reperfusion. The hearts were perfused with an 
Epac selective-agonist, 8-pCPT-2'-O-Me-cAMP (CPT, 2 µM) or novel Epac inhibitor, 
ESI-09 (5 µM) (Figure. 2.3). In order to determine the mechanism of cardioprotection 
by Epac on I/R injury, the involvement of the Reperfusion injury salvage kinase (RISK) 
pathway was investigated by co-treatment of CPT (2 µM) with a MEK-ERK inhibitor 
(PD98059, 10 µM), and a selective PKB inhibitor (A6730, 2.5 µM) respectively (Figure 
2.3).  
 
Figure 2. 3 The experimental protocol for hearts post-treated after I/R (see detailled 
protociols  with results). 
 
2.2.6 Assessment of cardiac function 
 
Baseline measurements were taken 10 minutes into working mode, and included 
coronary flow (CF, ml/min), aortic flow (AF, ml/min), cardiac output (CO, ml/min), heart 
rate (HR, beats/min), peak systolic pressure (PSP, mmHg) and total work performance 
(TW, mWatts). Left ventricular rate of work production (power) was calculated using 
the formula of Kannengiesser et al. (1979): Total work performance (TW) = 0002222 
x PSP x CO.  
 
Post-regional ischaemia cardiac function measurements were taken 20 minutes into 
working mode during reperfusion. Functional recovery was assessed as post-
ischaemic CO and TW expressed as a percentage of pre-ischaemic values using the 
formula: 
 
Percentage recovery (%) = Post-ischaemia measurement x 100 





2.2.7 Assessment of infarct size 
 
After an hour of reperfusion, the coronary artery was re-occluded permanently, and 
~1ml of a 0.25% Evans blue solution was infused via the aorta to outline viable tissues. 
Hearts were removed and frozen at -20°C and then sliced into 2 mm thick transverse 
sections. The latter were stained with 1% triphenyl tetrazolium chloride (TTC) in 
phosphate buffer, pH 7.4 for 10-15 minutes. TTC is used to differentiate between the 
metabolically active and inactive heart tissue. In healthy viable heart tissue, the TTC 
is enzymatically reduced to a deep red TPF (1,3,5-triphenylformazan) due to the 
activity of cardiac lactate dehydrogenases (enzymes important in cellular metabolism). 
In dead necrotic tissue (infarct), the enzymes are either denatured or degraded and 
therefore the heart tissue remains unreacted with a paler (white) colour (Figure 2.4). 
The TTC reaction was stopped by placing heart tissue sections in a 10% v/v 
formaldehyde solution to enhance the contrast between stained viable tissue and 
unstained necrotic tissue (Lochner et al., 2003). The sections were placed between 
two glass plates, scanned and saved in a tiff image format in a resolution of 1024 X 
796. The images were then traced (Figure 2.4) and infract size (I/S) was determined 
using computerised planimetry (UTHSCSA Image Tool, University of Texas Health 
Science Centre at San Antonio, Texas, USA). The volume of infarcted tissue (I) and 
the risk zone or area at risk (R) were then calculated by multiplying each area with the 
slice thickness and calculating the sum of the products. The degree of occlusion is 
indicated as (R) R and was expressed as a percentage of the total viable area (VA+R) 
of the left ventricle. Infarct size was expressed as a percentage of the area at risk (I/R 
%) (Lochner et al., 2003). 
 
 
Figure 2. 4 Illustration of infarct size determination 
Blue: Non-risk / viable area (VA, stained with Evan’s blue) 
Deep red: Area at risk (R, healthy heart tissue in the risk zone, stained with TTC) 
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Pale (white): Infarcted area (I, Necrotic heart tissue in the risk zone)  
 
2.2.8 Western blot measurements 
 
After 10 minutes of reperfusion, the area at risk of the left ventricle was removed, snap-
frozen in liquid nitrogen and stored at -80°C for subsequent biochemical analyses. For 
protein extraction, ∼80mg of pulverised heart tissue was lysed in 800 µL lysis buffer 
containing: Triton X-100 1%, Tris-Hydro chloride (pH 7.5) 20 mM, Ethylene glycol tetra 
acetic acid (EGTA) 1 mM, Ethylene diamine tetra acetic acid (EDTA) 1 mM, Sodium 
chloride (NaCl) 150 mM, Beta-glycerophosphate 1 mM, Tetra-sodium-pyrophosphate 
2.5 mM, Sodium fluoride (NaF) 50 nM, Sodium orthovanadate 1 mM, Leupeptin 10 
µg/ml, Aprotinin 10 µg/ml, sodium dodecyl sulphate (SDS) 0.1%, phenylmethylsulfonyl 
fluoride (PMSF) 50 µg/ml. Stainless steel beads (1.6 mm) were added to the tissue 
lysate and then it was homogenised at 4ºC in a Bullet blender (Next Advance 
laboratory, NY, USA) at a speed of 8 for three one-minute cycles. The lysates were 
rested at 4ºC for 20 minutes and then centrifuged at 15,000 rpm (12074 x g) for 20 
minutes at 4ºC. The Bradford protein assay was used to measure the concentration 
of the proteins (Bradford, 1976). For protein separation, an equal amount of lysate (60 
µg per well) in Laemmli sample buffer (62.5 mM Tris-HCl (pH 6.8), 4% SDS, 10% 
glycerol, 0.03% Bromophenol blue and 5% mercaptoethanol) were separated by SDS-
PAGE using 12% stain-free SDS-polyacrylamide gel. The stain-free gels were then 
photoactivated for immediate vitalisation of proteins in the gel using Bio-Rad 
Chemidoc-XRs imager (Bio-Rad Laboratories, USA). The Stain-free gel imaging 
technology utilizes a proprietary polyacrylamide gel chemistry to make proteins 
fluorescent directly in the gel allowing visualization of proteins at any stage of blotting, 
without staining the gel (BioRad Laboratories, 2019). The proteins were transferred to 
polyvinylidene fluoride (PVDF) membrane, blocked for an hour with 5% long life fat-
free milk in Tris-buffered Saline-Tween (TBS-T: 20 mM Tris-HCl (pH 7.6), 137 mM 
NaCl, 0.1% Tween-20). PVDF membranes were then probed with the specific primary 
antibody in TBS-T by overnight shaking at 4ºC (1:1000 dilutions of phosphorylated or 
total primary antibodies: Total ERKp44/p42, phospho-ERKp44/p42 (Thr202/Tyr204), 
total PKB, and phospho-PKB/ (Ser473), phospho-CREB (Ser133), total-CREB, cleaved 
caspase-3 from Cell signalling. Membranes were washed with TBS-T and then 
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incubated with horseradish peroxidase-linked secondary antibody (Cell signalling, 
USA) at 1:4000 dilution for an hour at room temperature. The protein signal was 
enhanced with a chemiluminescent agent (Bio-Rad Laboratories, USA) and quantified 
using a Chemidoc-XRs imager and analysed with Image Lab 5 Software (Bio-Rad 
Laboratories, USA).  
 
In addition, a Stain-Free technology was used for quality control and this approach 
offers a novel and unique quality control for data normalization in a standardized 
manner (Taylor and Posch, 2014). Briefly, the Stain-Free gels were activated with UV 
in Chemidoc-XRs imager and the proteins bands become visible and captured with a 
camera. After the proteins were transfer to the PVDF membranes, the blot (reference 
blot) is immediately imaged to verify the transfer of proteins for each lane. The image 
data is then analysed using Image lab software by selecting is a single band in each 
lane and stretched the band width to cover all volume peaks in a lane profile. The blot 
is then probed for a specific antibody and normalized using the reference blot images. 
 
 
2.2.9 Epac/Rap1 activation assay (Pull-down assay) 
 
 Rap is a small GTPase that regulates molecular events by cycling an inactive GDP-
bound form and an active GTP-bound form. The Rap1 assay is based on the 
differential affinity of Rap1 GTP-bound form and Rap1 GDP-bound form for Rap 
binding domain of Ral GDS. For determination of Epac activation, the downstream 
Rap1 activation assay was performed with a Rap1-activity Assay Kit (EMD Millipore 
Corp, MA, USA) according to the manufacturer’s instructions. The Rap1 assay utilizes 
Ral GDS-RBD agarose beats to selectively isolate and pull down the activated GTP 
form of Rap1. Briefly, the left ventricle of the hearts was removed and snap-frozen 
after 15 min pre-treatment with CPT and ESI-09 during the perfusion protocol. The 
samples were homogenised in the provided Rap1 activation lysis buffer  [Tris-HCl 100 
mM, pH 7.4, NaCl 1 M, NP40 2%, MgCl2  5 mM and glycerol 10%] which was 1:1 
diluted, prior to use, with 10% glycerol in deionized water and added 10 µg/ml 
aprotinin, 10 µg/ml leupeptin 25 mM, sodium fluoride and 1mM sodium orthovanadate. 
The heart lysates were by centrifugation for 10 minutes at 15,000 rpm and the Bradford 
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assay was used for protein determination. An equal amount of proteins was added in 
each tube and incubated with Ral- GDS-RBD agarose beads for 45 minutes at 4ºC. 
The beads were rinsed three times with ice-cold lysis buffer, resuspended in 40 µl of 
2X Laemmli reducing sample buffer and 2 µl of 1 M dithiothreitol prior to boiling for 5 
minutes. Then, the activated Rap1 GTP is detected by western blotting (as described 
in section 2.2.8) using the anti-Rap1 primary antibody.  
 
2.2.10 Statistics  
 
All data are expressed as mean ± standard error of the mean (SEM) and Graph Pad 
Prism™ 6 used for statistical analyses. Comparisons of groups were performed by 
ANOVA (one-way analysis of variance) followed by Bonferroni post-hoc test or 
student’s t-tests (indicated in grey asterisk) where applicable. Significance was 






























2.3 Results  
 
2.3.1 The effect of drugs (CPT and ESI-09) on cardiac function 
 
The effect of the Epac agonist, CPT and different concentrations of the Epac 
antagonist, ESI-09 on cardiac function was investigated using the heart perfusion 
protocol as shown in Figure 2.5. The baseline function was measured after 30 minutes 
Langendorff and 10 minutes working mode and the recovery function was measured 
after 15 minutes drug treatment and 10 minutes working mode. NOTE: the hearts were 
not subjected to ischaemia.  
 
 
Figure 2. 5 Perfusion protocol for drug effect on cardiac function. 
 
 
2.3.1 (a) Baseline cardiac function (before drug treatment)  
 
 Cardiac function was measured using the ex vivo working mode perfusion system. 
CF, AF, CO, HR, PSP and TW were measured before the hearts were perfused with 
either CPT 2 µM (see Appendix A, Figure A.2A) or different concentrations of ESI-09 
[5 µM, 10 µM and 20 µM]. Baseline parameters were comparable since there were no 














Table 2. 1 Baseline Cardiac function before treatment 
  
Control 
(n = 3) 
CPT 2 µM 9 
(n = 3) 
ESI-09 5 µM 
(n = 3) 
ESI-09 10 µM 
(n =  3) 
ESI-09 20 µM 
(n = 3) 
      
CF 




36.5 ± 1.7 
 
41.3 ± 1.3 
 
37.3 ± 0.7 
 
39.1 ± 1.5 
 




52.5 ± 1.7 
 
58 ± 1.5 
 
51.7 ± 1.4 
 
51 ± 1.5 
 




91 ± 1.8 
 
87.3 ± 1.3 
 
87 ± 4.1 
 
90.7 ± 2.9 
 




391 ± 44.1 
 
351 ± 5.8 
 
331 ± 43.1 
 
340 ± 48.2 
 




10.8 ± 0.4 
 
11.2 ± 0.3 
 
9.6 ± 0.3 
 
10.2 ± 0.7 
 
10.4 ± 0.7 
All values are expressed as means ± SEM. Comparisons of groups were tested by ANOVA. n = 3 per 
group. 
 
2.3.1 (b) Cardiac function after treatment 
 
Hearts treated with 5 µM ESI-09 had significantly lower heart rates compared to the 
CPT treated hearts (5 µM ESI-09: 225.7 ± 18.9 vs. CPT: 324.3 ±. 6.2, P<0.05) (Figure 
2.6A). The PSP of the hearts were not significantly affected by different drugs (Figure 
2.6B). There were no significant difference between CPT and the control in cardiac 
function of CF, AF, CO, and TW (Figure 2.7A, B, C and D). Furthermore, hearts treated 





Figure 2. 6 The effect of drugs on cardiac function 
A), Heart Rate (rpm, beat per minute), B), Peak Systolic Pressure of hearts treated with CPT [2 µM] 
and different ESI-09 [5 µM, 10 µM, and 20 µM] concentrations. All values are expressed as mean ± 










Figure 2. 7 The effect of drugs on cardiac function. 
A) Coronary flow, B) Aortic Flow, C) Cardiac Output, D) Total Work performance of hearts treated with 

















2.3.1 (C) Western blot measurements (activated Rap1)  
 
 Figure 2.8 represents Rap-GTP activation and  Rap-GDP expression in hearts. CPT 
[2 µM] significantly increased percentage GTP-Rap1 compared to control (CPT: 74 ± 
7.59% vs. control: 39.85 ± 0%, P<0.05) (Figure 2.8). Co-treatment of CPT [2 µM] + 
ESI-09 [20 µM] reduced the percentage GTP-Rap1 when compared to CPT treated 
hearts (ESI-09 [20 µM] + CPT [2 µM]: 43.94 ± 5.21%  vs. CPT [2 µM]: 74 ± 7.59%, 
P<0.05) (Figure 2.8). 
 
Figure 2. 8 Effect of Drugs on Rap1 Activation and expression.  
(A) representative blots for activated GTP-rap1 and total Rap; (B), percentage of activated rap1. n= 2-










2.3.2 Effect of drug pre-treatment on I/R: Cardiac function and Infarct size 
 
The hearts were pre-treated with CPT [2 µM] (Epac agonist), ESI-09 [5 µM] (Epac 
antagonist) and ISO [0.1 µM] (beta-adrenergic agonist) (see protocol in Figure 2.9). 
 
 
Figure 2. 9 Pre-treatment experimental protocol. 
 
2.3.2 (a) Cardiac Function before and after ischaemia  
 
Table 2.2 demonstrates cardiac function before and after regional ischaemia. 
Comparable baseline cardiac function was observed as there were no significant 
differences among the groups before ischaemia groups (Table 2.2).  
 
There were no differences in post-ischaemic function in terms of CF, CO, PSP and 
HR among the treatment groups after 35 minutes of regional ischaemia and 65 
minutes reperfusion (Table 2.2).  
 
Epac inhibition with ESI-09 was detrimental on cardiac recovery post-I/R (Table 2.2). 
Co-treatment with CPT did not reverse the effects of ESI-09 (Table 2.2). Beta-
adrenergic stimulation with ISO increased AF compared to control (ISO: 31.7 ± 1.9 vs. 
control: 19 ± 1.5, P<0.01). Co-treatment of ISO with ESI-09 could not reverse the 







Table 2. 2 Drug pre-treatment: Cardiac function before and after 35 min regional ischaemia and 35 min reperfusion. 
 Control (n = 13) CPT (n = 4) ESI-09 (n = 3) ESI-09+CPT (n = 3) ISO (n = 3) ISO+ESI-09 (n = 5) 
Cardiac function before drug administration and ischaemia   
CF  
(ml/min) 10.8 ± 2.9 12 ± 1.2 14.6 ± 0.7 10.7 ± 1.3 13.3 ± 1.3 13.8 ± 1.03 
AF  
(ml/min) 35.3 ± 0.7 38.7 ± 2.4 41.3 ± 1.33 42.1 ± 1.33 40.7 ± 0.7 39 ± 1.7 
CO (ml/min) 47.3 ± 1.3 50.7 ± 1.3 56 ± 2.1 54.1 ± 2.2 54 ± 1.2 52.8 ± 2.4 
PSP (mmHg) 79.7 ± 4.4 86.3 ± 0.1 94 ± 0.1 86.3 ± 1.7 97.3 ± 8.9 84.8 ± 0.1 
HR  
(bpm) 360 ± 28.8 296 ± 26.6 311 ± 28.5 329 ± 27.3 268 ± 21.5 364 ± 40.6 
TW (mWatts) 9.8 ± 0.4 9.6 ± 0.3 11.7 ± 0.5 10.8 ± 0.8 10.2 ± 0.4 10.5 ± 0.6 
 
Cardiac function after ischaemia  
CF  
(ml/min) 11 ± 1.1 10.2 ± 1.5 11.1 ± 1.5 10 ± 2.5 14.3 ± 1.8 13 ± 1.47 
AF 
 (ml/min) 19 ± 1.5 24.1 ± 6.3 0 0 31.7 ± 1.9* 0 
CO 
(ml/min) 30 ± 2.5 35.5 ± 6.5 11.1 ± 1.5 12.7 ± 4.3 45.67 ± 3.8 13.2 ± 1.5 
PSP 
(mmHg) 77 ± 3.1 78 ± 2.6 67 ± 5.5 76.7 ± 2.3 88.3 ± 5.6 71 ± 0.4 
HR 
(bpm) 336 ± 18.3 297 ± 44.5 183 ± 23.9 245 ± 61.4 304 ± 18.77 146 ± 21.5 
TW  
mWatts) 3.2 ± 0.8 5.8 ± 0.8 0 0 8.3 ± 1.7 0 
All values are expressed as mean ± SEM. Comparisons of groups were tested by ANOVA.  n = 3-13 per group. *p < 0.05 vs Control. .  (“zero”, the hearts did 




2.3.2 (b) Recovery of cardiac function 
 
 
ISO pre-treated hearts had a significant improvement in the percentage recovery of 
CO compared to control hearts (ISO: 84.4 ± 4.6 % vs. control: 46.5 ± 5.5%, P<0.05) 
(Figure 2.10A). The percentage recovery of TW between CPT pre-treated hearts and 
the control hearts was not significantly different. However, the beta-adrenergic agonist 
ISO significantly improved the percentage recovery of TW compared to the control 
hearts (ISO: 82.1 ± 19.3 % vs. control: 31.5 ± 7.8 %, P<0.05) (Figure 2.10B). Epac 
inhibition with ESI-09 [5 µM] was detrimental to the percentage recovery post I/R 





   
 
Figure 2. 10 Cardiac output and Total work of hearts after 35 min regional ischaemia and 30 
min reperfusion, pre-treated with CPT [2 µM], ESI-09 [5 µM] and ISO [0.1 µM] 15 min before 
ischaemia. 
(A) Cardiac output, percentage recovery; (B) Total work, percentage recovery. All values are expressed 












2.3.2 (c) Infarct size  
 
Epac activation with CPT before ischaemia significantly reduced infarct size compared 
to control hearts (CPT: 8.2 ± 1.7% vs. control: 23.7 ± 2.9%, P<0.01) (Figure 2.11A). 
Furthermore, beta-adrenergic stimulation with ISO also reduced infarct size compared 
to control hearts (ISO: 6.1 ± 2.2% vs. control: 23.7 ± 2.9%, P<0.01) (Figure 2.11A).  
 
With regard to the effect of ESI-09: Firstly, ESI-09 did not affect the percentage infarct 
size compared to control. Secondly, the protection by CPT and ISO was lost/reversed 
when co-treated with ESI-09, because ESI-09+CPT and ESI-09+ISO were not 
significantly different compared to control. Thirdly, ESI-09 significantly increased the 
percentage of total area at risk compared to control (ESI-09: 65.75 ± 4.1% vs. Control: 
47.9 ± 1.1%, P<0.001; ESI-09+CPT: 62.9 ± 3.8% vs. control: 47.9 ± 1.1%, P<0.01) 
(Figure 2.11B). This could be due to the fact that the hearts were unable to perfuse 
the Evans blue dye for viable tissue since ESI-09 impaired the cardiac function (Figure 
2.10). It is essential that the total area at risk should be the same/comparable among 






Figure 2. 11 Infarct size and Area at risk of hearts after 35 min regional ischaemia and 60 min 
reperfusion, pre-treated with CPT [2 µM], ESI-09 [5 µM] and [ISO 0.1 µM] 15 min before ischaemia. 
(A), Infarct size, percentage of the area at risk; (B), Area at risk, percentage of the left ventricle. All 






2.3.3 Effect of drug Post-treatment on I/R: cardiac function, infarct size and 
signalling pathways 
 
The hearts were post-treated with CPT [2 µM] (Epac agonist) and ESI-09 [5 µM] 
(Epac antagonist) (see protocol in Figure 2.12). 
 
 
Figure 2. 12 Post-treatment experimental protocol.  
 
 
2.3.3 (a) Cardiac Function before and after ischaemia (see protocol in Figure 2.12). 
 
Comparable baseline cardiac function was observed as there were no significant 
differences among the groups before ischaemia (Table 2.3). There were no 
differences in post-ischaemic function in terms of CF, AF, CO, PSP, HR and TW 
among the treatment groups after 35 minutes of regional ischaemia and 30 minutes 
reperfusion (Table 2.3). Post-treatment with Epac inhibitor ESI-09 was detrimental on 
















Table 2. 3 Drug post-treatment: Cardiac function before and after 35 min regional ischaemia and 30 min reperfusion. 
 DMSO 0.01% (n = 8) CPT (n = 6) ESI-09 (n = 5)  CPT+ESI-09 (n = 7) 
Cardiac function before ischaemia 
CF (ml/min) 13.4 ± 0.8 14.8 ± 0.8 15.2 ± 1.0 12.4 ± 1.2 
AF (ml/min) 38.5 ± 1.1 37.4 ± 1.2 38.4 ± 0.7 37.6 ± 1.2 
CO (ml/min) 51.9 ± 1.5 52.2 + 1.6 53.6 ± 1.4 50.0 ± 2.3 
PSP (mmHg) 80.5 ± 1.4 83. 4 ± 1.0 86.6 ± 2.5 87.6 ± 2.8 
HR (bpm) 313 ± 15.8 315 ± 9.6 385 ± 40.3 256 ± 4.33 
TW (mWatts) 9.1 ± 0.3 9.9 ± 0.3 8.3 ± 1.8 9.8 ± 0.7 
     
Cardiac function after ischaemia 
CF (ml/min) 12.5 ± 0.7 15.4 ± 1.5 12.2 ± 1.4 13.6 ± 1.2 
AF (ml/min) 13 ± 2.3 18.8 ± 0.8 0  0 
CO (ml/min) 25.5 ± 2.5 34.2 ±1.2 12.2 ± 1.4 15.2 ± 2.4 
PSP (mmHg) 72.3 ± 1.5 77.1 ± 1.1 66.4 ± 2.2 75.8 ± 3.9 
HR (bpm) 367 ± 16.2 330 ± 49.9 258 ± 23.5 279 ± 22.5 
TW (mWatts) 4.5 ± 0.5 6.1 ± 0.2 0 0 
     






2.3.3 (b) Recovery of cardiac function  
 
Epac activation with CPT during reperfusion did not change the percentage recovery 
of CO and TW compared to the vehicle control (DMSO 0.01%) (Figure 2.13A and B). 
However, in our pilot study (PhD proposal) post-treatment with CPT significantly 
improved total work performance (TW %) compared to normal control (without the 
vehicle DMSO) (see Appendix A, Figure A.3). Post-treatment with Epac inhibitor ESI-




   
 
Figure 2. 13 Cardiac output and Total work of hearts, after 35 min regional ischaemia and 30 
min reperfusion, post-treated with an Epac activator [CPT 2 µM] and Epac inhibitor [ESI-09 5 µM] 
in the first 10 minutes reperfusion. 
(A), Cardiac output, percentage recovery; (B), Total work, percentage recovery. All values are 















2.3.3 (c) Infarct size  
 
Epac activation with CPT at the onset of reperfusion, significantly reduced infarct size 
compared to vehicle-control hearts (CPT: 11.6 ± 2.4% vs. DSMO: 23.8 ± 1.2%, 
P<0.05) (Figure 2.14A). Interestingly, hearts post-treated with ESI-09 had no 
significant effect on the infarct size (Figure 2.14A), but (as seen before with pre-
treatment, Figure 2.11B) significantly increased the area at risk compared to the 
vehicle-controls (ESI-09: 66.7 ± 2.5% vs DMSO: 47.0 ± 1.3%, P<0.05) (Figure 2.14B). 
However, the combination of ESI-09 with CPT did not reverse the small infarct size 
(Figure 2.14A) and the area at risk (Figure 2.14B) was not significantly increased as 





Figure 2. 14 Infarct size and Area at risk of hearts after 35 min regional ischaemia and 60 min 
reperfusion, post-treated with an Epac activator [CPT 2 µM] and Epac inhibitor [ESI-09 5 µM] in 
the first 10 minutes reperfusion. 
(A), Infarct size, percentage of the area at risk; (B), Area at risk, percentage of the left ventricle. All 






2.3.3 (d) Signaling Pathways (protein phosphorylation and expression during 
reperfusion)  
 
There were no differences in PKB phosphorylation among the groups (Figure 2.15B). 
ESI-09 post-treatment increased total PKB expression compared to the vehicle control 
(ESI-09: 1.6 ± 0.1 vs. DMSO: 1.0 ± 0.1, P<0.05) (Figure 2.15C). However, co-
treatment of ESI-09 with CPT significantly reduced the phospho: total PKB ratio 
compared to vehicle-control (ESI-09+CPT: 0.2 ± 0.1 vs. DMSO: 1.02 ± 0.2, P<0.01) 








Figure 2. 15 PKB phosphorylation and expression in hearts after 35 min regional ischaemia 
and 10 min reperfusion, post-treated with an Epac activator [CPT 2 µM] and Epac inhibitor [ESI-
09 5 µM] in the first 10 minutes reperfusion. 
(A), representative Western blots for phosphorylated and total PKB; (B), phosphorylated PKB levels; 
(C), total PKB levels; (D), phospho/total ratio for PKB. n = 3-4 per group. All values are expressed as 








Epac activation with CPT post-ischaemia had no effect on ERK1/2 phosphorylation, 
total expression or phospho: total ERK1/2 ratio compared to DMSO (Figure 12.16 B, 
C, and D).  
 
Epac inhibition with ESI-09 at reperfusion caused a significant reduction in ERK1/2 
phosphorylation compared to CPT treated hearts (ESI-09: 0.7 ± 0.11 vs. CPT: 1.0 ± 
0.1, P<0.001; ESI-09+CPT: 0.5 ± 0.03 vs. CPT: 1.0 ± 0.1, P<0.05) (Figure 2.16B). 
Furthermore, the phospho: total ERK1/2 ratio was also reduced by ESI-09 compared 
to CPT treated hearts (ESI-09: 0.6 ± 0.1 vs. CPT: 1.2 ± 0.2, P<0.01; ESI-09+CPT: 0.5 
± 0.03 vs. CPT: 1.2 ± 0.2, P<0.01) (Figure 2.16D). The total ERK1/2 expression 






































Figure 2. 16 ERK1/2 phosphorylation and expression in hearts after 35 min regional ischaemia 
and 10 min reperfusion, post-treated with an Epac activator [CPT 2 µM] and Epac inhibitor [ESI-
09 5 µM] in the first 10 minutes reperfusion. 
(A), representative Western blots for phosphorylated and total ERK1/2; (B), phosphorylated ERK1/2  
levels; (C), total ERK1/2 levels; (D), phospho/total ratio for ERK1/2. n = 3-4 per group. All values are 
expressed as mean ± SEM. *P<0.05, **P<0.01, ***P<0.001. 
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There were no significant differences in CREB phosphorylation, CREB total 
expression and phospho: total CREB ratio among the treatment groups (Figure 2.17B, 













Figure 2. 17 CREB phosphorylation and expression in hearts after 35 min regional ischaemia 
and 10 min reperfusion, post-treated with an Epac activator [CPT 2 µM] and Epac inhibitor [ESI-
09 5 µM] in the first 10 minutes reperfusion. 
(A), representative Western blots for phosphorylated and total CREB; (B), phosphorylated CREB levels; 
(C), total CREB levels; (D), phospho/total ratio for CREB. n = 3-4 per group. All values are expressed 
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Epac activation with CPT did not affect cleaved caspase-3 expression when compared 
to DMSO vehicle controls (Figure 2.18B). However, hearts post-treated with ESI-09 
showed a significant increase in cleaved caspase-3 expression compared to DMSO 














Figure 2. 18 Cleaved Caspase-3 expression in hearts after 35 min regional ischaemia and 10 
min reperfusion, post-treated with an Epac activator [CPT 2 µM] and Epac inhibitor [ESI-09 5 µM] 
in the first 10 minutes reperfusion. 
 (A), representative Western blots for cleaved Caspase-3; (B), cleaved Caspase-3 levels. n = 3-4 per 
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2.3.4 Possible mechanism of protection: Epac stimulation and the Reperfusion 
Injury Salvage Kinase (RISK) pathway 
 
In order to determine the mechanism of cardioprotection by Epac on I/R injury, the 
involvement of the Reperfusion injury salvage kinase (RISK) pathway was 
investigated by post-treatment of CPT (2 µM) with a MEK-ERK inhibitor (PD98059, 10 




Figure 2. 19 Post-treatment protocol 
2.3.4 (a) Cardiac Function before and after ischaemia  
 
Comparable baseline cardiac function was observed as there were no significant 
differences among the groups before ischaemia (Table 2.4). There were also no 
differences in post-ischaemic function in terms of CF, PSP, HR among the post-
treatment groups after 35 minutes of regional ischaemia and 30 minutes reperfusion 
(Table 2.4). Post-treatment with CPT had no significant effect on the post-ischaemic 
function of AF, CO and TW compared to DMSO-vehicle control. PKB inhibition with 
A6730 reduced the post-ischaemic function of AF (P<0.01 vs. DMSO; P<0.01 vs. 
CPT), CO (P<0.001 vs. DMSO; P<0.0001 vs. CPT) and TW (P<0.01 vs. DMSO; 
P<0.0001 vs. CPT) compared to CPT and DMSO treated hearts (Table 2.4).  
Furthermore, co-treatment of CPT and A6730 did not reverse the detrimental effects 
of A6730 on the recovery of AF, CO and TW. Furthermore, ERK1/2 inhibition with 
PD98058 significantly reduced the recovery CO compared to CPT (P<0.05 vs. CPT) 
(Table 2.4). The co-treatment of CPT with PD98058 did not reverse the effect of 








Table 2. 4 Cardiac function of the different post-treated groups before and after 35 min regional ischaemia and 30 min reperfusion. 
 DMSO 0.01% (n = 8) CPT (n = 7) A6730 (n = 8) A6730+CPT (n = 4) PD98058 (n = 8) PD98058+CPT (n = 6) 
Cardiac function before ischaemia  
CF (ml/min) 13.4 ± 0.8 12.5 ± 0.8 12.6 ± 0.5 12.9 ± 0.9 13.4 ± 0.6 12.9 ± 0.1 
AF (ml/min) 38.5 ± 1.1 39.6 ± 1.1 40.4 ± 1.2 38.3 ± 0.8 38.8 ± 1.5 40.1 ± 1.2 
CO (ml/min) 51.7 ± 1.2 52.1 ± 1.6 52.9 ± 1.9 51.2 ± 1.7 52.2 ± 1.9 53.1 ± 1.3 
PSP (mmHg) 80.5 ± 1.4 82.9 ± 1.2 83.4 ± 1.8 81.0 ± 1.3 83.9 ± 1.9 82.8 ± 1.8 
HR (bpm) 313 ±1 5.8 310 ± 6.1 321 ± 15.9 320 ± 8.4 319 ± 11.4 325 ± 11.9 
TW (mWatts) 9.3 ± 0.3 9.6 ± 0.3 9.8 ± 0.4 9.1 ± 0.4 9.7 ± 0.4 9.7 ± 0.3 
 
Cardiac function after ischaemia  
CF (ml/min) 12.5 ± 0.7 14.9 ± 0.7 11.1 ± 1.3 12.7 ± 1.4 11.3 ± 0.7 11.8 ± 0.9 
AF (ml/min) 13.1 ± 2.3 15.1 ± 3.6 1.8 ± 1.4*† 0.9 ± 0.9*† 6.1 ± 2.5 8.3 ± 2.1 
CO (ml/min) 26.9 ± 2.4 30.1 ± 3.8 12.9 ± 2.1*† 13.6 ± 2.0*† 17.6 ± 2.8† 17.38 ± 2.4† 
PSP (mmHg) 72.3 ± 1.5 72.3 ± 1.2 61.3 ± 7.8 64.9 ± 2.3 72.1 ± 2.5 72.5 ± 1.4 
HR (bpm) 366 ± 16.2 341 ± 12.8 302 ± 57.9 313 ± 18.9 340 ± 17.9 353 ± 14.1 
TW (mWatts) 4.1 ± 0.5 5.2 ± 0.7 1.1 ± 0.4*† 0.7 ± 0.5*† 2.4 ± 0.7 2.9 ± 0.5 





2.3.4 (b) Recovery of cardiac function  
 
There were no differences in the percentage recovery of CO and TW between the 
CPT treated hearts and DMSO control hearts (Figure 2.20A and B). PKB inhibition 
significantly reduced the percentage recovery of CO and TW compared to DMSO 
vehicle control (CO: A6730: 25.7. ± 4.9 % vs. DMSO: 52.96 ± 4.7 % P<0.01) and (TW:  
A6730: 9.9 ± 4.1 % vs. DMSO: 44.9 ± 5.1%, P<0.01) (Figure 2.20A and B). Co-
treatment of CPT with A6730 also significantly decreased the percentage recovery of 
CO and TW compared the CPT treated hearts (CO: A6730+CPT: 29.44 ± 4.6 % vs 
CPT: 55.9 ± 6.7 %, P<0.05) and (TW: A6730+CPT: 6.89 ± 4.8 % vs. CPT: 42.2 ± 9.84 
%, P<0.01) (Figure 2.20A). ERK1/2 inhibition with PD98058 had no significant effect 
on both CO and TW percentage recovery (Figure 2.20B and C).  
9.9 ± 4.1 
 
 
Figure 2. 20 Cardiac output and Total work of hearts after 35 min regional ischaemia and 30 
min reperfusion, post-treated with an Epac activator [CPT 2 µM], PKB inhibitor [A6730 2,5 µM] 
and MEK-ERK inhibitor [PD98058 10 µM] in the first 10 minutes reperfusion.  
(A), Cardiac output, percentage recovery; (B), Total work, percentage recovery. All values are mean ± 







2.3.4 (c) Infarct size  
 
Epac activation with CPT post-ischaemia significantly reduced infarct size compared 
to vehicle controls (CPT: 11.2 ± 1.6% vs. DMSO: 24.8 ± 1.1%, P<0.0001) (Figure 
2.21A). A significant increase in infarct size was noted in hearts treated with A6730 
compared to DMSO-controls (A6730: 31.4 ± 1.4% vs. DMSO: 24.8 ± 1.1%, P<0.05) 
(Figure 2.21A). However, the co-treatment of CPT with PKB inhibitor, A6730 reversed 
the effects of both CPT and A6730, resulting in no significant difference when 
compared to the DMSO-controls. Co-treatment of CPT with ERK1/2 inhibitor 
PD098058 significantly increased the infarct size when compared to hearts treated 
with CPT alone (PD98058+CPT: 28.1 ± 4.8% vs. CPT: 11.2 ± 1.6%, P<0.05) (Figure 






Figure 2. 21 Infarct size and Area at risk of hearts after 35 min regional ischaemia and 60 min 
reperfusion, post-treated with an Epac activator [CPT 2 µM], PKB inhibitor [A6730 2,5 µM] and 
MEK-ERK inhibitor [PD98058 10 µM]  in the first 10 minutes reperfusion. 
(A), Infarct size, percentage of area at risk; (B), Area at risk, percentage of the left ventricle. All values 









2.4 Discussion  
 
The availability of a selective Epac agonist (CPT) and antagonist (ESI-09) made it 
possible to evaluate the involvement of Epac in the setting of beta-adrenergic induced 
cardioprotection. Therefore, in this preliminary study, we evaluated the specific role of 
Epac on myocardial I/R injury in a normal body weight rat model. Our results indicated 
that Epac stimulation pre- or post-ischaemia improved myocardial damage (Infarct 
size). In addition, treatment, but not post-treatment, with CPT also improved functional 
recovery. Furthermore, pharmacological inhibition of the RISK pathway suggested 
partial involvement of ERK1/2 and PKB in CPT-induced cardioprotection (Infarct size).  
 
2.4.1 Effect of selective drug treatment on cardiac function of healthy rat 
hearts 
 
In the current study, Rap1 activation was significantly higher in hearts pre-treated with 
CPT [2 µM] compared to untreated hearts (Figure 2.8). Co-treatment with an Epac 
inhibitor ESI-09 [20 µM] significantly reduced Rap1 activation compared to CPT. We 
also found that ESI-09 had detrimental effects on cardiac function (Figure 2.7), but 
peak systolic pressure was not affected (Figure 2.6). Even though ESI-09 is a specific 
inhibitor for Epac 1 and 2 (Chen et al., 2013; Zhu et al., 2015), it was previously 
reported to have general protein denaturing properties, suggesting that ESI-09 
“inhibitory” properties might originate from its protein destabilizing effect (Rehmann, 
2013). This raised a concern that ESI-09 may not act exclusively on Epac (Rehmann, 
2013). However, other studies have demonstrated that ESI-09 inhibits Epac functions 
in vitro (Almahariq et al., 2012) and in vivo (Gong et al., 2013). Zhu and co-workers 
(2017) have also demonstrated that ESI-09 acts as a competitive inhibitor for Epac at 
a concentration below 20 µM, but that non-specific binding or protein denaturing are 
a concern at higher concentrations (Zhu et al., 2015). In the present study, we decided 
to use the lower concentration of ESI-09 [5 µM] even though the CPT-induced Rap1 
activation was significantly reduced with ESI-09 co-treatment at a concentration of 20 
µM (Figure 2.8). This was mainly due to the detrimental effects of ESI-09 [20 µM] on 
cardiac function (Figure 2.6 and 2.7). This further also proves the importance of Epac 
in normal cardiac function. In support of our decision on the ESI-09 concentration of 5 
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µM other studies have used concentrations of ESI-09 as low as 1 µM (Khaliulin et al., 
2017).  
 
2.4.2 The contribution of Epac activation in beta-adrenergic induced 
cardioprotection against I/R: Pre-treatment study  
 
We investigated the effects of pre-treatment with isoproterenol (ISO 0.1 µM) (a beta-
agonist) in comparison to CPT 2 µM (Epac agonist) on cardiac function and infarct 
size in hearts subjected to I/R injury. After I/R, it was evident that pre-treatment with 
ISO protected the hearts against I/R injury. ISO significantly reduced myocardial 
damage (infarct size) (Figure 2.11) and improved the percentage recovery of cardiac 
output and total work performance (Figure 2.10). These results confirmed the initial 
studies (Lochner et al., 1999), which demonstrated that pharmacological 
preconditioning with ISO/Forskolin protected hearts from I/R injury through cAMP 
elevation (Lochner et al., 1999; Marais et al., 2001). The latter and resultant PKA 
activation during preconditioning was considered a prerequisite for cardioprotection 
(Lochner et al., 1999). However, reducing PKA activity in Forskolin-preconditioned 
hearts with H89 (non-specific PKA inhibitor) did not abolish cardioprotection but rather 
promoted it (Makaula et al., 2005). Thus, suggesting the involvement of an alternative, 
PKA-independent, pathway in cAMP-induced cardioprotection. It was discovered that 
cAMP downstream effects were not only via PKA but Epac proteins as well (Bos, 2006; 
De Rooij et al., 1998; Kawasaki et al., 1998). In addition, we have shown that direct 
activation of Epac proteins before I/R is cardioprotective.  
 
Pre-treatment with CPT (2 µM) (Epac agonist) improved the percentage cardiac output 
recovery (Figure 2.10). Furthermore, in similar studies performed previously,  Epac 
activation with CPT (10 µM) increased cardiac pump function (Khaliulin et al., 2017; 
Surinkaew et al., 2019), however, preconditioning with CPT (1 µM) had no effect on 
cardiac function after I/R injury (Duquesnes et al., 2010). CPT has been reported to 
exert positive inotropic effects (increase contractility) and positive lusitropy (increased 
relaxation rate) (Ruiz-Hurtado et al., 2012). Positive inotropic agents are associated 
with increased cardiac output (Amin and Maleki, 2012). However, sustained activation 
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of Epac proteins with CPT may exert negative effects such as proarrhythmic effects 
and cardiac hypertrophy (Brette et al., 2013; Ruiz-Hurtado et al., 2012).   
 
The reduced myocardial damage (infarct size) (Figure 2.11) in the current study 
suggested that the [2 µM] CPT protection was Epac mediated. However, in a recent 
study, Epac activation with CPT [10 µM] did not protect the ex-vivo isolated rat hearts 
from I/R injury but simultaneous activation of Epac and PKA protected the hearts 
against I/R injury (Khaliulin et al., 2017).  
 
 
2.4.3 The role of Epac stimulation in cardioprotection against I/R injury: Post-
treatment study  
 
We investigated the effects of post-treatment with an Epac agonist (CPT) on cardiac 
function and infarct size in hearts subjected to I/R injury. Post-treatment with 2 µM 
CPT reduced myocardial infarction by approximately 48% compared to untreated 
hearts (Figure 2.14). Similar findings were reported in mice were Epac activation with 
CPT improved cardiac function, left atrial fibrosis and reduced infarct size post-
myocardial infarction (Surinkaew et al., 2019). However, Epac stimulation at 
reperfusion did not affect cardiac functional recovery compared to untreated hearts 
(Figure 2.13). In animal models, smaller infarct size after I/R injury is considered as 
the point reference or more reliable in cardioprotection and this not always associated 
with an improvement in cardiac functional/mechanical recovery (Cohen et al., 1999; 
Jenkins et al., 1995; Lochner et al., 2003; Salie et al., 2011). Clinically, infarct size is 
directly associated with mortality (heart failure and death) (Lønborg et al., 2010; 
McAlindon et al., 2015). Therefore, our findings suggest that Epac stimulation, during 
early reperfusion is cardioprotective. 
 
Furthermore, activation of the RISK pathway plays a central role in cardioprotection 
(Baxter et al., 2001; Yellon and Baxter, 1999). Epac mediated activation of the RISK 
pathway, selective inhibition of the RISK pathway with A6730 (PKB inhibitor) and 
PD98050 (MEK-ERK1/2 inhibitor) suggested the involvement of the RISK pathway 
based on the infarct size findings (Figure 2.21). However, in the current study, the 
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cardioprotective mechanism is not clear, as the western blot data indicated that 
CPT/Epac stimulation could not activate the ERK 1/2 or PKB (RISK pathway) (Figure 
2.15, Figure 2.16). We also found that co-treatment of CPT and ESI-09 reduced the 
phosphorylation of both ERK1/2 and PKB compared to untreated hearts. Therefore 
even though CPT’s effect on the RISK pathway was inconclusive, Epac inhibition with 
5 µM ESI-09 negatively affected the RISK pathway. This might explain the detrimental 
effects of ESI-09. In addition, we also found that ESI-09 significantly increased the 
pro-apoptotic caspase-3 versus untreated hearts (Figure. 2.18). Caspase-3 
overexpression is associated with an increase in infarct size and a reduced cardiac 
function (Condorelli et al., 2001; Mocanu et al., 2000; Teringova and Tousek, 2017) 
 
Our findings further proposed that post-treatment with CPT activates Epac 
independent of PKA-CREB. This was confirmed by the fact that CREB 
phosphorylation and expression was not affected by CPT treatment (Fig. 2.17) and 
therefore excluding the involvement of the PKA-CREB pathway. In conclusion, both 
pre- and post-ischaemic acute Epac stimulation with CPT (2 µM) protected the hearts 
against I/R injury (Surinkaew et al., 2019) via Epac-PKB and ERK1/2 pathway while 




















The role of Epac in myocardial I/R of ex vivo hearts from a 
rat model of high-calorie diet-induced obesity  
 
3.1 Introduction  
 
Obesity could increase the risk of coronary artery disease (CAD) and heart failure 
(Clark, 2003), and worsen outcomes from myocardial infarction (Aronson et al., 2010; 
Clavijo et al., 2006). Previous studies have demonstrated that myocardial injury 
(infarction) at reperfusion is mediated by the opening of mitochondrial permeability 
transition pore (mPTP) (Hausenloy and Yellon, 2007). Inhibition of mPTP via the 
Reperfusion injury salvage kinase (RISK) (ERK1/2 and PKB) pathway provides 
cardioprotection against I/R injury by preventing ROS accumulation and Ca2+ overload 
(Hausenloy and Yellon, 2007; Xia et al., 2016). In our preliminary studies, we have 
shown that cAMP is involved in mediating cardioprotection via the cAMP-Epac-PKB 
pathway (see Chapter 2, section 2.1).  
 
Knockout animal models have revealed diverse functions of Epac in different organs. 
In the brain, Epac1 deletion is associated with improved leptin sensitivity in mice fed 
high-fat diet (Yan et al., 2013) and Epac2 is associated with impaired leptin sensitivity 
(Hwang et al., 2017). Interestingly, Epac1 deletion is associated with the development 
of the metabolic syndrome followed by pancreatic !-cell dysfunction (Kai et al., 2013). 
Furthermore, studies with Rap1 knockout mice also showed metabolic syndrome 
characteristics and developed hepatic steatosis (Martínez et al., 2013). In vitro studies 
have revealed that Epac contributes to cardiac remodelling and arrhythmias (Lee et 
al., 2013; Okumura et al., 2014; Pereira et al., 2017; Yang et al., 2016). 
 
In the heart, Epac1 deletion has cardioprotective against isoproterenol- and ageing-
induced cardiomyopathy (Okumura et al., 2014). In knockout mice fed with a high-fat 
diet (HFD), Epac1 deletion increased infarct size, but HFD reduced infarct size in 
Epac2 knockout mice (Edland et al., 2016). In rats fed with a normal laboratory chow, 
pharmacological activation of Epac1/2 with CPT had no effect on infarct size. 
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However, co-treatment with a PKA activator (6-Bnz) and CPT reduced the infarct size 
(Khaliulin et al., 2017). Therefore, in the current study, we aimed to investigate the role 
of Epac in myocardial I/R, obesity and insulin resistance. Furthermore, we aimed to 
elucidate the mechanisms involved in Epac-induced cardioprotection by evaluation of 
the following: RISK pathway, nitric oxide signalling, calcium signalling, apoptotic 
signalling and autophagy.  
 
3.2 Methods  
 
3.2.1 General materials used 
 
Cell Signaling Technologies (Beverly, MA, USA): Antibodies   
 
1. Total ERKp44/p42 (catalogue number:  #9102)  
2. Phospho-ERKp44/p42 (Thr202/Tyr204) (catalogue number:  #9101) 
3. Total PKB (catalogue number:  #4691) 
4. Phospho-PKB (Ser473) (catalogue number:  #4058) 
5. Total AMPKα (catalogue number:  #5832) 
6. Phospho-AMPKα (Thr172) (catalogue number:  #2535) 
7. Total CaMKII (pan) (catalogue number:  #4436) 
8. Phospho-CaMKII (Thr286) (catalogue number:  #12716) 
9. Calcineurin (pan) (catalogue number: #2614) 
10. cleaved-Caspase-3 (catalogue number:  #9664)  
11. Total eNOS (catalogue number: #9572) 
12.  Phospho-eNOS (Ser1177) (catalogue number: #9571) 
13. Total GSK3β (catalogue number: #9315) 
14.  Phospho- GSK3β (Ser9) (catalogue number: #9336) 
15. Total DRP1 (catalogue number: #8570) 
16.  Phospho-DRP1 (Ser616) (catalogue number: #3455) 
17. Total ULK1 (catalogue number: #8054) 
18.  Phospho-ULK1 (Ser555) (catalogue number: #5869) 
19. Cleaved PARP (catalogue number: #5625) 
Santa Cruz Biotechnology (Dallas, TX, USA): Antibodies 
1. Nitrotyrosine (catalogue number:  #39B6) 
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3.2.2 Animal and ethical approval  
 
The study was approved by the University of Stellenbosch animal ethics committee 
(SU-ACUD14-00020). Animals used were housed at the University of Stellenbosch 
Central Research Facility (Tygerberg Campus). The animals were treated in 
accordance with the South African National Standard (SANS) guidelines for animal 
care and usage. The rats had free access to food and water and house in a 
temperature of (22°C), the humidity of (40%) and a 12 hour light/dark cycle. Male 
Wistar rats weighing (180-200 g) were fed either a control diet (CD), of standard 
laboratory rat chow or a high-calorie diet (HC), of rat chow supplemented with sucrose 
and Holsum cooking fat, for 16 weeks (Table 3.1). 
 
Table 3. 1 Macronutrient content of experimental diets 
Macronutrient  (CD) Control Diet (HC) High-calorie diet 
Fat (g/100g) 4.8 11.5 
Cholesterol (mg/100g) 3.0 13 
Sugar (g/100g) 6.6 24.4 
Carbohydrate (%)  34.6 42 
Protein (%)  17 8.3 




3.2.3 Rat Heart Perfusion Technique 
 
The isolated working heart model was used, using the well-characterized perfusion 
technique as described previously (Lochner et al., 1999; Salie et al., 2019). The 
detailed description of the heart perfusion protocol is in Chapter 2, Section 2.2.3.  
 
3.2.4 Experimental protocol 
 
Hearts were stabilized for 55 minutes followed by 35 minutes of regional ischaemia 
(see section 2.2.4) and 60 minutes reperfusion.  Drug administration was through an 
aortic cannula and perfused retrogradely in the first 10 minutes of reperfusion (post-
treatment). The hearts were perfused with an Epac selective-agonist, 8-pCPT-2'-O-
Me-cAMP (CPT, 2 µM) or novel Epac inhibitor, ESI-09 (5 µM) (Figure 3.1). In order to 
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investigate the mechanism of Epac-induced cardioprotection on ischaemia-
reperfusion injury, the involvement of RISK pathway was investigated by co-treatment 
of CPT (2 µM) with a MEK-ERK inhibitor (PD98059, 10 µM), and a selective PKB 
inhibitor (A6730, 2,5 µM) respectively (Figure 3.1).  
 
 
Figure 3. 1 Heart perfusion protocol for cardiac function and infarct size determination. 
DMSO 0.01%: vehicle control, CPT: Epac agonist (2 µM), ESI-09: Epac antagonist (5 µM), A6730: 
selective PKB inhibitor (2,5 µM) and  PD98059: MEK-ERK inhibitor (10 µM).  
 
 
3.2.5 Assessment of cardiac function 
 
Cardiac function was assessed and described in Chapter 2, section 2.2.6. Briefly, 
baseline measurements were taken 10 minutes into working mode during stabilization 
(Figure 3.1) and that included coronary flow (CF) (ml/min), aortic output (AO) (ml/min), 
cardiac output (CO) (ml/min), heart rate (HR) (bpm), peak systolic pressure (PSP) 
(mmHg) and total work performance (TW) (mWatts). Post-regional ischaemia cardiac 
function measurements were taken 20 minutes into working mode during reperfusion. 
Functional recovery was assessed as post-ischaemic CO and TW expressed as a 









3.2.6 Assessment of infarct size 
 
After an hour of reperfusion, the coronary artery was re-occluded permanently, and 
~1ml of a 0.25% Evans blue solution was infused via the aorta to outline viable tissues 
(see Chapter 2, Section 2.2.7 for detailed description). Briefly, the heart was sectioned 
and stained with 1% w/v triphenyl tetrazolium chloride in phosphate buffer (pH 7.4) 
and then fixed in 10% v/v formaldehyde solution. The volume of infarcted tissue (I) 
and the area at risk (R) were determined using computerised planimetry (UTHSCSA 
Image Tool, University of Texas Health Science Centre at San Antonio, Texas). The 
infarct size was expressed as a percentage of the area at risk (I/R %) as described by 
Lochner et al (2003). 
 
3.2.7 Western blot measurements  
 
After 10 minutes of reperfusion (Figure 3.2) the left ventricle was removed and snap-
frozen in liquid nitrogen and stored at -80°C for Western blot analysis as previously 
described in Chapter 2, section 2.2.8, to assess the degree of phosphorylation and 
total expression of pro-survival kinases: Total ERKp44/p42 (1:1000), phospho-
ERKp44/p42 (Thr-202/Tyr-204) (1:1000), total PKB (1:1000), and phospho-PKB (Ser473) 
(1:1000); metabolic signalling: total AMPKα (1:1000) and phospho-AMPKα (Thr172) 
(1:1000); calcium signalling: total CaMKII!	 (1:1000), phospho-CaMKII (Thr286) 
(1:1000) and Pan-Calcineurin (1:1000); oxidative stress: Nitrotyrosine (1:1000); 
apoptotic signalling: cleaved-PARP(1:1000) and cleaved-Caspase-3 (1:1000); nitric 
oxide signalling: total eNOS (1:1000 with SignalBoostTM immunoreaction Enhancer 
Kit) and phospho-eNOS (Ser1177) (1:1000 with SignalBoostTM immunoreaction 
Enhancer Kit); glycogen synthase kinase-3 (GSK3) signalling: total GSK3β (1:1000) 
and phospho- GSK3β (Ser9) (1:1000); autophagy: total (Dynamin-related protein 1) 
DRP1 (1:1000) and phospho-DRP1 (Ser616) (1:1000) and total (Unc-51 like autophagy 
activating kinase 1) ULK1 (1:1000) and Phospho-ULK1 (Ser555) (1:1000). All primary 






Figure 3. 2 Heart perfusion protocol for western blot determination. 
DMSO 0.01%: vehicle control, CPT: Epac agonist (2 µM), ESI-09: Epac antagonist (5 µM), A6730: 
selective PKB inhibitor (2,5 µM) and  PD98059: MEK-ERK inhibitor (10 µM).  
 
3.2.8 Statistics  
All data are expressed as mean ± standard error of the mean (SEM) and Graph Pad 
Prism™ 6 used for statistical analyses. Comparisons of groups were performed by 
ANOVA (one-way) followed by Bonferroni’s post-test or student’s t-tests (indicated in 





















3.3 Results  
 
3.3.1 Body weight, heart weight, glucose level and HOMA-IR after 16 weeks 
feeding  
 
This study was part of a much larger cohort of rats.  The food consumption, water 
intake, oral glucose tolerance test (OGTT) and homeostatic model for insulin 
resistance (HOMA-IR) were assessed by Dr Sybrand Smith as part of his PhD study 
(2018) (see supplementary Appendix A Table A.1 and Figure A.1). In summary: after 
16 weeks of feeding the HC group had elevated non-fasting blood glucose levels (HC: 
7.78 ± 0.14 vs. CD: 6.88 ± 0.11, P<0.001, N= 63-65 per group) (Table A.1), increase 
in HOMA-IR index (HC: 3.5 ± 0.34 vs. CD: 2.2 ± 0.3, P < 0.05, N = 4) (Figure A.1C) 
and developed insulin resistance (according to OGTT measurements) (Figure A.1A).  
 
In addition, the HC group had a significant increase in body weight (HC: 388.5 ± 6.99 
g vs CD: 354.8 ± 6.33 g, P<0.001) and intraperitoneal fat percentage (HC: 6.38 ± 0.22 
% vs CD: 3.87 ± 0.17 %, P<0.0001) (Figure 3.3A, B and C) compared to the CD group. 
However, there were no significant changes in heart weight or heart weight/body 





















Figure 3. 3 Body weights (BW) and intraperitoneal fat (IP) percentage in control diet (CD) and 
high calorie diet (HC). 
(A), Body weight (BW) at (16 weeks); (B), intraperitoneal fat; (C), % intraperitoneal fat/body weight; (D), 
Heart weight (HW); (E), Ratio (heart weight/body weight); (F), Ratio (heart weight/tibia length). All 
values are expressed as mean ± SEM.  *p < 0.05. n = 34-38 per group. 
 
3.3.2 Baseline cardiac function (pre-ischaemic) 
 
The cardiac function was determined on the ex vivo working heart perfusion system. 
Haemodynamics such as coronary flow (CF), aortic output (AO), cardiac output (CO), 
heart rate (HR), peak systolic pressure (PSP) and total work performance (TW) were 
measured before the hearts were subjected to 35 minutes regional ischaemia (Table 
3.2). There were no significant differences between the baseline, pre-ischaemic 
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3.3.3 Cardiac function of the different post-treated groups after 35 min regional 
ischaemia and 30 min reperfusion (post-ischaemic) 
 
There were no significant differences post-ischaemia in CF, AO, CO, HR, PSP, and 
TW between hearts of vehicle-controls from the control diet (CD+DMSO 0.01%) and 
the high-calorie diet (HC+DMSO 0.01%) groups (Table 3.3).  
 
Cardiac function: CD hearts with treatment 
 
Hearts treated with CPT during reperfusion showed a significant increase in AO 
(ml/min: CD+CPT: 14.60 ± 2.40 vs. CD+DMSO: 4.29 ± 1.87) and CO (ml/min: 
CD+CPT: 28.80 ± 2.56 vs. CD+DMSO: 19.86 ± 2.58) compared to DMSO group 
(P<0.05) (Table 3.3) However, these changes did not affect the cardiac output 
percentage recovery (Figure 3.4A) as well as total work percentage recovery (Figure 
3.5A). Also, CF, HR, PSP and TW did not differ among the groups. 
 
Epac inhibition with its antagonist ESI-09 was detrimental on cardiac recovery of CF, 
AO, CO, HR, PSP and TW (Table 3.3) (Figure 3.4, 3.5). Furthermore, co-treatment of 
CPT with its antagonist ESI-09 did not reverse the detrimental effects of Epac inhibition 
on cardiac function.  
 
In addition, we investigated the effect of co-treatment of hearts with CPT and the PKB 
(A6730) inhibitor or MEK-ERK (PD98059) inhibitor on cardiac function. The hearts 
treated with A6730 had a poor recovery of CF, AO, CO and PSP only when compared 
to the DMSO group (P<0.05) (Table 3.3). Co-treatment of CPT with A6730 did not 
prevent the damaging effects of the PKB inhibitor on cardiac function (Table 3.3). The 
percentage recovery of CO was significantly lower in the A6730 (24.64 ± 3.17 %) and 
the A6730+CPT (21.16 ± 2.02 %) groups compared to both CPT (58.12 ± 4.14  %) 
and DMSO (41.28 ± 4.68 %) groups (P<0.05) (Figure 3.4A). PKB inhibition also 
reduced the TW percentage recovery compared to CPT: CD+A6730+CPT: 13.48 ± 
3.7 % vs. CD+CPT: 49.71 ± 6.1 %, P<0.05) and DMSO (CD+A6730: 12.32 ± 4.6 % 
vs.  CD+DMSO: 38.55 ± 3.91 %, P<0.05; CD+A6730+CPT: 13.48 ± 3.7 % vs. 




MEK-ERK inhibition with PD98059 (10µM) had no significant effect on the cardiac 
recovery of CF, AO, CO, HR, PSP and TW compare to the DMSO control hearts (Table 
3.3). The co-treatment of PD98059 with CPT showed a significant reduction in post-
ischaemic AO and CO compared to CPT treated hearts (p<0.05)(Table 3.3). The 
percentage recovery of CO (CD+PD98059+CPT: 29.95 ± 6.29 % vs. CD+CPT:  
58.12 ± 4.14 %, P<0.05) (Figure 3.4A).  
 
 
Cardiac function: HC hearts with treatment 
 
Hearts from the HC group treated with an Epac agonist CPT showed a significant post-
ischaemic improvement in TW (Table 3.3). However, the percentage TW recovery did 
not change compared to the DMSO group (Figure 3.5B). Furthermore, there were no 
changes in the recovery of CF, AO, CO, HR and PSP among the groups (Table 3.3).  
 
The HC hearts treated with ESI-09 also did not recover after post I/R (Table 3.3). 
Furthermore, co-treatment of CPT with its antagonist ESI-09 did not improve the 
detrimental effects of Epac inhibition (Table 3.3).  
 
The PKB inhibitor A6730 showed no significant effect on the cardiac function of the 
hearts from HC diet rats, however, A6730 significantly reduced PSP with or without 
the Epac activator, CPT (Table3.3).  
 
ERK1/2 inhibition (PD98059) in hearts from the HC diet rats showed no significant 
changes in CF, AO, CO, HR, PSP and TW compare to both DMSO and the Epac 




 Table 3. 2 Baseline cardiac function (before ischaemia or drug treatment)  
All values are expressed as mean ± SEM. Comparisons of groups were tested by ANOVA. n = 5-7 per group. 
 
DMSO: 0.01%  
CD: control diet                                          CPT: Epac agonist (2 µM)                   A6730: selective PKB inhibitor (2,5 µM) 
















CD+DMSO 13.40 ± 0.58 34.71 ± 1.79 48.10 ± 2.01 282.9 ± 11.82 87.53 ± 1.10 9.49 ± 0.31 
CD+CPT 15.25 ± 0.67 34.25 ±  2.49 49.50 ± 2.605 278.4 ± 7.34 88.65 ± 1.39 10.11 ± 0.44 
CD+ESI-09 10.17 ± 1.55 29.92 ±  2.85 41.75 ± 2.91 267.2 ± 30.43 85.20 ± 1.39 8.81 ± 0.22 
CD+ESI-09+CPT  10.17 ± 2.32 31.67 ± 3.48 41.83 ± 4.08 258 ± 13.71 87.60 ± 1.75 8.71 ± 0.74 
CD+A6730 12.33 ± 1.59 33.33 ± 2.17 45.67 ± 2.94  329.8 ± 20.25 85.60 ±1.75 8.74 ± 0.70 
CD+A6730+CPT 10.36 ± 0.28 29.43 ± 2.57 39.79 ± 2.37 289.4 ± 20.69 86.57 ± 1.89 7.56 ± 0.46 
CD+PD98059 15.51 ± 4.11 32.01 ± 1.37 47.50 ± 4.29 294.8 ± 12.4 86.50 ± 1.77 9.05 ± 0.86 
CD+PD98058+CPT  11.83 ± 0.98 34.33 ± 3.40 46.17 ± 4.28 308.4 ± 9.48 88.33 ± 2.70 9.88 ± 0.79 
HC+DMSO  14.01 ± 0.76 29.78 ± 4.07 43.78 ± 4.22 316.9 ± 15.97 88.86 ± 2.01 9.39 ± 0.57 
HC+CPT 12.29 ± 0.71 38.29 ± 2.16 50.57 ± 2.53 272.1 ± 9.26 88.25 ± 0.79 9.26 ± 0.45 
HC+ESI-09 11.25 ± 1.06 28.67 ±  3.32 39.92 ± 4.28 277.7 ± 24.56 83.50 ± 1.52 7.92 ± 0.87 
HC+ESI-09 CPT 12.01 ± 0.67 29.08 ± 1.93 41.08 ± 2.35 294 ± 15.97 84.8 ± 1.319 8.39 ± 0.38 
HC+A6730 13.61 ± 1.94 30.20 ± 2.29 43.60 ± 4.17 322.8 ± 25.09 85.01 ± 2.45 9.52 ± 0.91 
HC+A6730+CPT 12.21 ± 1.20 28.80 ± 3.61 41.01 ± 4.54  307.2 ± 25.1 84.80 ± 2.84 8.49 ± 1.02 
HC+PD98059 11.91 ± 0.78 29.2 ± 1.74 41.30 ± 2.42 302.4 ± 10.99 84.25 ± 0.85 7.73 ± 0.46 
























Table 3. 3 Cardiac function of the different post-treatment groups after 35 min regional ischaemia and 60 min reperfusion  
All values are expressed as mean ± SEM. Comparisons of groups were tested by ANOVA. *p < 0.05 vs CD+DMSO, †p < 0.05 vs CD+CPT, ‡p < 0.05 vs. 
HC+DMSO, §p < 0.05 vs HC+CPT. n = 5-7 per group.  (“zero”, the hearts did not recover post I/R).  
 
DMSO: 0.01% 
CD: control diet                                          CPT: Epac agonist (2 µM)                   A6730: selective PKB inhibitor (2.5 µM) 
HC: high calorie diet                                  ESI-09: Epac antagonist (5 µM)           PD98059: MEK-ERK inhibitor (10 µM)












CD+DMSO  15.57 ± 1.09 4.29 ± 1.87 19.86 ± 2.58 272.8 ± 43.98 78.75 ± 1.15 2.92 ± 0.57 
CD+CPT 14.20 ± 1.02 14.60 ± 2.40* 28.80 ± 2.56* 230.8 ± 42.05 78.2 ± 1.62 3.73 ± 0.8 
CD+ESI-09 3.83 ± 1.72 0 3.83 ± 1.72  0  0  0  
CD+ESI-09+CPT  3.50 ± 2.2 0 3.50 ± 2.25  0 0 0 
CD+A6730 11.25 ± 1.25 0 11.25 ± 1.25 204.3 ± 69.02 60.25 ± 2.25* 1.02 ± 0.35 
CD+A6730+CPT 8.50 ±  0.29*† 0 8.50 ±  0.29† 218.9 ± 80.76 70 ± 4.49*†  0.84 ± 0.28† 
CD+PD98059 13.08 ± 1.88 4.08 ± 1.69 17.17 ± 3.41 349.3 ± 23.9 77.33 ± 0.95 2.91 ± 0.61 
CD+PD98058+ CPT  10.83 ± 1.38 3.01 ± 2.62† 13.83 ± 3.90† 324.8 ± 70.89 76.2 ± 0.9695 
 
2.01 ± 0.81 
HC+DMSO  13.02 ± 1.53 5.33 ± 5.33 18.33 ± 5.04 206.5 ± 47.76 77.33 ± 0.75 1.18 ± 0.65 
HC+CPT 15.01 ± 1.05 8.57 ± 2.72 23.57 ± 3.42 267.1 ± 35.94 78.23 ± 0.98 4.13 ± 0.64‡ 
HC+ESI-09 9.08 ± 0.78 0 9.08 ± 0.78 0 0  0 
HC+ESI-09 + CPT 6.25 ± 1.42  0 6.25 ± 1.42 0 0  0 
HC+A6730 12.75 ± 1.97 0 12.75 ± 1.97 257.3 ± 96.43   68.33 ± 6.12‡ 1.37 ± 0.56 
HC+A6730+CPT 17.01 ± 1.53 0 17.01 ± 1.53 278.0 ± 105.6 66.67 ± 7.36‡§ 1.887 ± 0.70§ 
HC+PD98059 11.90 ± 0.95 6.60 ± 3.6 18.50 ± 3.92 353.6 ± 23.72 78.6 ± 1.47 3.18 ± 0.73 
























   
 
 
Figure 3. 4 Post-ischaemic cardiac output (% recovery) of treated groups after 35 min regional 
ischaemia and 60 min reperfusion. 
(A), cardiac output percentage recovery in CD; (B), cardiac output percentage recovery in HC. All values 








Figure 3. 5 Post-ischaemic total work (% recovery) of treated groups after 35 min regional 
ischaemia and 60 min reperfusion. 
 (A), cardiac output percentage recovery in CD; (B), cardiac output percentage recovery in HC. All 
values are expressed as mean ± SEM. n = 5-7 per group.  
 
 
3.3.4 Infarct size in the different post-treated groups after 35 min regional 






There were no significant differences in infarct size or the area at risk between CD and 




Figure 3. 6 The effect of diet on infarct size after 35 min regional ischaemia and 60 min 
reperfusion. 




Infarct size: CD hearts with treatment 
 
CPT post-treated hearts exhibited a significant reduction in infarct size compared to 
the DMSO control group (CD+CPT: 12.95 ± 2.13 % vs. CD+DMSO: 23.15 ± 1.46 %, 
P<0.01) (Figure 3.7A). However, Epac inhibition with ESI-09 did affect the CPT 
protection as would have been expected. The reason for this was that the hearts 
treated with ESI-09 (5 µM) for 10 minutes at reperfusion went into contracture in the 
first 5 minutes of treatment and followed by a loss cardiac function (Table 3.3). The 
fact that the hearts could not perfuse hampered the infusion of Evan’s blue dye for the 
staining of viable tissue. This resulted in a significant increase in the total area at risk 
in ESI-09 treated hearts (CD+ESI-09: 59.78 ± 3.28 % vs. CD+DMSO: 47.17 ± 1.67 %, 
P<0.01); and ESI-09+CPT treated hearts (CD+ESI-09+CPT: 66.4 ± 2.02 % vs. 
CD+DMSO: 47.17 ± 1.67 %, P<0.0001); (CD+ESI-09+CPT: 66.4 ± 2.02 % vs. 
CD+CPT: 53.97 ± 1.61 %, P<0.01) (Figure 3.7B).  
 
The mechanisms of protection were also investigated through the inhibition of the 




and ERK1/2 had a detrimental effect on the infarct size in CD hearts (CD+A6730: 
43.55 ± 5.75 % vs. CD+DMSO: 24.1 ± 1.27 %, P<0.01) (Figure 3.8A); (CD+PD98058: 
36.33 ± 2.946 % vs. CD+DMSO: 24.1 ± 1.27 %, P<0.05) (Figure 3.9A). In addition, 
CPT protection was abolished by both PKB and ERK1/2 inhibitors in CD hearts 
(CD+A6730+CPT: 21.81 ± 2.13 % vs. CD+CPT: 12.95 ± 2.13 %, P<0.05) (Figure 
3.8A); (CD+PD98058+CPT: 26.51 ± 3.97 % vs. CD+CPT: 12.95 ± 2.13 %, P<0.01) 





Figure 3. 7 Infarct size of hearts from Control Diet animals. 
The effects of Epac agonist, CPT, and antagonist, ESI-09, administered in the first 10 minutes of 
reperfusion, on infarct size after 35 minutes regional ischaemia and 60 min reperfusion. (A), 
Infarct size (%); (B), Area at risk (%). All values are expressed as mean ± SEM. **P < 0.01, ***P < 

















Figure 3. 8 Infarct size of hearts from Control Diet animals. 
 Effects of PKB (A6730) inhibition on Epac stimulation (CPT) in the first 10 min of reperfusion, 
on infarct size after 35 min regional ischaemia and 60 min reperfusion.  (A), Infarct size (%);  (B), 







Figure 3. 9 Infarct size of hearts from Control Diet animals. 
Effects of MEK-ERK (PD98059) inhibition on Epac stimulation (CPT) in the first 10 min of, on 
infarct size after 35 min regional ischaemia and 60 min reperfusion.  (A), Infarct size (%);  (B), Area 










Infarct size: hearts from HC animals with treatment  
 
Epac activation with CPT after regional ischaemia significantly reduced infarct size in 
the HC group. (HC+DMSO: 25.49 ± 4.39 % vs. HC+CPT: 13.56 ± 2.21 %, P<0.05) 
(Figure 3.10A). Similarly to the CD group, the post treatment with Epac inhibitor ESI-
09 did not affect the CPT protection. In fact, the HC hearts also showed a significant  
increase in area at risk (HC+ESI-09: 69.85 ± 2.91 % vs. HC+DMSO: 53.31± 2.05 %, 
P<0.001; HC+ESI-09+CPT: 66.31 ± 3.24 % vs. HC+DMSO: 53.31 ±  2.05 %,P<0.01; 
HC+ESI-09+CPT: 66.31 ± 3.24 %  vs. HC+CPT: 50.59 ± 1.85 %, P< 0.01) (Figure 
3.10B). 
 
CPT protection was abolished by post-treatment with the PKB inhibitor in the HC 
hearts (Infarct size: HC+A6730+CPT: 26.65 ± 1.43 % vs. HC+CPT: 13.56 ± 2.21 %, 
P<0.01) (Figure 3.11A). There were no significant differences in the area at risk (Figure 
3.11B). Furthermore, post-treatment with the ERK1/2 inhibitor (PD98058) did not 
affect CPT protection in HC hearts (Figure 3.12A). The % area at risk was the same 




Figure 3. 10 Infarct size of hearts from High-calorie Diet animals. 
 The effects of Epac agonist, CPT, and antagonist, ESI-09, administered in the first 10 minutes 
of reperfusion, on infarct size after 35 min regional ischaemia and 60 min reperfusion. (A), Infarct 
size (%); (B), Area at risk (%). All values are expressed as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 






Figure 3. 11 Infarct size of hearts from High-calorie Diet animals. 
 Effects of PKB (A6730) inhibition on Epac stimulation (CPT) in the first 10 min of reperfusion, 
on infarct size after 35 min regional ischaemia and 60 min reperfusion. (A), Infarct size (%); (B), 






Figure 3. 12 Infarct size of hearts from High-calorie Diet animals. 
 Effects of MEK-ERK (PD98059) inhibition on Epac stimulation (CPT) in the first 10 min of 
reperfusion, on infarct size after 35 min regional ischaemia and 60 min reperfusion. (A), Infarct 








3.3.5 Cardiac Signal Transduction after treatment with CPT (Epac agonist), ESI-
09 (Epac antagonist), A6730 (PKB antagonist) and PD98058 (ERK1/2 
antagonist).  
 
Protein expression and phosphorylation in the left ventricle tissue were measured by 
Western blot analysis after 35 min regional ischaemia and subsequent exposure to 
different treatment in the first 10 minutes of reperfusion. 
 
3.3.5.1 PKB phosphorylation and expression 
 
In CD hearts  
There were no significant differences in PKB phosphorylation between CPT treated 
hearts and DMSO control hearts (Figure 3.13B). PKB inhibition with A6730 
significantly reduced PKB phosphorylation compared to DMSO control (CD+A6730: 
0.33 ± 0.08 vs. CD+DMSO: 1 ± 0.21, P<0.05) (Figure 3.13B). A significant decrease 
in PKB phosphorylation was also observed in CPT co-treatment with A6730 compared 
to CPT treatment (CD+A6730+CPT: 0.46 ± 0.08 vs. CD+CPT: 1.11 ± 0.22, P<0.05) 
(Figure 3.13B). In addition, when phosphorylated PKB was expressed as a ratio of 
total PKB, the CPT co-treatment with PKB inhibitor A6730 remained decreased 
compared to CPT treated hearts (CD+A6730+CPT: 0.48 ± 0.08 vs. CD+CPT: 1.18 ± 
0.23, P<0.05) (Figure 3.13 D). Total PKB expression showed no significant changes 
between different treatment groups.  
 
In figure 3.14 Epac inhibition with ESI-09 resulted in decreased PKB phosphorylation, 
and phospho:total PKB ratio compared to DMSO control, even though the reduction 
was not significant. (CD+ESI-09: 0.1605 ± 0.05 vs. CD+DMSO: 1 ± 0.31, P=0.052; 
CD+ESI-09+CPT: 0.24 ± 0.01 vs. CD+DMSO: 1 ± 0.31, P=0.07) (Figure 3.14 B). This 

















Figure 3. 13 PKB phosphorylation and expression in hearts from the CD group post-treated 
with an Epac activator (CPT) and PKB inhibitor (A6730) in the first 10 minutes reperfusion. 
(A), representative Western blots for phosphorylated and total PKB; (B), phosphorylated PKB levels; 
(C), total PKB levels; (D), phospho/total ratio for PKB. n= 3 per group. All values are expressed as mean 
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Figure 3. 14 PKB phosphorylation and expression in hearts from the CD group post-treated 
with an Epac activator (CPT, 2 µM) and Epac inhibitor (ESI-09, 5 µM) in the first 10 minutes 
reperfusion. 
(A), representative Western blots for phosphorylated and total PKB; (B), phosphorylated PKB levels; 
(C), total PKB levels; (D), phospho/total ratio for PKB. n = 3 per group. All values are expressed as 
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In HC hearts  
 
The HC hearts showed a significant increase in both phosphorylated PKB 
(HC+DMSO: 2.79 ± 0.12 vs. CD+DMSO: 1 ± 0.21, P<0.01) (Figure 3.15B) and 
phospho:total PKB ratio (Ratio: HC+DMSO: 3.69 ± 0.37 vs. CD+DMSO: 1.07 ± 0.39, 
P<0.05) (Figure 3.15D) compared to the hearts in CD group.   
 
PKB phosphorylation did not differ between CPT treated hearts and DMSO controls in 
the HC group. PKB inhibition in hearts from HC with A6730 led to a significant 
reduction in phosphorylated PKB compared to DMSO control hearts (HC+A6730: 0.79 
± 0.21 vs. HC+DMSO: 2.79 ± 0.12 ,P<0.01) (Figure 3.15B). In addition, PKB 
phosphorylation was also significantly decreased in hearts co-treated with CPT and 
A6730 compared to CPT treated hearts (HC+A6730+CPT: 1.13 ± 0.55 vs. HC+CPT: 
3.3 2 ± 0.64, P<0.05) (Figure 3.15B.) There were no changes observed in total PKB 
expression among the groups, therefore the phospho:total PKB ratio reflected the 
same changes as seen in PKB phosphorylation. For example, the phospho: total PKB 
ratio was decreased by A6730 in both CPT treated (HC+A6730+CPT: 1.27 ± 0.62 vs. 
HC+CPT: 4.08 ± 0.76, P<0.05) (Figure 3.15D) and DMSO control hearts (HC+A6730: 
1.29 ± 0.51 vs. HC+DMSO: 3.699 ± 0.37, P<0.05) (Figure 3.15D).  
  
Epac inhibition with ESI-09 in HC hearts had no significant effect on PKB 



















Figure 3. 15 PKB phosphorylation and expression in hearts from the HC group post-treated 
with an Epac activator (CPT) and PKB inhibitor (A6730) in the first 10 minutes reperfusion.  
(A), representative Western blots for phosphorylated and total PKB; (B), phosphorylated PKB levels; 
(C), total PKB levels; (D), phospho/total ratio for PKB. n = 2-3 per group. All values are expressed as 
mean ± SEM.* P<0.05,** P<0.01.  
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Figure 3. 16 PKB phosphorylation and expression in hearts from the HC group post-treated 
with an Epac activator (CPT, 2 µM) and Epac inhibitor (ESI-09, 5 µM) in the first 10 minutes 
reperfusion. 
 (A), representative Western blots for phosphorylated and total PKB; (B), phosphorylated PKB levels; 
(C), total PKB levels; (D), phospho/total ratio for PKB. n =2- 3 per group. All values are expressed as 
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3.3.5.2 ERK1/2 phosphorylation and expression 
 
In CD hearts 
 
In CD hearts, Epac activation with CPT decreased ERK1/2 phosphorylation compared 
to DMSO controls. However, this decrease was not significant in Figure 3.17, but 
statistically significant in Figure 3.18B (pERK1/2: CD+CPT: 0.58 ± 0.09 vs. 
CD+DMSO: 1 ± 0.08, P<0.05). MEK-ERK inhibition with PD98058 in CD hearts did 
not significantly affect ERK1/2 phosphorylation, ERK1/2 total expression nor phospho: 
total ERK1/2 ratio (Figure 3.17).  
 
However, following Epac inhibition with ESI-09, ERK1/2 phosphorylation and 
phospho:total ERK1/2 ratio were significantly reduced compared to DMSO control (p-
ERK1/2: CD+ESI-09: 0.3 ± 0.08 vs. CD+DMSO: 1 ± 0.08, P<0.01, Figure 3.18B); (p-
ERK1/2:t-ERK1/2 ratio: CD+ESI-09: 0.41 ± 0.05 vs. CD+DMSO: 1.02 ± 0.16, P<0.05, 
Figure 3.18D). The total ERK1/2 expression remained the same in all treatment groups 



























Figure 3. 17 ERK1/2 phosphorylation and expression in hearts from the CD group post-treated 
with an Epac activator (CPT) and ERK1/2 inhibitor (PD98058) in the first 10 minutes reperfusion. 
(A), representative Western blots for phosphorylated and total ERK1/2; (B), phosphorylated ERK1/2 
levels; (C), total ERK1/2 levels; (D), phospho/total ratio for ERK1/2. n = 3 per group All values are 
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Figure 3. 18 ERK1/2 phosphorylation and expression in hearts from the CD group post-treated 
with an Epac activator (CPT, 2 µM) and Epac inhibitor (ESI-09, 5 µM) in the first 10 minutes 
reperfusion.  
(A), representative Western blots for phosphorylated and total ERK1/2; (B), phosphorylated ERK1/2  
levels; (C), total ERK1/2  levels; (D), phospho/total ratio for ERK1/2. n = 3 per group. All values are 
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In HC hearts 
 
The HC hearts showed a decrease in both phosphorylated ERK1/2 and phospho:total 
ERK1/2 ratio compared to the hearts in the CD group, although not significant (Figure 
3.19B,D). The CPT treated hearts had an elevation in phospho-ERK1/2 and phospho: 
total ERK1/2 compared to DMSO controls, but this was not significant. (Figure 3.19B, 
D). In addition, MEK-ERK1/2 inhibition with PD98058 showed no significant difference 
in total ERK1/2 expression in all treatment groups (Figure 3.19C).  
 
Epac inhibition with ESI-09 showed a significant reduction both phospho-ERK1/2 and 
phospho:total ERK1/2 ratio compared to DMSO control hearts (pERK1/2: HC+ESI-09: 
0.79± 0.02 vs. HC+DMSO: 1.304 ± 0.18, P<0.05, Figure 3.20B) (p-ERK1/2/t-ERK1/2: 
HC+ESI-09: 0.58 ± 0.05 vs. HC+DMSO: 1.09 ± 0.15, P<0.05, Figure 3.20D). Total 




























Figure 3. 19 ERK1/2 phosphorylation and expression in hearts from the HC group post-treated 
with an Epac activator (CPT) and ERK1/2 inhibitor (PD98058) in the first 10 minutes reperfusion. 
(A), representative Western blots for phosphorylated and total ERK1/2; (B), phosphorylated ERK1/2 
levels; (C), total ERK1/2 levels; (D), phospho/total ratio for ERK1/2. n =2- 3 per group. All values are 
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Figure 3. 20 ERK1/2 phosphorylation and expression in hearts from the HC group post-treated 
with an Epac activator (CPT, 2 µM) and Epac inhibitor (ESI-09, 5 µM) in the first 10 minutes 
reperfusion. 
(A), representative Western blots for phosphorylated and total ERK1/2; (B), phosphorylated ERK1/2 
levels; (C), total ERK1/2  levels; (D), phospho/total ratio for ERK1/2. n = 2-3 per group. All values are 
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3.3.5.3 GSK3b expression and activation  
 
In CD hearts 
Hearts treated with ESI-09 had a reduced phospho-GSK3b expression compared to 
the DMSO control hearts (p-GSK3b: CD+ESI-09: 0.21 ± 0.03 vs. CD+DMSO: 1 ± 0.28, 
P<0.05) (Figure 3.21). Epac activation with CPT could not reverse the reduced 
phospho-GSK3b cause by ESI-09 in hearts co-treated with CPT and ESI-09 when 
compared to the DMSO control (CD+ESI-09+CPT: 0.19 ± 0.02 vs. CD+DMSO: 1 ± 
0.28, P<0.05) (Figure 3.21B). An elevation in phospho-GSK3b and phospho: total 
GSK3b levels was also noted in CPT treated hearts compared to the CPT hearts co-
treated with an Epac inhibitor (p-GSK3b: CD+CPT: 0.59 ± 0.09 vs. CD+ESI-09+CPT: 
0.19 ± 0.02, P<0.05, Figure 3.21B) (p/t-GSK3b ratio: CD+CPT: 0.58 ± 0.08 vs. 
CD+ESI-09+CPT: 0.16 ± 0.03, P<0.01, Figure 3.21D). There were no significant 
changes in total GSK3b expression in any of the treatment groups (Figure 3.21C).  
 
In HC hearts 
 Even though there were indications of a decrease in phospho-GSK3b in hearts of HC 
compared to CD, and increased phospho-GSK3b in hearts of HC treated with CPT 






















     
 
 
Figure 3. 21 GSK3b   phosphorylation and expression in hearts from the CD group post-treated 
with an Epac activator (CPT, 2 µM) and Epac inhibitor (ESI-09, 5 µM) in the first 10 minutes 
reperfusion. 
(A), representative Western blots for phosphorylated and total GSK3b; (B), phosphorylated levels; (C), 
total GSK3b  levels; (D), phospho/total ratio for GSK3b. n = 3 per group. All values are expressed as 
mean ± SEM.*P<0.05,**P<0.01. 
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Figure 3. 22 GSK3b phosphorylation and expression in hearts from the HD group post-treated 
with an Epac activator (CPT, 2 µM) and Epac inhibitor (ESI-09, 5 µM) in the first 10 minutes 
reperfusion. 
(A), representative Western blots for phosphorylated and total GSK3b; (B), phosphorylated GSK3b 
levels; (C), total GSK3b levels; (D), phospho/total ratio for GSK3b. n = 2-3 per group. All values are 
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3.3.5.4 Total CaMKII expression and activation  
 
In CD hearts 
Epac activation with CPT in the CD hearts showed no significant increase in phospho-
CaMKII or phospho: total CaMKII in any of the treatment groups (Figure 3.23). In 
addition, the decrease following ESI-09 treatment was also not significant. 
 
In HC hearts 
In HC DMSO control hearts, the decrease in phospho-CaMKII, total CaMKII 
expression and phospho: total CaMKII versus CD DMSO controls was not significant 
(Figure 3.22). However, Epac activation with CPT significantly increased CaMKII 
phosphorylation and phospho: total CaMKII ratio compared to HC DMSO control (p-
CaMKII: HC+CPT: 1.21 ± 0.17 vs. HC+DMSO: 0.59 ± 0.11, P<0.05, Figure 3.24B) (p-
CaMKII/t-CaMKII: HC+CPT: 1.47 ± 0.17 vs. HC+DMSO: 0.76 ± 0.19, P<0.05, Figure 
3.24D). Furthermore, co-treatment of CPT with the Epac inhibitor (ESI-09) showed 
reduced (borderline significant, P=0.05) phospho-CaMKII levels compared to hearts 
treated with CPT alone (Figure 3.24B). On the other hand, the phospho:total CaMKII 
ratio was significantly decreased in ESI-09 and CPT co-treated hearts versus hearts 
treated with CPT alone (HC+ESI-09+CPT: 0.52 ± 0.07 vs. HC+CPT: 1.47 ± 0.17, 
P<0.01) (Figure 3.24D). The total CaMKII expression was not altered among the 
treatments groups (Figure 3.24C).  
 
 
3.3.5.5 Calcineurin total expression 
 
Epac activation with CPT did not significantly increase calcineurin in CD hearts (Figure 
3.25B) 
The HC DMSO hearts showed a significant increase in total calcineurin expression 
compared to CD DMSO hearts (HC+DMSO: 1.61 ± 0.08 vs. CD+DMSO: 1 ± 0.01, 
P<0.01) (Figure 3.25D). However, there were no differences in total calcineurin 














Figure 3. 23 CaMKII phosphorylation and expression in hearts from the CD group post-treated 
with an Epac activator (CPT, 2 µM) and Epac inhibitor (ESI-09, 5 µM)in the first 10 minutes 
reperfusion. 
(A), representative Western blots for phosphorylated and total CaMKII; (B), phosphorylated CaMKII 
levels; (C), total CaMKII levels; (D), phospho/total ratio for CaMKII. n = 3 per group. All values are 
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Figure 3. 24 CaMKII phosphorylation and expression in hearts from the HC group post-treated 
with an Epac activator (CPT, 2 µM) and Epac inhibitor (ESI-09, 5 µM) in the first 10 minutes 
reperfusion. 
(A), representative Western blots for phosphorylated and total CaMKII; (B), phosphorylated CaMKII 
levels; (C), total CaMKII levels; (D), phospho/total ratio for CaMKII. n = 2-3 per group. All values are 
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Figure 3. 25 Calcineurin expression in hearts from the CD and HC groups post-treated with 
an Epac activator (CPT, 2 µM) and Epac inhibitor (ESI-09, 5 µM) in the first 10 minutes 
reperfusion. 
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(A), representative Western blots for CD total calcineurin; (B), CD total calcineurin levels; (C), 
representative Western blots for HC total calcineurin; (D), HC total calcineurin level. n = 2-3 per group. 
All values are expressed as mean ± SEM.**P<0.01. 
 
 
3.3.5.6 Cleaved PARP expression 
 
In CD hearts, both CPT and ESI-09 treated hearts showed a significant increase in 
cleaved PARP expression as compared to DMSO control (CD+CPT: 2.26 ± 0.38 vs. 
CD+DMSO: 1 ± 0.17, P<0.05; CD+ESI-09: 3.78 ± 0.60 vs. CD+DMSO: 1 ± 0.17, 
P<0.05) (Figure 3.26B).  
  
Furthermore, the HC hearts also showed an elevation in cleaved PARP expression 
compared to CD DMSO controls (HC+DMSO: 1.381 ± 0.03 vs. CD+DMSO: 1 ± 0.00, 
P<0.01) (Figure 3.26D).  
 
3.3.5.7 Cleaved Caspase-3 expression 
 
Despite the fact that there were indications of an increase in cleaved caspase-3 
expression in hearts of HC compared to CD, as well as an increased cleaved caspase-
3 expression in hearts of HC treated with CPT compared to HC controls, these 
changes were not significant (Figure 3.27D). 
 
3.3.5.8 Nitrotyrosine total expression 
 
There were no significant differences in nitrotyrosine expression between the CD 
DMSO and the HC DMSO groups. Neither Epac activation nor inhibition caused 





















Figure 3. 26 Cleaved PARP expression in hearts from the CD and HC groups post-treated with 
an Epac activator (CPT, 2 µM) and Epac inhibitor (ESI-09, 5 µM) in the first 10 minutes 
reperfusion.  
(A), representative Western blots for CD total cleaved PARP; (B), CD total cleaved PARP levels; (C), 
representative Western blots for HC total cleaved PARP; (D), HC total cleaved PARP level. n = 2-3 per 
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Figure 3. 27 Cleaved Caspase-3 expression in hearts from the CD and HC groups post-treated 
with an Epac activator (CPT, 2 µM) and Epac inhibitor (ESI-09, 5 µM) in the first 10 minutes 
reperfusion.  
(A), representative Western blots for CD total cleaved Caspase-3; (B), CD total cleaved Caspase-3 
levels; (C), representative Western blots for HC total cleaved Caspase-3; (D), HC total cleaved 
Caspase-3 level. n = 2-3 per group. All values are expressed as mean ± SEM.  
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Figure 3. 28 Nitrotyrosine expression in hearts from the CD and HC groups post-treated with 
an Epac activator (CPT, 2 µM) and Epac inhibitor (ESI-09, 5 µM) in the first 10 minutes 
reperfusion.  
(A), representative Western blots for CD Nitrotyrosine; (B), CD total Nitrotyrosine levels; (C), 
representative Western blots for HC total Nitrotyrosine; (D), HC total Nitrotyrosine level. n = 2-3 per 
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3.3.5.9 AMPK phosphorylation and expression 
 
In CD hearts 
 
The CD hearts showed no significant differences in phospho-AMPK, total AMPK or 
phospho: total AMPK ratio in any of the treatment groups (Figure 3.29). However, the 
co-treatment with ESI-09 and CPT demonstrated borderline significant increases in 
phospho-AMPK and phospho:total AMPK ratios as compared to CD DMSO control (p-
AMPK: CD+ESI-09+CPT: 0.85 ± 0.11 vs. CD+DMSO: 0.39 ± 0.06, P=0.050, Figure 
3.29B) (p-AMPK/t-AMPK: CD+ESI-09+CPT: 0.97 ± 0.12 vs. CD+DMSO: 0.45 ± 0.07, 
P=0.05, Figure 3.29D).  
 
In HC hearts 
 
Epac activation with CPT showed no changes in phospho-AMPK, total AMPK 
expression or phospho: total AMPK ratio as compared to HC DMSO control. However, 
hearts treated with ESI-09 demonstrated significant increases in phospho-AMPK level 
and phospho: total AMPK ratio compared to HC DMSO control hearts (p-AMPK: 
HC+ESI-09: 3.74 ± 0.63 vs. HC+DMSO: 0.54 ± 0.09, P<0.05, Figure 3.30B) (p-
AMPK/t-AMPK: HC+ESI-09: 5.43 ± 0.91 vs. HC+DMSO: 0.79 ± 0.13, P<0.05, Figure 
3.30D). In addition, phospho-AMPK and phospho: total AMPK ratio remained elevated 
in hearts treated with the combination of CPT and ESI-09 compared to HC DMSO 
control hearts (p-AMPK: HC+ESI-09+CPT: 3.33 ± 0.25 vs. HC+DMSO: 0.54 ± 0.09, 
P<0.01, Figure 3.30B) (p-AMPK/t-AMPK: HC+ESI-09+CPT: 4.835 ± 0.36 vs. 
HC+DMSO: 0.79 ± 0.13), P<0.01, Figure 3.30D). There were no changes in total 




















Figure 3. 29 AMPK phosphorylation and expression in hearts from the CD group post-treated 
with an Epac activator (CPT, 2 µM) and Epac inhibitor (ESI-09, 5 µM) in the first 10 minutes 
reperfusion. 
 (A), representative Western blots for phosphorylated and total AMPK; (B), phosphorylated AMPK 
levels; (C), total AMPK levels; (D), phospho/total ratio for AMPK. n = 2-3 per group. All values are 
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Figure 3. 30 AMPK phosphorylation and expression in hearts from the HC group post-treated 
with an Epac activator (CPT, 2 µM) and Epac inhibitor (ESI-09, 5 µM) in the first 10 minutes 
reperfusion.  
(A), representative Western blots for phosphorylated and total AMPK; (B), phosphorylated AMPK levels; 
(C), total AMPK levels; (D), phospho/total ratio for AMPK. n = 2- 3 per group. All values are expressed 
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3.3.5.10 eNOS phosphorylation and expression 
 
Treatment of the hearts from the CD animals had no significant effect on phospho-
eNOS, total eNOS expression or phospho: total eNOS ratio (Figure 3.31).  
 
In HC hearts 
 
The HC hearts showed an increase in phospho-eNOS as compared to CD hearts 
(HC+DMSO: 1.57 ± 0.03 vs. CD+DMSO: 1 ± 0.12, P<0.05) (Figure 3.32B). Hearts 
treated with CPT had a reduced phospho-eNOS compared to the DMSO control hearts 
(HC+CPT: 0.58 ± 0.04 vs. HC+DMSO: 1.57 ± 0.03, P<0.0001) (Figure 3.32B). Epac 
inhibition with ESI-09 and co-treatment with CPT also exerted a reduced effect on 
phospho-eNOS levels compared to DMSO control (HC+ESI-09: 0.61 ± 0.10 vs. 
HC+DMSO: 1.57 ± 0.03 P<0.001; HC+ESI-09+CPT: 0.35 ± 0.09 vs. HC+DMSO: 1.57 
± 0.03, P<0.001) (Figure 3.32B).  
 
The phospho:total eNOS ratio was also reduced in CPT, ESI-09 and ESI-09+CPT 
treated hearts compared to DMSO control (HC+CPT: 0.31 ± 0.03 vs. HC+DMSO: 1.22 
± 0.18, P<0.01; HC+ESI-09: 0.42 ± 0.09 vs. HC+DMSO: 1.22 ± 0.18, P<0.05; HC+ESI-























Figure 3. 31 eNOS phosphorylation and expression in hearts from the CD group post-treated 
with an Epac activator (CPT, 2 µM) and Epac inhibitor (ESI-09, 5 µM) in the first 10 minutes 
reperfusion.  
(A), representative Western blots for phosphorylated and total eNOS; (B), phosphorylated eNOS levels; 
(C), total eNOS levels; (D), phospho/total ratio for eNOS. n = 3 per group. All values are expressed as 
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Figure 3. 32 eNOS phosphorylation and expression in hearts from the HC group post-treated 
with an Epac activator (CPT, 2 µM) and Epac inhibitor (ESI-09, 5 µM) in the first 10 minutes 
reperfusion.  
(A), representative Western blots for phosphorylated and total eNOS; (B), phosphorylated eNOS levels; 
(C), total eNOS levels; (D), phospho/total ratio for eNOS. n = 3 per group. All values are expressed as 
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3.3.5.11 DRP1 phosphorylation and expression 
 
Treatment of the hearts from the CD group had no significant effect on phospho-DRP1, 
total DRP1 expression or phospho: total DRP1 ratio (Figure 3.33).  
 
In HC hearts 
 
In HC hearts, ESI-09 treatment showed an increase in phospho-DRP1 as well as 
phospho: total DRP1 ratio compared to HC DMSO control hearts, although the 
increase was not significant (Figure 3.34B and D). There were no changes in total 































   
 
Figure 3. 33 DRP1 phosphorylation and expression in hearts from the CD group post-treated 
with an Epac activator (CPT, 2 µM) and Epac inhibitor (ESI-09, 5 µM) in the first 10 minutes 
reperfusion.  
(A), representative Western blots for phosphorylated and total DRP1; (B), phosphorylated DRP1 levels; 
(C), total DRP1 levels; (D), phospho/total ratio for DRP1. n = 3 per group. All values are expressed as 
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Figure 3. 34 DRP1 phosphorylation and expression in hearts from the HC group post-treated 
with an Epac activator (CPT, 2 µM) and Epac inhibitor (ESI-09, 5 µM) in the first 10 minutes 
reperfusion.   
(A), representative Western blots for phosphorylated and total DRP1; (B), phosphorylated DRP1 levels; 
(C), total DRP1 levels; (D), phospho/total ratio for DRP1. n = 2-3 per group. All values are expressed 
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3.3.5.12 ULK1 phosphorylation and expression 
 
In CD hearts 
 
CPT treated hearts had  reduced phospho-ULK1 compared to DMSO control hearts 
(CD+CPT: 0.78 ± 0.02 vs. CD+DMSO: 1 ± 0.04, P<0.01) (Figure 3.35B). Co-treatment 
with ESI-09 increased phospho-ULK1 compare to CPT treated hearts (CD+ESI-
09+CPT: 1.07 ± 0.04 vs. CD+CPT: 0.78 ± 0.02, P<0.01) (Figure 3.35B). There were 
no significant differences in total ULK1 in any of the treatment groups (Figure 3.35C). 
  
In HC hearts 
 
Treatment of the hearts from the HC group had no significant effect on phospho-ULK1, 





























Figure 3. 35 ULK1 phosphorylation and expression in hearts from the CD group post-treated 
with an Epac activator (CPT, 2 µM) and Epac inhibitor (ESI-09, 5 µM) in the first 10 minutes 
reperfusion.  
(A), representative Western blots for phosphorylated and total ULK1; (B), phosphorylated ULK1 levels; 
(C), total ULK1 levels; (D), phospho/total ratio for ULK1. n = 3 per group. All values are expressed as 
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Figure 3. 36 ULK1 phosphorylation and expression in hearts from the HC group post-treated 
with an Epac activator (CPT, 2 µM) and Epac inhibitor (ESI-09, 5 µM) in the first 10 minutes 
reperfusion.  
(A), representative Western blots for phosphorylated and total ULK1; (B), phosphorylated ULK1 levels; 
(C), total ULK1 levels; (D), phospho/total ratio for ULK1. n = 3 per group. All values are expressed as 
mean ± SEM.  
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In this study, we aimed to elucidate the mechanisms involved in Epac-induced 
cardioprotection by evaluation of the following cellular pathways and processes: the 
RISK pathway, nitric oxide signalling, calcium signalling, apoptotic signalling and 
autophagy. Therefore, we have established a pre-diabetic model with rats on a HC 
diet for 16 weeks. These rats had increased body weight, increased intraperitoneal fat, 
elevated non-fasting glucose concentration and increased HOMA-IR index. However, 
the HC diet had no detrimental effects on post ischaemic cardiac function and infarct 
size. The HC diet effects were associated with activated cardioprotective proteins PKB 
(Figure 3.15) and eNOS, but also increased Calcineurin and cleaved PARP.   
 
We have demonstrated that Epac activation, with a selective agonist, CPT (2µM), at 
reperfusion protected the hearts against I/R injury, independent of the diet. The CPT-
mediated protection, based on post ischaemic recovery of cardiac function and infarct 
size, was partially mediated by PKB and ERK (Figure 3.9) in the CD group, but mainly 
by PKB in the HC group. 
 
Interestingly, CPT activated CaMKII in the HC group but not eNOS and therefore this 
needs further elucidation. Epac inhibitor (ESI-09, 5 µM) was detrimental to cardiac 
function and was associated with decreased phosphorylated ERK1/2 in both diets, 
decreased phosphorylated GSK-3b in CD, increased phosphorylated AMPK in both 
diets, increased PARP cleavage in CD and increased autophagy (phosphorylated 
ULK-1) in CD.  
 
3.4.1 The effect of diet on I/R  
 
In the current study, Wistar rats fed a HC had a significant increase in body weight 
and intraperitoneal fat which may be an indication of overweight/obesity. This was 
associated with an elevation in non-fasting glucose concentration and insulin 
resistance (HOMA-IR index) after 16 weeks on diet. These data confirm the insulin 
resistant, pre-diabetic model from previous findings by Salie and colleagues (Salie et 
al., 2014). In the clinical setting, obesity is a risk factor for hypertension, dyslipidemia, 
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insulin resistance and diabetes, which may all increase the risk of myocardial infarction 
and eventually heart failure (Martí, 2016; Pi-Sunyer, 2009; Ritchie and Connell, 2007).  
 
 We found that, even though the HC rats developed metabolic disturbances, the 
baseline cardiac function was comparable to the CD group (Table 3.2). The infarct 
size was also the same as the CD group after I/R injury. However, our research 
indicated that the post-ischaemic cardiac function was affected by HC diet as shown 
by a decrease in percentage recovery of TW compared to CD group (Figure 3.5B). In 
contrast, Salie and co-workers (2014) have demonstrated that a high-fat diet protects 
the hearts against I/R injury in non-preconditioned hearts (Salie et al., 2014). Similar 
to our work, Thim and co-workers (2006) also showed that Sprague–Dawley rats fed 
moderate high-fat diets for 13 weeks developed metabolic disturbances (similar to 
metabolic syndrome), but the infarct size did not change after the hearts were exposed 
to I/R (Thim et al., 2006). The explanation for these findings in our study might be due 
to the fact that the rats did not develop diabetes. Therefore, HC feeding in rats mimics 
the prediabetic condition and it has been reported that up to 70% of prediabetic 
patients eventually develop diabetes, which increases the chances of developing 
cardiovascular disease (Rahmati-Najarkolaei et al., 2017). Another explanation might 
be the type of fat we used to induce obesity. Holsum, used in our HC, is a solid 
vegetable oil made from palm oil which contains palmitic acid as the main saturated 
fat. It has been reported that palmitic acid from palm oil has the same effect on the 
lipid profile as oleic acid (a monosaturated fat) (Odia, 2015). Furthermore, palm oil 
contains powerful antioxidants including oleic and linoleic acids, and vitamin E 
tocotrienols which may be cardioprotective (Chong and Ng, 1991; Odia, 2015). In most 
studies, animal fat (lard) is used to induce the insulin resistance, diabetes and to mimic 
metabolic syndrome (Briaud et al., 2002; Gustafson et al., 2002; Haluzik et al., 2004; 
Yaspelkis et al., 2001). Hence, in our study, despite the lack of animal fat, the rats on 
the HC presented with early signs of metabolic disturbances.  
 
The HC model in our study also demonstrated a significant rise in phosphorylated 
PKB. Insulin activation of PKB, a pro-survival kinase has been reported to be 
cardioprotective against I/R injury by preventing mPTP opening (Davidson et al., 2006; 
Matsui et al., 2001). Our findings suggest that the HC diet did not impair the insulin-
dependent activation of PKB even though the animals had signs of insulin resistance. 
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However, it has been shown that high-fat induced hyperinsulinemia and high plasma 
FFAs improved cardiac metabolism in spite of peripheral insulin resistance (Gupte et 
al., 2013). Insulin resistance in peripheral tissues (skeletal muscle, liver and adipose 
tissue) is believed to be the factor behind impaired glucose homeostasis and diabetes 
(Kahn et al., 2006). The heart is an insulin-sensitive organ and the impairment of 
insulin PI3K-PKB-eNOS-NO pathway may affect cardiovascular performance and 
could eventually lead to heart failure (Mangmool et al., 2017).  
 
Surprisingly, we found that the hearts from the HC group had an increase in 
phosphorylated eNOS which could be cardioprotective when compared to the CD 
group. In models of obesity and insulin resistance, phosphorylation of eNOS 
(downstream of PKB) is downregulated (HuisamenB et al., 2011; Wensley et al., 
2013). However, it has also been demonstrated that high carbohydrate-induced 
obesity improved PKB and eNOS indicating cardioprotection in insulin resultant rats 
(Donner et al., 2013). 
 
Furthermore, a study by Donner and co-workers (2012), demonstrated that obesity 
improves myocardial tolerance to I/R through activation of PKB, eNOS, ERK1/2 and 
phosho-inhibition of GSK3b in insulin-sensitive Wistar rats (Donner et al., 2012). The 
phospho-inhibition of GSK3b at Ser9 is known to protect the heart through inhibition of 
mPTP opening (Fullmer et al., 2013; Tsang et al., 2005; Yu and Cui, 2016).  We found 
that phosphorylated PKB in HC hearts was not associated with phospho-inhibited 
GSK3b which was not consistent with the previous finding (Donner et al., 2012). It has 
previously demonstrated that GSK3b inhibition is not essential IPreC and IPosC in 
mice (Nishino et al., 2008). 
 
MEK-ERK 1/2 is part of the RISK pathway and the downregulation of ERK1/2 leads to 
Ca2+ overload which could contribute to cell death by inducing cardiomyocyte 
hypercontracture and mPTP opening (Hausenloy et al., 2009). ERK1/2 has been 
reported to participate cardioprotection of IPreC, IPosC and pharmacological 
postconditioning against I/R injury (Chen et al., 2008; Tai et al., 2012). In the current 
study, the HC diet had no detrimental effects on ERK1/2. In most studies, diabetes, 
rather than a non-diabetes inducing high-fat diet, seems to be the main factor that 
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contributes to downregulation of ERK1/2 (Kim et al., 2010; Lambert et al., 2014; Tai et 
al., 2012).  
 
Interestingly, we found that the HC hearts had an increase in calcineurin compared to 
controls. Calcineurin is a calcium-calmodulin-activated, serine/threonine protein 
phosphatase that responds to elevated intracellular Ca2+ (Crabtree, 1999; Klee et al., 
1998). Calcineurin is known for its role in hypertrophy (Wilkins and Molkentin, 2002) 
and also known to trigger apoptosis or mediate pro-apoptotic effects in cardiomyocytes 
(Wang et al., 2011). A study by He and co-workers (2014) suggests that activated 
calcineurin induces apoptosis by suppressing AMPK/mTOR-dependent autophagy is 
a mechanism that protects cardiomyocytes against oxidative stress (He et al., 2014). 
It is still not clear whether calcineurin is protective or anti-protective in the heart. 
Furthermore, it has been reported to be cardioprotective in a muscle lim protein (MLP) 
knock-out mice (Heineke et al., 2010). We also observed that the HC diet had no 
effects on nitrotyrosine, a marker for oxidative stress (Ahsan, 2013). Others have 
shown high-fat increases the expression of nitrotyrosine and alter myocardial oxidative 
stress and function after I/R injury (Liu and Lloyd, 2013).  
 
Even though we did not see changes in nitrotyrosine, the apoptotic proteins poly (ADP-
ribose) polymerases (cleaved-PARP) and cleaved -caspase-3 were higher (but not 
significant) in these hearts versus the CD group. This might be attributed to the palmitic 
acid which is the major saturated fatty acid in our HC diet. Palmitate has been 
demonstrated to induce apoptosis by increasing the activity of caspase-3 and PARP 
in cardiomyocytes (Wei et al., 2013). Although PARP is involved in routine DNA repair 
processes, its activation is an indicator of cellular stress (Chaitanya et al., 2010). 
 
 
3.4.2 The role of Epac and the RISK pathway on cardiac function and infarct 
size  
 
Epac-Rap has a broad spectrum of effects in cardiac pathophysiology including 
cardiac hypertrophy, arrhythmias and heart failure (Morel et al., 2005; Okumura et al., 
2014; Pereira et al., 2017). However, little is known about Epac’s cardioprotective 
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effects.  In the current study, we have found that an acute administration of an Epac 
selective agonist CPT (2 µM) in the first 10 minutes of reperfusion significantly 
improved post ischaemic cardiac function (Table 3.3) and reduced infarct size (Figure 
3.9 and 3.10) in both HC and CD groups. These findings suggests that Epac-mediated 
protection was independent of the HC diet and resultant increased body weight. 
 
On the other hand, we observed that the selective inhibition of Epac with ESI-9 (5 µM) 
did not affect infarct size, instead it enlarged the area risk (as explained in chapter 2, 
section 2.4). In addition, ESI-09 had a detrimental effect on cardiac function in both 
HC and CD groups. This emphasizes the important role of Epac in normal cardiac 
physiology. 
 
The current study focused on ischaemic post-treatment with CPT as a potential clinical 
relevant model of cardioprotection. Our findings showed that post-treatment with CPT 
improved post-ischaemic total work performance of the heats in the HC group, as well 
as aortic flow and cardiac output recovery in the CD group. In contrast, others who 
also used a similar model of I/R injury found that pre-treatment with CPT (1 µM) for 10 
minutes had no effect on post-ischaemic cardiac functional recovery (Duquesnes et 
al., 2010). Another recent study by Khaliulin and co-workers (2017) demonstrated that 
pre-treatment with CPT (10 µM)  alone had no effect on haemodynamic functional 
recovery but co-treatment with a PKA activator yielded a significant haemodynamic 
functional recovery (Khaliulin et al., 2017). Therefore our post-treatment model was 
more effective since a low concentration of CPT could elicit protection. The protection 
was likely to be PKA independent as it was previously shown that CPT has a low 
affinity for PKA (Enserink et al., 2002; Poppe et al., 2008) and therefore, treating hearts  
with CPT did not alter PKA activity (Khaliulin et al., 2017). Furthermore, Mangmool et 
al. (2015) reported that Epac has a crucial role in glucagon-like peptide-1 receptor 
(GLP-1R)- mediated inhibition of oxidative stress and apoptosis in neonatal 
cardiomyocytes (Mangmool et al., 2015). Edland and co-workers (2016) have reported 
that Epac1 is required in HFD cardioprotection which may explain the so-called 
“obesity paradox” (Edland et al., 2016). Therefore, when we pharmacologically 
activated Epac with CPT in the first 10 minutes of reperfusion it elicited 
cardioprotection against I/R injury. In cardioprotection, time is an important factor 
especially during early reperfusion to prevent ROS production. In this regard, we 
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further investigated the mechanism of Epac-induced protection by studying the pro-
apoptotic cascades and the RISK pathway, after activation with CPT at reperfusion.  
 
We defined the role of the RISK pathway in CPT-induced cardioprotection using PKB 
(A6730) and MEK-ERK1/2 (PD98058) inhibitors, respectively. In the HC group, ERK 
inhibition did not affect CPT protection. However, the PKB antagonist A6730 abolished 
CPT induced functional recovery in HC hearts. PKB is a key player in the modulation 
of myocardial contractility and intracellular Ca2+ handling (Cittadini et al., 2006; 
Condorelli et al., 2002). Furthermore, Epac activation with CPT (10 µM) enhances 
phosphorylation of PKB at Ser473  suggesting its contribution to Ca2+ spark via NOS 
(Pereira et al., 2017). Therefore, the findings suggest that Epac activation with CPT 
enhances myocardial contractility and could be partially medicated via PKB. We also 
found that CPT reduced infarct size in the HC group and co-treatment of CPT and 
A6730 abolished the protection. We speculate that the post-treatment with CPT 
enhanced activation of the survival kinase PKB in that first 10 minutes of reperfusion 
and prevented the opening of the mPTP which led to the reduced infarct size. 
 
 
3.4.3 Mechanism of cardioprotection: signalling pathways  
 
We showed that Post-treatment with CPT in the HC group increased phosphorylated 
PKB compared to CD DMSO control group but not HC DMSO control (Figure 3.15). 
This effect was abolished by a PKB inhibitor A6730. Furthermore, CPT administration 
had no significant effect on the MEK-ERK1/2 signalling cascades. However, Epac 
inhibition with ESI-09 significantly reduced ERK1/2 phosphorylation, but had no effect 
on PKB. It has been shown that IPosC is cardioprotective against I/R injury through 
activation of PI3K-PKB and its downstream targets eNOS and GSK3! (but not 
ERK1/2) (Zhu et al., 2006). The PI3K-PKB-eNOS-NO signalling pathway is also known 
to be cardioprotective (Zhang and Casadei, 2012). We demonstrated that Epac 
activation with CPT significantly decreased phosphorylated eNOS in the HC group.  
However, we also found that the HC diet alone significantly increased phosphorylated 
eNOS compared to hearts from the CD control group. Therefore, the western blot 
results do not confirm or explain the reduction of infarct size caused by CPT. An 
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alternative pathway needs to be investigated e.g. connexins (Schulz et al., 2007) or 
the survivor activating factor enhancement (SAFE) pathway (Lecour, 2009).  
 
Interestingly, we found that CPT significantly increased CaMKII (Thr286) 
phosphorylation which was reversed by ESI-09. It has been demonstrated that 
oxidative stress and I/R injury downregulate the anti-apoptotic isoforms of CaMKII -
delta B and upregulate the pro-apoptotic isoform of CaMKII-delta C (Little et al., 2009; 
Peng et al., 2010). Sarcoplasmic reticulum Ca2+ leakage is associated with CaMKII-
dependent phosphorylation of RyR2 in heart failure myocytes, thus leading to 
arrhythmias and contractile dysfunction (Ai et al., 2005). Oxidative stress increases 
Ca2+ leaks causing mitochondrial Ca2+ overload that leads to a release of caspase 
cofactors and apoptosis (Pinton et al., 2008). In this regard, it has been shown that 
Epac activation with CPT increases Ca2+ sparks via CaMKII activation in 
cardiomyocytes (Pereira et al., 2007). Therefore, the phosphorylation of CaMKII at 
Thr286 by CPT (2 µM) had no detriment effects, instead, it was cardioprotective as 
shown by the reduced infarct size in HC hearts in this study.  
 
Epac inhibition with ESI-09 significantly increased AMPK phosphorylation in the 
current study. AMPK is a stress-activated kinase that responds to intercellular stress 
such as glucose deprivation, hypoxia, oxidative stress and ATP depletion (Nagata et 
al., 2003). We demonstrated that the hearts treated with ESI-09 (5 µM) went into 
contracture in the first 5 minutes of treatment, followed by a loss in cardiac function 
(Table 3.3). Therefore, we can speculate that an increase in AMPK was due to cellular 
stress caused by ESI-09 and resulted in poor cardiac perfusion. On the other hand, 
AMPK activation in early reperfusion was shown to be cardioprotective by reducing 
infarct size (Paiva et al., 2011, 2010).  Even though we found that the ESI-09 treated 
hearts also had a reduction in infarct size, this was rather due to a significant increase 
in the area at risk than a true decrease in necrotic tissue. ESI-09 was previously 
reported to have general protein denaturing properties, suggesting that ESI-09’s 
“inhibitory” properties originate from its protein destabilizing effect (Rehmann, 2013). 
This raised a concern that ESI-09 may not act exclusively on Epac (Rehmann, 2013). 
Studies have demonstrated that ESI-09 synergistically suppresses pancreatic cancer 
cell proliferation and survival (Wang et al., 2017). Interestingly, we found that both CPT 
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and ESI-09 increased the apoptotic marker, cleaved PARP in the control group. The 
reason for this is unclear and needs to be investigated further. In the HC group, on the 
other hand, we found that ESI-09 had no effect on apoptosis markers, cleaved 
caspase-3 and PARP, nor on the oxidative stress maker, nitrotyrosine.  
 
3.4.4 The role of Epac in autophagy   
 
Epac has been reported to promote cardiac remodelling and ventricular hypertrophy 
(Métrich et al., 2008; Morel et al., 2005; Schwede et al., 2015). Emerging evidence 
suggests that cardiac autophagy is upregulated in cardiac remodelling to reverse 
ventricular hypertrophy by increasing protein degradation (Gottlieb and Mentzer, 
2013). In our study, Epac inhibition with ESI-09 increased (though not significantly) 
phospho-dynamin-related protein 1 (DRP1 Ser616) in the HC group. DRP1 is 
upregulated in excessive mitochondrial fusion which contributes to cell death during 
I/R injury (Ong et al., 2010). Excessive mitochondrial fusion causes mitochondrial 
fragmentation, ATP depletion, ROS accumulation and a release of apoptotic cofactors 
(Hu et al., 2017; Park et al., 2018). In contrast, some studies indicate that inhibition of 
DRP1 reduces mitochondrial damage and myocardial injury (Disatnik et al., 2013; Lin 
et al., 2017). Recently Huang and colleagues (2018) showed that inhibition of the ERK-
DPR1 pathway reduces insulin-like growth factor receptor II (IGF-IIR)-mediated 
mitochondrial dysfunction during heart failure (Huang et al., 2018). IGF-IIR has been 
demonstrated to promote activation of JNK-mediated Bcl-2 phosphorylation to 
promote ULK1/Beclin 1-dependent autophagosome formation (Huang et al., 2018). In 
our study Epac activation with CPT reduced phospho ULK1 at (Ser555) and co-
treatment with ESI-09 increased its phosphorylation in the CD group. In the HC group, 
however, CPT and ESI-09 had no effect on phosphorylation or expression of ULK1. 
Collectively, this suggests that an association exists between Epac and autophagy. 
This needs further investigation and the use of autophagy inhibitors might provide a 






The role of Epac signalling in ex vivo thoracic aortas from 
a rat model of high-calorie diet-induced obesity  
 
4.1 Introduction  
 
The vascular endothelium modulates vascular function and homeostasis, and serves 
as the structural barrier between blood vessels and surrounding tissues (Tousoulis et 
al., 2011). Furthermore, vascular endothelial cells are the primary targets for a range 
of harmful metabolic stimuli associated with cardiovascular risk factors, including 
obesity and insulin resistance (Bakker et al., 2000; Heusch et al., 2014; Steinberg et 
al., 1994). Such stimuli can cause both vascular smooth muscle cells and vascular 
endothelial cells to undergo phenotypic changes resulting in the development of cells 
with a proliferative and migratory phenotype that can contribute to endothelial 
dysfunction (Lezoualc’H et al., 2016). Prolonged exposure of the endothelium to 
potentially noxious stimuli such as inflammation, high circulating free fatty acids, 
increased levels of oxidised low-density lipoproteins (LDLox) and hyperglycaemia can 
be associated with obesity-induced endothelial dysfunction (Deanfield et al., 2007).  
Endothelial dysfunction is characterised by reduced nitric oxide (NO) bioavailability 
resulting in an increase in oxidative stress in the endothelium and this results in a 
phenotype characterized by impaired endothelium vasodilation and a proinflammatory 
and prothrombic status (Rogier van der Velde et al., 2015). The endothelium mainly 
secretes mediators such as NO to maintain homoeostasis (Tousoulis et al., 2011). NO 
is a soluble gas synthesised from the amino acid L-arginine in endothelial cells by the 
nitric oxide synthase (NOS) (Behrendt and Ganz, 2002; Palmer et al., 1988). 
Endothelial NOS (eNOS) is one of the three distinct isoforms of NOS and is 
constitutively expressed. eNOS is referred to as a Ca2+- calmodulin-dependent 
enzyme even though it can also be activated in a Ca2+-independent manner (Behrendt 
and Ganz, 2002; Förstermann and Kleinert, 1995). Shear stress (forces exerted on 
the vascular wall by blood flow) is the main trigger of NO production under 
physiological conditions. Other triggers include acetylcholine (ACh), serotonin, 
thrombin and bradykinin (Behrendt and Ganz, 2002).  
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cAMP is one of the well-known second messenger signalling molecules which 
mediates a wide range of vascular processes, including endothelial barrier function 
and vasodilation (Patterson et al., 2000; Roberts and Dart, 2014).  
Impaired cGMP and cAMP-mediated vasorelaxation in the smooth muscle cells was 
associated with reduced endothelium-derived NO production in rats with chronic heart 
failure (Nasa et al., 1996). Epac proteins (downstream effectors of cAMP) are a family 
of guanine nucleotide exchange factors (GEFs) for the small GTPases, Rap1(Epac1) 
and Rap2 (Epac2) (De Rooij et al., 2000; Kawasaki et al., 1998). Current studies have 
provided evidence on the role of Epac in the vasculature using healthy animal model 
(Cuíñas et al., 2016; García-Morales et al., 2017, 2014; Lakshmikanthan et al., 2014). 
However, based on our knowledge there are no studies on rat models that show a link 
or a role for Epac in obesity/high-calorie induced endothelium dysfunction. Therefore, 
the aim of this chapter was to elucidate a putative role Epac signalling in ex vivo 

















4.2 Materials and methods 
 
4.2.1 General materials used  
 
Cell Signaling Technologies (Beverly, MA, USA): antibodies   
1. Total ERKp44/p42 (catalogue number:  #9102)  
2. Phospho-ERKp44/p42 (Thr202/Tyr204) (catalogue number:  #9101) 
3. Total PKB (catalogue number:  #4691) 
4. Phospho-PKB (Ser473) (catalogue number:  #4058)  
5. Total CREB (catalogue number:  #4820) 
6. Phospho-CREB (Ser133) (catalogue number:  #9198) 
7. Total eNOS (catalogue number: #9572) 
8.  Phospho-eNOS (Ser1177) (catalogue number: #9571)  
 
Sigma-Aldrich (St Louis, Mo, USA)  
1. 8-pCPT-2'-O-Me-cAMP (CPT):  Epac agonist. (catalogue number: #C8988) 
2. Isoproterenol hydrochloride (ISO): (catalogue number: #I6504) 
3. N(ω)-nitro-L-arginine methyl ester (L-NAME) (catalogue number: #N5751) 
4. Phenylephrine (PE) (catalogue number: #P6126) 
5. Acetylcholine (ACh) (catalogue number: #A6625) 
 
Biolog Life Science Institute (Bremen, Germany) 
2. 3- [5- (tert.-Butyl)isoxazol- 3- yl]- 2- [2- (3- chlorophenyl)hydrazono]- 3- 
oxopropanenitrile (ESI-09):  Epac antagonist (catalogue number: #B133-05) 
 
Millipore (Billerica, MA, USA) 
1. Signal Boost™ Immunoreaction Enhancer Kit (catalogue number: #4072070) 
2. Anti-Rap1 antibody (catalogue number #07-916) 
 
All other chemicals were of Analar grade and were purchased from Merck (including 
methanol, standard salts for solutions and buffers, and dimethyl sulfoxide (DMSO)). 
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4.2.2 Assessment of vascular reactivity 
 
Male Wistar rats were obtained from the University of Stellenbosch Central Research 
Facility (Tygerberg Campus) and the study was approved by the University of 
Stellenbosch ethics committee (SU-ACUD14-00020). The animals were housed as 
described in Chapter 3, Section 3.2.2. After 16 weeks on the different diets (as 
described in Chapter3, Section 3.2.2, Table 3.1), rats were anaesthetized by lethal 
intraperitoneal injection of pentobarbital (160 mg/kg) for sacrifice. The chest cavity was 
opened by incision. The thoracic aorta was carefully excised and placed in ice-cold 
Krebs Henseleit buffer (mmol/L: NaCl 119, KCl 4.74, CaCl2 1.25, MgSO4 0.6, Na2SO4 
0.59, KH2PO4 1.79, NaHCO3 24.9, Glucose 10). Excess perivascular fat (PVAT) and 
connective tissue were removed. Aortas were cut into 3 - 5 mm ring segments, 
mounted onto 2 steel hooks and suspended horizontally in a 25 ml organ bath (AD 
Instruments, Bella Vista, New South Wales, Australia) containing oxygenated (95% 
O2, 5% CO2) Krebs-Henseleit buffer at 37°C. Aortic ring tension was recorded with an 
isometric force transducer (TRI202PAD, Panlab, lCornellà, BCN, Spain) and data 
analysed with AD LabChart 7 software (Dunedin, New Zealand). The isometric tension 
measurement followed a modified protocol of a previously described technique (Privett 
et al., 2004). 
Briefly, aorta rings were equilibrated at a resting tension of 1.5 g for at least 30 minutes, 
during which the Krebs buffer was replaced every 10 minutes with pre-warmed Krebs 
buffer. After stabilization, the isometric contraction was induced with 100 nM 
phenylephrine (PE), followed by 10 µM acetylcholine (ACh)-induced relaxation to 
confirm the presence of functional endothelium.  
For the assessment of vascular reactivity, aortic ring function was evaluated by pre-
contraction with cumulative PE: 100 nM-1 µM, followed by cumulative ACh induced 
relaxation (30 nM-10 µM) (Fig. 4.1). Preceding this cumulative contraction-relaxation 
responses, aortas were stabilized for 30 minutes and pre-incubated for 15 min with 
either a beta-adrenergic agonist, isoproterenol (ISO, 0.1µM) or Epac selective-agonist, 
8-pCPT-2'-O-Me-cAMP (CPT, 2 µM) or novel Epac inhibitor, ESI-09 (5 µM) or NOS 







Figure 4. 1 Vascular reactivity experimental protocol. 
(A) Wistar rat thoracic aorta, (B) aorta without PVAT, (C) 25 ml organ bath used for isometric tension 
studies, (D) isometric tension chart (AD LabChart 7 software).  
 
4.2.3 Western blot measurements 
 
Rat thoracic aortas were excised and PVAT and connective tissue were removed, and 
incubated into an organ bath containing 25 ml Krebs-Henseleit buffer solution 
completely submerge for 30 minutes stabilization followed by 15 minutes treatment 
with the following drugs (beta-adrenergic agonist, isoproterenol (ISO, 0.1 µM) or Epac 
selective-agonist, 8-pCPT-2'-O-Me-cAMP (CPT, 2 µM) or novel Epac inhibitor, ESI-09 
(5 µM), respectively). Thereafter, the aortas were snap-frozen in liquid nitrogen and 
stored at -80°C.  Frozen aortic tissues were pulverized, and 2-3 aortas were pooled 
per sample for each experimental group. Aortic tissues were then lysed in 
homogenization buffer, the composition of the lysis buffer in mM: 20 Tris-HCl, 1 EGTA, 
1 EDTA, 150 NaCl, 1 b-glycerophosphate, 2,5 tetra-sodium-pyrophosphate, 1 
Na3VO4, along with 50 µg/ml PMSF, 10 µg/ml leupeptin, 10 µg/ml aprotinin, 1% Triton 
PE 100 nM 




30 nM – 10 µM  PE 

















X-100, 0.1% sodium dodecyl sulphate (SDS). A Bradford protein assay was used to 
measure the concentration of the proteins. For protein separation, an equal amount of 
lysate (15 µg per well) was separated by SDS-PAGE using 4-15% Criterionä TGXä 
precast gradient gels (Bio-Rad Laboratories, USA). The proteins were transferred to 
polyvinylidene fluoride (PVDF) membrane, blocked for an hour with 5% long life fat-
free milk in Tris-buffered Saline (TBS) containing 0.1% Tween-20. PVDF membranes 
were then probed with a specific primary antibody in TBS-tween by overnight shaking 
at 4°C (dilutions of primary antibodies: phosphorylated (p) -ERK, Total (t)-ERK, p-PKB, 
t-PKB, p-CREB, t-CREB, p-AMPK, t-AMPK p-eNOS, t-eNOS (from Cell signalling, 
USA) at 1:1000 dilution; for p-eNOS and t-eNOS signal boost (from Millipore, USA) at 
1:1000 dilution was used. Membranes were washed and then incubated with 
horseradish peroxidase-linked secondary antibody (Cell signalling, USA) at 1:4000 
dilution for an hour at room temperature. The protein signal was enhanced with a 
chemiluminescent agent (Bio-Rad Laboratories, USA) and quantified using a 
Chemidoc-XRs imager and analysed with Image Labä 5 Software (Bio-Rad 
Laboratories, USA). 
 
4.2.4 Statistical analysis  
 
All data are expressed as mean ± standard error of the mean (SEM) and Graph Pad 
Prism™ 6 used for statistical analyses. Comparisons of groups were performed by 
one-way ANOVA followed by Bonferroni’s post-test or student’s t-tests (indicated in 
grey asterisk) where applicable. Significance was established at a p-value of <0.05.  
Vascular reactivity data (Emax, maximal tension and Rmax, maximal relaxation) were 
analysed by two-way ANOVA followed by Bonferroni’s post-test. The EC50 (the drug 
concentration inducing 50% of the maximal response), was determined by nonlinear 
regression model analysis following the log X (dose) vs. response transformation of 








4.3.1 Biometric data 
 
Body weights, intraperitoneal fat percentage, glucose and insulin are described in 
chapter 3, section 3.3.1.  
 
4.3.2 The effect of diet and NOS inhibition on aortic function 
 
Aortas from HC fed rats showed no significant difference in vascular reactivity 
compared to the CD-fed rats (Fig.4.2A and Fig.4.2B). To assess the NO contribution 
to endothelium-dependent contraction and relaxation, aortic rings were pre-incubated 
with a nitric oxide synthase (NOS) inhibitor L-NAME (100 µM) for 30 minutes. PE 
induced a maximal contraction response (Emax) in absence of NO which was 
significantly higher compared to control rings in both diet groups: CD + L-NAME versus 
CD (Emax: CD + L- NAME: 1.85 ± 0.19 g vs. CD: 0.90 ± 0.09 g, P<0.05) (Table 1 and 
Fig. 4.2A), HC+L-NAME versus HC group (Emax: HC+L-NAME: 1.98 ± 0.18 g vs. HC: 
0.78 ± 0.07 g, P<0.05) (Table 4.1 and Fig. 4.2A).  
 
The maximal relaxation (Rmax), as induced by Ach, was similar in aortas from both CD 
and HC groups. Pre-treatment with L-NAME significantly attenuated the ACh-induced 
relaxation, thereby confirming NOS-dependence in both diet groups. (Rmax: CD+L-
NAME: 8.59 ± 1.72 % vs. CD: 90.70 ± 3.18 %, P<0.05; HC+L-NAME: 6.35 ± 1.54 % 











Figure 4. 2 The effect of diet and L-NAME on aortic function. 
Aortic rings from rats fed a CD or HC for 16 weeks. (A), aortic tension (g) after phenylephrine (PE) 
induced contraction in absence or presence of L-NAME; (B), aortic relaxation (percentage) induced by 
Acetylcholine (ACh) in absence and presence of L-NAME. Data are expressed as mean ± SEM. Two-
way ANOVA p-vales: *p < 0.05 CD+L-NAME vs CD, #p < 0.05 HC+L-NAME vs HC,. n = 4 per group.  
CD: Control diet  
HC: high calorie diet 




Table 4. 1 The effect of diet and L-NAME on the sensitivity (-LogEC50) and maximal effect (Emax of PE-induced contraction and Rmax of Ach -induced 
relaxation).  
All values are expressed as mean ± SEM. *p < 0.05 vs CD, †p < 0.05 vs HC. n = 4 per group.  
CD: Control diet  
HC: high calorie diet 




Phenylephrine induced contraction   Acetylcholine induced relaxation 
Experimental group (n = 4) Emax Tension (g) (-LogEC50)   Experimental group (n = 4) Rmax (% relaxation) (-LogEC50) 
CD   0.9 ± 0.09 0.83 ± 0.96   CD 90.70 ± 3.18 7.07 ± 0.08 
HC 0.78 ± 0.07 0.74 ± 0.68  HC 87.89 ± 3.47 7.04 ± 0.13 
CD+L-NAME 1.36 ± 0.32* 0.89 ± 2.18  CD+L-NAME   8.59 ± 1.72* 6.50 ± 0.26 




4.3.3 Role of Epac in beta-adrenergic stimulation on aortic function 
 
To test the involvement of Epac in beta-adrenergic stimulation on aortic function, aorta 
rings were pre-incubated with isoproterenol (ISO) (0.1 µM), a beta-adrenergic receptor 
agonist and Epac was inhibited with a selective inhibitor, ESI-09 (5 µM) prior to PE 
induced vasocontraction and ACh induced vasorelaxation.  
Aorta rings from CD 
 
Pre-incubation of the rat aorta rings from CD animals for 15 min with ISO (0.1 µM) 
caused a significant increase in PE-induced vasocontraction compared to DMSO 
vehicle control (Emax: CD+ISO: 1.57 ± 0.11 g vs. CD+DMSO: 1.24 ± 0.11 g, P<0.05) 
(Table 4.2 and Fig. 4.3A). Co-incubation with ESI-09 partially reduced the pro-
contractile effect of both ISO (Emax: CD+ISO+ESI-06: 1.46 ± 0.11 g vs. CD+ISO: 1.57 
± 0.11 g, not significant, ns) (Table 4.2 and Fig. 4.3A) as well as with the vehicle (Emax: 
CD+ESI-06: 1.09 ± 0.14 g vs CD+DMSO: 1.24 ± 0.11 g, ns). There were no significant 
differences observed in ACh-induced vasorelaxation among the groups (Fig. 4.3B). 
 
Aorta rings from HC 
 
Pre-incubation of the rat aorta rings from HC with ISO had no significant effect in PE 
induced contraction in HC groups (Fig. 4.4A).  
However, ISO (0.1 µM) significantly improved vasorelaxation induced by ACh at the 
following concentrations: 30 nM (HC+ISO: 40.03 ± 5.36 % vs. HC+DMSO: 17.09 ± 
3.40 %, p<0.05); 100 nM (HC+ISO: 71.21 ± 5.83 % vs. HC+DMSO: 45.68 ± 6.66 %, 
p<0.05); 1 µM (HC+ISO: 85.21 ± 6.39 % vs. HC+DMSO: 63.21 ± 6.62 %, p<0.05) (Fig. 
4.4B).  
Furthermore, ISO (0.1 µM) was able to effectively improve relaxation of the aortas 
compared to HC+DMSO aortas (-LogEC50: HC+ISO: 7.45 ± 0.09 vs. HC+DMSO: 7.07 
± 0.12, p<0.05 (Table 4.2). Co-incubation of ISO (0.1 µM) with ESI-09 partially reduced 
the pro-relaxant effect of ISO compared to vehicle (-LogEC50: HC+ISO+ESI-09: 7.29 






Figure 4. 3 Role of Epac in beta-adrenergic stimulation of aortic function in CD groups. 
(A), Phenylephrine (PE) induced endothelium contraction (aortic tension) and (B), Acetylcholine (Ach) 
induced relaxation (aortic percentage relaxation) on rat aortas fed a CD for 16 weeks. All values are 
expressed as mean ± SEM. Two-way ANOVA p-vales:  *p < 0.05 CD+ISO vs CD+DMSO. n =  6-10 per 
group. 
CD: control diet 
ISO: beta-adrenergic agonist (0.1 µM)  
ESI-05: Epac antagonist (5 µM) 





Figure 4. 4 Role of Epac in beta-adrenergic stimulation of aortic function in HC groups. 
(A), Phenylephrine (PE) induced endothelium contraction (aortic tension) and (B), Acetylcholine (Ach) 
induced relaxation (aortic percentage relaxation) on rat aortas fed a HC for 16 weeks. All values are 
expressed as mean ± SEM. Two-way ANOVA p-vales: *p < 0.05 HC+ISO vs HC+DMSO. n = 6-10 per 
group. 
HC: high calorie diet 
ISO: beta-adrenergic agonist (0.1µM) 
ESI-05: Epac antagonist (5µM) 
DMSO: vehicle control (0.01%) 
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4.3.4 The effect of Epac on aortic function  
 
To assess the effect of Epac manipulation on PE-induced vasocontraction and ACh-
induced vasorelaxation, the aortic rings were pre-incubated for 15 min with CPT, a 
selective Epac agonist or ESI-09, a specific Epac antagonist prior aortic tension 
studies.  
 
Aorta rings from CD 
 
Pre-incubation of the rat aorta rings with CPT (2 µM) for 15 min had no significant 
effect on PE-induced dependent contraction (Fig. 4.5A).  
 
However, the CPT (2 µM) treated aortas showed a significant improvement in ACh-
induced vasorelaxation versus the untreated aortas at the following ACh 
concentrations: 30 nM (CD+CPT: 49.57 ± 10.25 % vs. CD+DMSO: 19.69 ± 4.86 %, 
p<0.05); 100 nM (CD+CPT: 73.60 ± 4.47 % vs. CD+DMSO: 46.19 ± 6.62 %, p<0.05) 
(Fig. 4.5B). 
Furthermore, Epac activation with its agonist CPT (2 µM) was able to significantly 
improve the sensitivity in CD+CPT aortas compared to CD+DMSO aortas (-LogEC50: 
CD+CPT: 7.60 ± 0.14 vs. CD+DMSO: 7.01 ± 0.08, P<0.05)(Table 4.2 and Fig. 4.5B). 
In addition, co-incubation of CPT (2 µM) with its antagonist ESI-09 (5 µM) significantly 
reduced the sensitivity compared to CPT (-LogEC50: CD+CPT+ESI-09: 7.29 ± 0.06 vs. 
CD+CPT: 7.60 ± 0.14, P<0.05)(Table 4.2 and Fig. 4.5B). These findings confirm that 









Aorta rings from HC 
 
CPT (2 µM) significantly decreased the maximal contractile response (Emax) response 
of the aorta rings to PE in HC (Emax: HC+CPT: 1.02 ± 0.11 g vs, HC+DMSO: 1.29 ± 
0.19 g, P<0.05) (Fig. 4.6A).  
 
CPT (2 µM) treated HC aortas significantly increased ACh-induced vascular relaxation 
as compared to the untreated HC+DMSO aortas at the following ACh concentrations: 
100 nM (HC+CPT: 69.23 ± 5.95 % vs. HC+DMSO: 45.68 ± 6.97 %, P<0.01) 300 nM 
(HC+CPT: 84.87 ± 4.25 % vs. HC+DMSO: 63.21 ± 6.62 %, P<0.05 (Fig. 4.6B). Epac 
activation with CPT (2 µM) was able to significantly improve the sensitivity of HC aortas 
to ACh-induced vasorelaxation ( -LogEC50: HC+CPT: 7.34 ± 0.08 vs. HC+DMSO: 7.07 
± 0.12, p<0.05 (Table 4.2 and Fig. 4.6B) which was reduced by the ESI-09 (5 µM) (-
LogEC50: HC+CPT+ESI-09: 7.11 ± 0.07 vs. HC+CPT: 7.34 ± 0.08,  P<0.05 (Table 4.2 
and Fig. 4.6B). There were, however, no significant differences in the maximal 







Figure 4. 5 The effect of Epac on aortic function in CD groups. 
(A), Phenylephrine (PE) induced endothelium contraction (aortic tension) and (B), Acetylcholine (Ach) 
induced relaxation (aortic percentage relaxation) on rat aortas fed a CD for 16 weeks. All values are 
expressed as mean ± SEM.  Two-way ANOVA p-vales: *p < 0.05 CD+CPT vs CD+DMSO. n = 6-10 per 
group. 
CD: control diet 
CPT: Epac agonist (2 µM) 
ESI-09:Epac antagonist (5 µM) 





Figure 4. 6 The effect of Epac on aortic function in HC groups. 
 (A), Phenylephrine (PE) induced endothelium contraction (aortic tension) and (B), Acetylcholine (Ach) 
induced relaxation (aortic percentage relaxation) on rat aortas fed a HC for 16 weeks. All values are 
expressed as mean ± SEM. Two-way ANOVA p-vales: *p < 0.05 HC+CPT vs HC+DMSO. n = 6-10 per 
group. 
HC: high calorie diet  
CPT: Epac agonist (2µM) 
ESI-09: Eapc antagonist (5µM) 
DMSO: vehicle control (0.01% 
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4.3.5 The role of NOS on CPT-induced vasorelaxation  
 
We further investigated whether direct Epac activation could independently induce 
vasorelaxation. The isolated aortic rings were pre-contracted with PE and then 
cumulative concentrations of only the specific Epac activator, CPT (2 – 10 µM) were 
directly administered to the aortas. In addition, to determine the influence of NOS on 
CPT-induced relaxation, aortas were pre-incubated with L-NAME (100 µM) for 30 
minutes. The CPT induced relaxation was significantly attenuated by L-NAME in CD 
but not in HC aortas (Rmax :CD+L-NAME: 5.28 ± 0.76 % vs. CD: 10.96 ± 1.97 %, P< 
0.05) (Table 4.3 and Fig. 4.7). Furthermore, the CD+CPT and HC+CPT aortas showed 
greater relaxation compared to baseline controls (Rmax : CD: 3.11 ± 0.06% vs. 
CD+CPT: 10.96 ± 1.97, P < 0.05; HC:  3.15 ± 0.74% vs. HC+CPT: 7.27 ± 1.91%, P < 
0.05). This suggests that CPT-induced vasorelaxation is mediated by NOS in CD 
aortas.  
 
Figure 4. 7 CPT induced aortic relaxation in both CD and HC groups in absence or presence 
of L-NAME.  
All values are expressed as mean ± SEM. Two-way ANOVA p-vales: *p < 0.05 vs. CD L-NAME, @p < 




Table 4. 2 The effect of Epac manipulation on the sensitivity (-LogEC50) and the maximal effect (Emax of PE-induced contraction and Rmax of Ach -
induced relaxation).  
All values are mean ± SEM. n = 6-10 per group.*p < 0.05 vs CD+DMSO, †p < 0.05 vs CD+CPT, ‡p < 0.05 vs. HC+DMSO, §p < 0.05 vs HC+CPT.  
CD: control diet                                          CPT: Epac agonist (2 µM) 
HC: high calorie diet                                  ESI-09: Epac antagonist (5 µM)  
ISO: beta-adrenergic agonist (0.1 µM)       DMSO: vehicle control (0.01%
Phenylephrine induced contraction   Acetylcholine induced relaxation 
Experimental group Emax Tension  (g) (-LogEC50)   Experimental group Rmax (% relaxation) (-LogEC50) 
CD+DMSO  1,24 ± 0,11 0,87 ± 0,97  CD+DMSO  89,29 ± 3,87 7,01 ± 0,08 
CD+CPT 1,13 ± 0,17 0,87 ± 1,97  CD+CPT 94,17 ± 7,62 7,60 ± 0,14* 
CD+ESI-09  1,09 ± 0,14 1,21 ± 2,41  CD+ESI-09  83,32 ± 2,77 7,18 ± 0,09 
CD+ESI-09 + CPT  1,19 ± 0,12 1,42 ± 2,48  CD+ESI-09 + CPT  91,09 ± 3,77 7,29 ± 0,06† 
CD+ISO 1,57 ± 0,11* 0,72 ± 0,62  CD+ISO 77,55 ± 8,80 7,11 ± 0,18 
CD+ESI-09 + ISO 1,46 ± 0,17 0,60 ± 1,02  CD+ESI-09 + ISO 81,49 ± 6,23 7,28 ± 0,14 
HC+DMSO  1,29 ± 0,187     0,92 ± 1,79  HC+DMSO  81,02 ± 5,44 7,07 ± 0,12 
HC+CPT 1,03 ± 0,11 1,06 ± 1,46  HC+CPT 98,11 ± 3,37 7,34 ± 0,08‡ 
HC+ESI-09  1,06 ± 0,11 1,14 ± 1,45  HC+ESI-09  93,80 ± 7,59 7,09 ± 0,12 
HC+ESI-09 + CPT  1,18 ± 0,06 1,20 ± 0,88  HC+ESI-09 + CPT  92,77 ± 3,00 7,11 ± 0,07§ 
HC+ISO 1,12 ± 0,13 0,78 ± 0,80  HC+ISO 93,44 ± 5,18 7,45 ± 0,09‡ 






Table 4. 3 Direct effect of CPT on maximal response (Rmax) and sensitivity (-LogEC50) values to 
CPT, with and without L-NAME in both diet groups.  
CPT induced relaxation 
Experimental group Rmax (% relaxation) (-LogEC50) 
CD (baseline) 3.11 ± 0.06 6.1 ± 0.12 
CD+CPT 10.96 ± 1.97*@ 5.38 ± 0.31 
CD+CPT+L-NAME  5.28 ± 0.7 5.59 ± 0.24 
HC (baseline) 3.15 ± 0.74 5.26 ± 0.34 
HC+CPT  7.27 ± 1.91# $ 5.58 ± 0.39 
HC+CPT+L-NAME  2.97 ± 1.10 5.82 ± 0.64 
Aortic percentage relaxation by CPT in absence and presence of L-NAME on thoracic aorta rings fed a 
CD and HC for 16 weeks. Maximal response and EC50 are expressed as mean ± SEM. *p < 0.05 vs. 
CD+CPT+L-NAME, @p < 0.05 vs. CD, #p < 0.05 vs. HC+CPT+L-NAME, $p < 0.05 vs. HC. n = 3-4 per 
group.  
HC: high calorie diet                           
L-NAME: NOS inhibitor (100 µM)   



















4.3.6 Western blot results 
 
4.3.6.1 Rap-GDP expression 
 
There were no significant differences in aortic Rap expression between the CD DMSO 
and the HC DMSO groups. Neither Epac activation nor inhibition caused significant 









    
 
Figure 4. 8 Aortic Rap-GDP expression in CD and HC groups exposed to different treatments.  
(A), representative western blots for total Rap-GDP in CD groups; (B) representative western blots for 
total Rap-GDP in HC groups, (C) total Rap-GDP in CD groups (D), total Rap-GDP in HC groups. All 
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4.3.6.2 PKB phosphorylation and expression 
 
In CD groups, ESI-09 reduced phosphorylated PKB compared to DMSO (ESI-09: 0.69 
± 0.06 vs. DMSO: 1 ± 0.04, P<0.01; ESI-09+CPT: 0.72 ± 0.02 vs. DMSO: 1 ± 0.04, 
P<0.01) (Figure 4.9B). ISO significantly reduced phosphorylated PKB compared to 
DMSO (ISO: 0.62 ± 0.08 vs. DMSO: 1 ± 0.04, P<0.01) (Figure 4.9B). There were no 







Figure 4. 9 Aortic PKB phosphorylation and expression in CD groups exposed to different 
treatments. 
(A), representative western blots for total PKB and phosphorylated PKB; (B), phosphorylated PKB; (C), 
total PKB; (D), phospho/total ratio for PKB in rat thoracic aortas. All values are expressed as mean ± 
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In HC groups, there were no differences in phosphorylated PKB, total PKB and 
phospho: total PKB ratio between CD DMSO and HC DMSO (Figure 4.10B, C and D). 
ESI-09 reduced phosphorylated PKB (ESI-09+CPT:0.69 ± 0.02 vs. DMSO: 0.8 ± 0.04, 
P<0.05) (Figure 4.10B). ISO significantly increased phospho: total PKB ratio  
compared to DMSO (ISO: 1.34 ± 0.05 vs. DMSO: 1.02 ± 0.1, P<0.001) (Figure 4.10D).  








Figure 4. 10 Aortic PKB phosphorylation and expression in HC groups exposed to different 
treatments. 
 (A), representative western blots for total PKB and phosphorylated PKB; (B), phosphorylated PKB; (C), 
total PKB; (D), phospho/total ratio for PKB. All values are expressed as mean ± SEM. n = 3-4 per group. 
*P < 0.05, ***P<0.001. 
B) 
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4.3.6.3 eNOS phosphorylation and expression  
 
Figure 4.11 demonstrates phosphorylated eNOS, total eNOS and phospho: total 
eNOS ratio for aortas from CD groups. There were no significant differences among 






Figure 4. 11 Aortic eNOS phosphorylation and expression in CD groups exposed to different 
treatments. 
 (A), representative Western blots for phosphorylated and total eNOS; (B), phosphorylated eNOS 
levels; (C), total eNOS levels; (D), phospho/total ratio for eNOS. All values are expressed as mean ± 
SEM. n = 3-4 per group.   
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In HC groups, ESI-09 inhibition in aortas co-treated with ISO resulted in reduced eNOS 
phosphorylation (ESI-09+ISO: 0.88 ± 0.11 vs. ISO: 1.59 ± 0.23, P<0.05, Figure 4.12B) 
and phospho: total eNOS ratio (ESI-09+ISO: 1.01 ± 0.08 vs. ISO: 1.5 ± 0.16, P<0.05, 
Figure 4.12D) compared to ISO treated aortas. There were no differences in total 









Figure 4. 12 Aortic eNOS phosphorylation and expression in HC groups exposed to different 
treatments. 
 (A), representative western blots for total eNOS and phosphorylated and total eNOS; (B), 
phosphorylated eNOS; (C), total eNOS; (D), phospho/total ratio for eNOS in rat thoracic aortas (without 
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4.3.6.4 ERK1/2 phosphorylation and expression  
 
Figure 4.13 demonstrates phosphorylated ERK1/2, total ERK1/2 and phospho: total 
ERK1/2 ratio for aortas from CD groups. There were no significant differences among 







Figure 4. 13 Aortic ERK phosphorylation and expression in CD groups exposed to different 
treatments. 
(A), representative western blots for total ERK1/2 and phosphorylated ERK1/2; (B), phosphorylated 
ERK1/2; (C), total ERK1/2; (D), phospho/total ratio for ERK1/2 in rat thoracic aortas (without 
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In HC aortas, ISO reduced total ERK1/2 expression (ISO: 0.62 ± 0.05 vs. DMSO:1 ± 
0.05, P<0.01, Figure 4.14C) and significantly increased phospho: total ERK1/2 ratio 









Figure 4. 14 Aortic ERK phosphorylation and expression in HC groups exposed to different 
treatments. 
(A), representative western blots for total ERK1/2 and phosphorylated ERK1/2; (B), phosphorylated 
ERK1/2; (C), total ERK1/2; (D), phospho/total ratio for ERK1/2 in rat thoracic aortas (without 
perivascular fat). All values are expressed as mean ± SEM. n = 3-4 per group. *P<0.05,**P<0.01.  
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4.3.6.5 AMPK phosphorylation and expression  
 
In CD groups, ESI-09 inhibition increased AMPK phosphorylation (ESI-09: 2.77 ± 
0.03 vs. DMSO: 1 ± 0.27, P<0.05, Figure 4.15B) and phospho: total AMPK ratio 
(ESI-09: 3.78 ± 0.86 vs. DMSO: 0.97 ± 0.18, P<0.05, Figure 4.15D.  
 
CPT and ISO could not reverse the effects of ESI-09 on phosphorylated AMPK 
(CPT+ESI-09: 2.61 ± 0.63 vs. DMSO: 1 ± 0.27, P<0.05;  ISO+ESI-09: 2.1 ± 0.54 vs. 
DMSO: 1 ± 0.27,P<0.05, Figure 4.15B) and phospho: total AMPK ratio (CPT+ESI-
09: 5.18 ± 0.59 vs. DMSO: 0.97 ± 0.18, P<0.001;  ISO+ESI-09: 4.52 ± 1.01 vs. 
DMSO: 0.97 ± 0.18, P<0.05, Figure 4.15D). There were differences in total AMPK 
expression among the groups.   
 
In HC groups, there were no differences in phosphorylated AMPK, total AMPK and 
phospho: total AMPK ratio between CD DMSO and HC DMSO. ESI-09 significantly 
increased AMPK phosphorylation compared to HC DMSO (ESI-09: 2.51 ± 0.35 vs. 
DMSO: 0.91 ± 0.11, P<0.05, Figure 4.16B).  
Epac inhibition increased phospho: total AMPK ratio (ESI-09: 4.12 ± 0.96  vs. 
DMSO: 1.38 ± 0.26 , P<0.05, Figure 4.16D), which was reversed by CPT (CPT+ESI-
09: 3.01 ± 1.03 vs. DMSO: 1.38 ± 0.26, ns), but not by ISO (ISO+ESI: 4.33 ± 0.81 
vs. DMSO: 1.02 ± 38, P<0.05, Figure 4.16D). There were no differences in total 



















Figure 4. 15 Aortic AMPK phosphorylation and expression in CD groups exposed to 
different treatments.  
(A), representative  western blots for total AMPK and phosphorylated AMPK; (B), phosphorylated 
AMPK; (C), total AMPK; (D), phospho/total ratio for AMPK in rat thoracic aortas (without perivascular 
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Figure 4. 16 Aortic AMPK phosphorylation and expression in HC groups exposed to different 
treatments 
(A), representative western blots for total AMPK and phosphorylated AMPK; (B), phosphorylated 
AMPK; (C), total AMPK; (D), phospho/total ratio for AMPK in rat thoracic aortas (without perivascular 
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4.3.6.6 CREB phosphorylation and expression  
 
Figure 4.17 represents CREB phosphorylation, total CREB and phospho: total CREB 
ratio in aortas from the CD group. ISO increased phospho:total CREB ration compared 
DMSO (ISO: 2.11 ± 0.33 vs. DMSO: 0.98 ± 0.15, P<0.05, Figure 4.17D). Epac 
inhibition reverse the effect of ISO (ISO+ESI-09: 1.11 ± 0.22 vs. DMSO: 0.98 ± 0.15, 
ns, Figure 4.17D). There were no significant differences in total CREB expression 







Figure 4. 17 Aortic CREB phosphorylation and expression in CD groups exposed to different 
treatments. 
(A), representative western blots for total CREB and phosphorylated CREB; (B), phosphorylated 
CREB; (C), total CREB; (D), phospho/total ratio for CREB in rat thoracic aortas (without perivascular 
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Figure 4.18 demonstrates phosphorylated CREB, total CREB and phospho: total 
CREB ratio for aortas from HC groups. There were no significant differences among 








Figure 4. 18 Aortic CREB phosphorylation and expression in HC groups exposed to different 
treatments 
A), representative western blots for total CREB and phosphorylated CREB; (B), phosphorylated 
CREB; (C), total CREB; (D), phospho/total ratio for CREB in rat thoracic aortas (without perivascular 
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4.4 Discussion  
 
The aim of this study was to elucidate a putative role Epac signalling in ex vivo thoracic 
aortas of a rat model of high calorie diet-induced obesity. This study has demonstrated 
that a high-calorie diet (HC) had no effect on PE and ACh induced vascular reactivity. 
Beta-adrenergic stimulation with ISO and selective Epac stimulation significantly 
improved vasorelaxation in HC and CD aortas which was abolished by an Epac 
inhibitor ESI-09. Furthermore, CPT directly induced vasorelaxation in a dose-
dependent manner in both HC and CD group and this effect was NOS-dependent, as 
it was abolished by L-NAME (NOS inhibitor). Acute stimulation of Epac with CPT (2 
µM) had no effect on PKB and eNOS phosphorylation in HC. However, ESI-09 
significantly reduced the PKB phosphorylation in CD aortas suggesting that blocking 
Epac activity may have a detrimental effect on the PKB pathway. Furthermore, ESI-
09 significantly increased stress-activated kinase AMPK in both HC and CD aortas.  
 
4.4.1 The role of Epac in vascular reactivity  
 
In this study, Wistar rats fed with an HC showed significant increases in body weight 
and intraperitoneal fat which may be an indication of overweight/obesity. This was 
followed by an elevation in non-fasting glucose concentration and insulin resistance 
(HOMA-IR index) after 16 weeks on diet (as previously discussed in Chapter 3, section 
3.4.1). Previous studies have reported the harmful effects of excessively high energy 
diets on vascular function. For example, both high-fat diet (HFD) and high sucrose diet 
have been shown to induce adiposity and oxidative stress which can lead to the 
development of endothelial dysfunction (Sweazea et al., 2010). In our study, we found 
no changes in vascular reactivity between the HC and CD rat aortas. We 
demonstrated that L-NAME attenuated ACh-induced relaxation in both CD and HC 
groups and therefore confirmed NOS dependence. The L-NAME pro-contractile and 
anti-relaxation on endothelium function was the same in both diet groups, thus HC did 
not adversely affect the endothelial function. Poncelas et al. (2015) have 
demonstrated that even 6 months of feeding high-fat diet in mice could not alter 





There is growing interest in the role of cAMP and in particular the Epac signalling 
pathway in cardiovascular health (Lezoualc’H et al., 2016). Therefore, in our study, we 
were interested in the role of Epac on vascular reactivity of rat aortas (ex vivo) pre-
exposed to “obesogenic” high energy diets. We investigated the effect of beta-
adrenergic stimulation on aortic vascular reactivity in aortas exposed to a 16 week 
high-calorie diet (HC). The beta-adrenergic agonist ISO activates the second 
messenger cAMP (Stamper et al., 2009), which could activate downstream cascades 
PKA and Epac. It has been shown that aortic rings from 1 week ISO-treated (in vivo) 
Wistar rats had an increase in the contraction response to PE but the relaxation 
response to ACh remained unchanged (Davel et al., 2006). In our study, we found 
similar results with an acute 15 minutes stimulation of the beta-adrenergic receptor 
with ISO (0.1 µM), with an increase in PE-induced vasocontraction in CD aortas but 
no effects on relaxation. However,  Cuíñas and colleagues (2016) suggests that 
activation of PKA and Epac by cAMP in vascular smooth muscle cells led to a decline 
in intracellular Ca2+ stores thereby reducing Ca2+ availability for vasocontraction 
(Cuíñas et al., 2016). On the other hand, we found that ISO administration to HC 
aortas did not affect the PE-induced vasocontraction but improved the response to 
ACh induced vasorelaxation. Epac1/2 inhibition with ESI-09 reduced these effects of 
beta-adrenergic stimulation on vascular reactivity in both HC and CD aortas. 
 
From these findings, we could conclude that the vasorelaxation in HC aortas was 
mediated, at least in part, by Epac. However since the effect was only partial, this does 
not exclude the effect of PKA. In rat aortas, PKA was reported to be involved in 
endothelium-dependent vasorelaxation induced by stimulation of beta-adrenergic 
receptors (Ferro et al., 2004). The study by García-Morales and colleagues (2014) 
demonstrated a role for PKA in vascular smooth muscle in relaxation from healthy 
Wistar rats aortas by directly activating PKA with is agonist 6-Benz-cAMP suggesting 
that PKA activates eNOS to catalyse the release of  NO in the vascular smooth muscle 
cells (García-Morales et al., 2014). They further investigated the participation of Epac 
on cAMP vasorelaxation effect and found that the Epac activator CPT significantly 
relaxed PE pre-contracted aortas with or without endothelium suggesting that Epac 
vasorelaxation act via both the endothelium as well as directly on the vascular smooth 





activators can relax not only vascular type but also the non-vascular type of smooth 
muscle cells (Roscioni et al., 2011). In our study, the selective Epac activation with 
CPT (2 µM) did not affect PE induced vasocontraction in CD aortas. However, the 
Epac activation was anti-contractile in HC aortas with a reduced maximal 
vasoconstrictor (Emax) response to PE.  
The present study showed that Epac activation with CPT, even at the low 
concentration of 2 µM, increased the sensitivity of both CD and HC aortas to ACh-
induced relaxation. This was abolished by Epac inhibitor ESI-09 in both CD and HC 
aortas. It has been shown that, in the vascular smooth muscle cell and endothelium, 
Epac (Rap1B) is required for the maintenance of vascular tone and blood pressure 
(Lakshmikanthan et al., 2014). Therefore, our study confirms that Epac plays an 
important role in vascular smooth muscle relaxation even in the context of “obesity”.  
We further investigated the mechanism of Epac’s vasorelaxation effect by blocking 
NOS with L-NAME and then exposed the aortic rings to a cumulative concentrations 
of CPT (1, 2, 5 and 10 µM) only. CPT relaxed both CD and HC aortas via NOS (Figure 
4.7). In the endothelium and vascular smooth cells, Epac can directly mediate 
vasorelaxation through regulation of Ca2+-sensitive and ATP-sensitive K+ channels 
(Purves et al., 2009; Roberts et al., 2013). For arterial smooth muscle relaxation, Epac 
activates eNOS which catalyses the release of NO from the vascular endothelial cells 
which is a potent vasodilator (García-Morales et al., 2014).  
 
4.4.2 Molecular mechanisms: signalling pathways  
  
Vascular function/tone is regulated through various signalling pathways, and cAMP 
and cGMP are considered to be the main second messengers involved (Morgado et 
al., 2012). Epac (cAMP-GEF) serves as guanine nucleotide exchange factors (GEFs) 
for the small G-protein (Rap1 and Rap2). Rap1 is a key regulator of endothelial barrier 
function (Aslam et al., 2014; Birukova et al., 2010, 2008, 2007; Pannekoek et al., 2014) 
,vascular tone, (Lakshmikanthan et al., 2014; Roberts et al., 2013; Roscioni et al., 
2011; Zieba et al., 2011), VSMC proliferation (Hewer et al., 2011), and vascular 
remodelling (Yokoyama et al., 2010, 2008b, 2008a). In this regard, it is necessary to 





fat induced endothelium dysfunction). In this study, we investigated the involvement 
of signalling pathways, in particular the cAMP-Epac/Rap pathway in aortas from male 
Wistar rat after a 16 week exposure to a HC. In addition, the Epac/Rap pathway was 
activated in ex vivo isolated aortas by the administration of an Epac agonist CPT 
(2µM). In the current study, Rap-GDP (inactive Rap) expression did not differ between 
the diet groups. Epac1/Rap1 is required for NO release and endothelium function 
(Chrzanowska-Wodnicka, 2017; García-Morales et al., 2014; Lakshmikanthan et al., 
2014). Rap1 deficiency in mice aortas is associated with an increase in oxidative 
stress and impaired endothelium-dependent NO production (Wong et al., 2018). In 
human endothelial cells, eNOS was activated by both PKA and Epac via the PI3K/PKB 
pathway (García-Morales et al., 2017). In the endothelium, the insulin-dependent NO 
production via insulin receptor substrate 1 (IRS1) activates PI3K/PKB pathway, which 
in turn phosphorylates eNOS at ser1177 (Arce-Esquivel. et al., 2013). However, an 
increase in circulating free fatty acids as observed in obesity and type 2 diabetes 
patients can lead to insulin resistance, thus compromising the IRS1-PI3K/PKB-eNOS 
pathway (Capurso and Capurso, 2012; Imrie et al., 2010).  
 
In this study, the diet and Epac activation with CPT showed no significant changes in 
PKB and eNOS phosphorylation and expression in rat aortas (without PVAT). 
However, ESI-09 inhibition reduced PKB phosphorylation in both CD and HC. These 
findings suggest that blocking Epac activity with ESI-09 may have detrimental effects 
on PKB and possibly also the eNOS pathway. In HC aortas, a significant increase in 
phosphorylated :total PKB was noted upon cAMP elevation with isoproterenol (ISO) 
and coincubation with ESI-09 did not reverse the effect, thus suggesting the 
involvement of PKA (García-Morales et al., 2017). Interestingly, ISO effects on HC 
phosphorylated :total eNOS were abolished by co-incubation of ISO and ESI-09. Thus, 
suggesting that both Epac and PKB are involved in PKB-eNOS phosphorylation in rat 
aortas from the HC group. Furthermore, Epac activation with CPT did not affect MEK-
ERK1/2 phosphorylation and expression in either CD or HC aortas. The Ras/Raf/MEK-
ERK1/2 pathway is known to play a crucial role in endothelial function (proliferation 
and migration during angiogenesis) (Hood et al., 2003; Liu et al., 2001; Srinivasan et 
al., 2009). In HC aortas, beta-adrenoreceptor activation with ISO showed an increase 





reversed the phosphorylated: total ERK1/2 ratio suggesting the involvement of Epac. 
Cai and co-worker (2008) suggested that the ERK1/2- myosin light chain kinase 
(MLCK) pathway is involved in CaMKII cytoskeleton reorganization and barrier 
function in both macrovascular and microvascular endothelial cells (Cai et al., 2008).  
 
We further investigated a possible association between Epac and the stress-activated 
kinase AMPK. In the present study, there were no differences in AMPK 
phosphorylation and expression between the CD and HC aortas. ISO and CPT did not 
affect phosphorylation and expression of this metabolic censor in the aortas. 
Surprisingly, Epac inhibition with ESI-09 significantly increased AMPK 
phosphorylation and phosphorylated: total ratio in both CD and HC aortas. In the 
previous chapter (Chapter 3, section 3.3.5.9), the ESI-09 also increased AMPK 
phosphorylation in hearts from the HC diet group. Further, the hearts went to 
contracture and cardiac function was lost. Therefore, the increase in AMPK might be 
due to intracellular stress such as hypoxia and ATP depletion within the cells (Nagata 
et al., 2003). However, the ESI-09 effect on AMPK requires further investigation. On 
the other hand, García-Prieto and colleagues (2015) have demonstrated that high-fat 
diet induced endothelial dysfunction was associated with a downregulation of the 
AMPK/PI3K/PKB/eNOS signalling pathway (García-Prieto et al., 2015). Furthermore, 
both PKB and AMPK are known to be involved in the activation of eNOS at Ser1177 by 
cAMP elevating agents (Hashimoto et al., 2006; Tanano et al., 2013; Zhang and 
Hintze, 2006). AMPK inhibition eradicates eNOS Ser1177 phosphorylation and NO 
production in human umbilical vein endothelial cells (Han et al., 2015). This suggests 
that AMPK contributes to NO production in endothelial cells. However, García-Morales 
and co-workers (2017) showed that Epac and PKB activated eNSO phosphorylation 
at Ser1177 via PKB, independent of AMPK, CaMKII activation or increased cytoplasmic 
Ca2+ concentration (García-Morales et al., 2017).  
Furthermore, Epac activation with CPT did not affect CREB phosphorylation and 
expression in either the HC or the CD group. However, beta-adrenergic stimulation 
with ISO resulted in the phosphorylation of CREB, a downstream effector on PKA, and 





In conclusion, agonist-induced Epac activation improved vasorelaxation via NOS in 
































The role of Epac signalling in palmitic and oleic acid 
induce endothelial dysfunction 
 
5.1 Introduction  
 
Elevated levels of free fatty acids (FFAs) in the blood circulation are associated with 
an increased risk of CVD and, are closely related to obesity and type 2 diabetes 
mellitus (Boden, 2011, 2008; Egan et al., 2001). Overconsumption of dietary fats 
induce obesity, increase serum FFAs and induce lipotoxicity and insulin resistance in 
vivo animal models (Liu et al., 2015). For in vitro studies, FFAs are used to mimic in 
vivo high fat diet-induced lipotoxicity (Liu et al., 2015). Abnormal elevation of FFAs has 
been shown to induce oxidative stress followed by an increase in inflammatory 
markers, which results in insulin resistance and impaired endothelial function (Boden, 
2008; Ellies et al., 2013; Fratantonio et al., 2015). Furthermore, excessive FFAs 
including palmitic acid (PA), are significant sources of reactive oxygen species (ROS) 
in vascular cells, leading to oxidative stress, a crucial step in the development of 
endothelial dysfunction (Ghosh et al., 2017). Endothelial dysfunction can be described 
as reduced production and/or availability of nitric oxide (NO) (as described in Chapter 
4, Section 4.1). Saturated FFAs such as PA have been associated with the 
downregulation of eNOS in porcine aortic endothelial cells (Van Vickle, 2005). 
Furthermore, FFAs overload inhibits Ca2+ signalling and NO production in endothelial 
cells (Esenabhalu et al., 2003). Previous studies have demonstrated the role of the 
cAMP-Epac pathway in vascular structure and function including endothelial cell 
barrier function, regulation of vascular tone, smooth muscle vasorelaxation and 
inflammation (Cullere et al., 2005; Lezoualc’H et al., 2016; Purves et al., 2009; Roberts 
et al., 2013; Sands et al., 2006). However, to our knowledge, this is the first study 
investigating the effect of the cAMP-Epac pathway in obesity/FFAs induced 
endothelial dysfunction. In this chapter, it was aimed to establish an in vitro model of 
FFAs (obesity)-induced endothelial dysfunction and to explore the role of the cAMP-
Epac pathway in this model. To achieve the aim, rat aortic endothelial cells (RAECs) 





acid, oleic acid (OA) to induce endothelial dysfunction. In addition, the cells were 
treated with an Epac agonist, CPT and Epac antagonist, ESI-09, respectively.  
 
 
5.2 Material and methods:  
Materials: 
 
Cell Applications, San Diego, CA, USA) 
1. Rat endothelial cell growth medium (catalogue number: #R211-500)  
2. Rat endothelial cell Basal medium (catalogue number: #R210-500) 
3. Foetal bovine serum (FBS) (catalogue number: #026-100) 
 
Thermo Fisher Scientific, MA, USA 
1. Gibco™ Trypsin 2.5%, no phenol red (catalogue number:  #15090046) 
2. Gibco™ Attachment factor (catalogue number:  #S006100) 
3. Dihydrorhodamine-1, 2, 3 (DHR-123) (catalogue number:  #D23806) 
4. Dihydroethidium (DHE) (catalogue number:  #D11347) 
 
Sigma-Aldrich (St Louis, Mo, USA)  
1. 8-pCPT-2'-O-Me-cAMP (CPT):  Epac agonist. (catalogue number: #C8988) 
2. Dimethyl Sulfoxide (DMSO) (catalogue number: #276855) 
3. Oleic acid (OA) (catalogue number:  #O1008) 
4. Palmitic acid (PA) (catalogue number: #P0500) 
5. Diethylamine NONOate diethylammonium salt (DEA/NO) (catalogue number: 
D5431) 
6. 4,5-diaminofluorescein-2/diacetate (DAF-2/DA) (catalogue number: D2813) 
7. Propidium Iodide (PI) (catalogue number: #P4170)  
 
Biolog Life Science Institute (Bremen, Germany)  





5.2.1 Rat aortic endothelial cells (RAECs) 
 
RAECs were purchased from VEC Technologies (Rensselaer, New York, USA). On 
arrival the cells were given fresh rat endothelial cell growth medium in a 75 mm2 flask  
and allowed to grow until confluent in a standard tissue culture incubator (Forma 
Series II, Thermo Electron Corporation, Waltham, MA, USA) and maintained at 37 °C 
in a 40 – 60% humidity with 5% CO2. For the first passage, the cells were subcultured 
into 5 x 25 mm2 flasks and allowed to grow until confluent. From the second (P1) , 
third (P2) to the fourth passage (P3), the cells were trypsinized (3 minutes with 0.25% 
trypsin) and suspended in a  freezing medium (90 % foetal bovine serum (FBS), 5 % 
growth medium and 5 % DMSO) (Genis, 2014). Aliquots were then stored in liquid 
nitrogen for experimental use as shown in Figure 5.1.  
 
5.2.2 Seeding of cells 
 
Stored RAEC’s were seeded in 35 mm petri dishes pre-coated with an attachment 
factor and given a fresh growth medium, and incubated in a standard tissue culture 
incubator until confluency. Every second day the RAECs were washed twice with 
phosphate buffered saline, PBS (137 mM NaCl, 2.68 mM KCl, 8.33 mM Na2HPO4, 
1.47 mM KH2PO4, pH 7.4), and given fresh growth medium. The RAECs were regularly 
monitored by light microscopic to validate purity by observing a typical monolayer, 
cobblestone appearance exhibited by cultured endothelial cells (Figure 5.2)(Westcott, 
2015). When the RAECs reached (90-100%) confluency, the cells were passaged to 







Figure 5. 1 Passaging and cell aliquot storage procedures (Genis, 2014) 
 
5.2.3 Passaging of cells 
 
Briefly, the cells were washed twice with PBS and trypsinized to detach cells from the 
bottom of gelatin-containing attachment factor-coated 35 mm petri dishes. Detached 
cells were then immediately transferred into a 15 ml conical tube containing growth 
media and centrifuged at 1000 rpm for 3 minutes at 4°C. The supernatant (medium 
containing trypsin) was then aspirated and pellet (cells) was transferred into a fresh 
growth medium and seeded into the next generation. The P3 generations of cells 
(stored cells) were also passaged until the seventh generation and used for plate 
reader assays (5-diaminofluorescein-2/diacetate (DAF-2/DA), Propidium Iodide (PI) 
and dihydrorhodamine 123 (DHR)) (Figure 5.3). All experiments were repeated thrice, 
each time using a new P3 generation of cells (plate reader assays), thus three 








Figure 5. 2 Micrograph of RAECs morphology in culture (10x magnification; Carl Zeiss 












































Figure 5. 3 Passaging of cells from P3 generation to the 7th generation for plate reader assays 
(two 35 x10 mm petri dish goes to one 24 well plate). 
 
P3 generation cells 
 
(P3 generation cells were seeded into a 35x10 mm petri 
dish pre-coated with attachment factor) 
 
P4  
 Passage    
 Passage    
P5  
Passage    
P6  
Passage    
The P6 generation was passaged and cells seeded in a 24 well plate (Vision 







5.2.4. Preparation of drugs and free fatty acids (FFA) 
 
Palmitic acid (0.256 g) (Sigma-Aldrich, St Louis, Mo, USA) and Oleic acid (0.282 g) 
(Sigma-Aldrich, St Louis, Mo, USA) were dissolved in 100% ethanol (5 ml) to make a 
200 mM stock of each. CPT (5 mg) (Sigma-Aldrich, St Louis, Mo, USA) was dissolved 
in distilled water (9.846 ml) to make 1 mM stock. ESI-09 (1.654 mg) (Sigma-Aldrich, 
St Louis, Mo, USA) was dissolved in DMSO (100 µl) to create a 50 mM stock.   
  
5.2.5 Treatment of cells   
 
For all experiments, the RAECs were allowed to grow up 80% confluency. The cells 
were then serum-starved for 24 hours with rat endothelial cell basal medium 
(containing 0% FBS) (Cell Applications, Inc, San Diego). The purpose of serum 
starvation is to synchronise the cells in different stages of the cell cycle to the G0 phase 
(Langan and Chou, 2011). After 24 hours, the basal medium containing 0% FBS was 
aspirated.  
 
The cells are incubated in rat endothelial cell growth medium (containing 10% FBS) 
(Cell Applications, San Diego, CA, USA) for 24 hours in control groups. For treatment 
groups, the rat endothelium growth medium was supplemented with 50 µM – 500 µM 
palmitic acid or 50 µM – 500 µM oleic acid or the combination (palmitic acid + oleic 
acid) to establish a model of obesity/FFA-induced endothelial dysfunction (Figure 5.4).   
 
Furthermore, cells were divided into control/”Lean” groups and FFA/”Obese” groups 
and treated with different concentrations of an Epac agonist (CPT 2, µM – 10 µM) or 














Figure 5. 4 Plate reader experimental setup for cells with different FFA concentrations. 
A), 50 µM – 200 µM FFA dosages and B), 300 µM – 500 µM FFA dosages, Ethanol 0.1% (vehicle). 
Palmitic acid (PA) and oleic acid (OA). Positive controls: Diethylamine NONOate diethyl ammonium 
salt (DEA/NO 100 µM) for DAF-2/DA assay, Peroxynitrite (100 µM) for DHR-123 assay, distilled water 

















Figure 5. 5 Plate reader experimental setup for cells with different drug concentrations in 
combination with “Lean” (without free fatty acids) and “Obese” (with palmitic acid, PA and oleic 
acid, OA) groups. 
Positive controls: Diethylamine NONOate diethyl ammonium salt (DEA/NO 100 µM) for DAF-2/DA 













5.2.6 Plate reader assays 
 
After a 24 hour treatment period, the cells were fully confluent and ready for the plate 
reader assays. The assays included, (a) NO measurements using DAF-2/DA, (b) 
oxidative stress measurements using DHR-123 (dihydrorhodamine 123) and (c) cell 
viability measurements using PI (Propidium Iodide).  
 
5.2.6 (a) NO measurements: DAF-2/DA 
 
After a 24 hour treatment, the growth medium containing the drugs was aspirated from 
24 well plates. The plates were then washed once with PBS followed by incubation 
with DAF-2/DA (10 µM) for 2 hours at 37ºC. DAF-2/DA is a cell permeable fluorescent 
NO indicator. It reacts to NO to yield the highly fluorescent triazolofluorescein (DAF-
2T) (Zhou and He, 2011).  
 
In the final 30 minutes of the 2 hour incubation period, a Diethylamine NONOate 
diethyl ammonium salt (DEA/NO 100 µM) (Sigma-Aldrich, St. Louis, MO, USA) was 
added in the positive control well (Genis, 2014). DEA/NO is a known NO donor.  
 
After two hours, the DAF-2/DA probe was aspirated from all wells and the cells were 
resuspended in PBS. The fluorescence was measured using a FLUOstar Omega 
microplate reader (BMG LABTECH, Ortenberg, Germany) (at 485 nm excitation and 
520 nm emission.  
 
The fluorescence intensity of the positive control and treatment groups are expressed 







Figure 5. 6 Effects of treatment with the NO donor, DEA/NO (positive control) to validate the 
NO-specificity of DAF-2/DA. 
DAE/NO (100 µM) showed a significant increase in fluorescent intensity compared to vehicle control 
(Ethanol),** P<0.01 vs. control (ethanol).  
 
5.2.6 (b) Oxidative stress measurement: DHR-123 
 
After 24 hours, the cells were washed with PBS once and DHR-123 (5µM) (Sigma-
Aldrich, St Louis, Mo, USA) was added and incubated for 3 hours at 37ºC. DHR-123 
is an uncharged nonfluorescent intracellular ROS indicator that can freely diffuse 
across membranes and be oxidized to form a cationic rhodamine 123 which localizes 
in the mitochondria and exhibits green fluorescence (Henderson and Chappell, 1993). 
DHR-123 has previously shown to be sensitive to oxidants including peroxynitrite 
(Valez et al., 2013). 
 
After an hour, authentic peroxynitrite (100 µM) was added to the positive control well 
and incubated for the final 2 hours of the total 3 hours at 37ºC. Peroxynitrite is a 
biological oxidant that can damage a wide range of molecules in cells including DNA 
and proteins. After 3 hours, the fluorescence was immediately read on the FLUOstar 
Omega plate reader at 485nm excitation and 520nm emission. The fluorescence 







Figure 5. 7 Effects of treatment with authentic peroxynitrite (positive control) to validate the 
relative peroxynitrite-specificity of DHR-123. 
Cells treated with peroxynitrite (100 µM) showed a significant increase in DHR fluorescence intensity, 
an indication of cellular oxidative stress.****P<0.0001 vs. control (ethanol).  
 
5.2.6 (c) Cell viability: Propidium iodide  (PI) 
 
PI is an indicator of cell death (apoptosis and necrosis) (Crowley et al., 2016; Wilkins 
et al., 2002). PI is a large molecule and cannot cross the cell membranes of normal 
healthy cells. Therefore in apoptotic and necrotic cells, when cell membranes have 
lost their integrity, PI can penetrate cells and bind to DNA in the nucleus and a 
fluorescent reaction is elicited (Wilkins et al., 2002). Cells that are fluorescent with PI 
are assumed to be damaged. Cells treated with distilled water were included as 
positive controls. Distilled water causes the cells to swell and burst through osmosis 
and allows the PI to bind to DNA and change colour.  
After 24 hours, the cells were washed with PBS and 900 µL of PBS was added to each 
well except for the wells used as positive controls. For the latter, 900µL of distilled 
water was used. Propidium iodide (PI) (5 μM) (100µL in 900 µL) was  added to each 
well to have an equal volume of 1ml per well and the plates were incubated for 15 
minutes. After 15 minutes, the fluorescence was immediately read on the FLUOstar 
Omega plate reader at 544nm excitation and 640nm emission. The fluorescence 







Figure 5. 8 Propidium iodide validation. 
The RAECs treated with distilled water had a significant increase in PI fluorescence intensity which 
indicates cell death. **P<0.01 vs. control (ethanol).  
 
 
5.2.7 Statistical analysis  
 
Fluorescence values from the positive control and treatment groups were expressed 
as a percentage of the vehicle control fluorescence. All values are expressed as mean 
± standard error of the mean (SEM) and Graph Pad Prism™ 6 was used for statistical 
analyses. Comparisons of groups were performed by ANOVA (one-way or two-way) 
followed by Bonferroni’s post-test or student’s t-tests where applicable. Significance 













5.3 Results  
 
5.3.1 Effect of FFA on RAECs: Dose-response 
 
The P7 generation RAECs were treated with different concentrations of palmitic acid 
(PA) or oleic acid (OA) or the combination of PA+OA for 24 hours with the aim of 
inducing endothelial dysfunction. Figure 5.9 (A and B) represents NO production using 
the DAF-2/DA fluorescent probe. NO production was reduced in RAECs treated with 
a combination of FFA (PA+OA) although the differences were not significant. 
However, this was a pilot study with an n-value of 2 per group. We then saw a 
significant difference with larger n-value of three per group (Figure 5.10).  
 
Figure 5.9 (C and D) represents fluorescence readings with the DHR probe. There 
were no significant differences between the groups. Furthermore, there were also no 

























Figure 5. 9 Effect of different concentrations of PA (50 µM – 500 µM) and the combination of 
PA + OA (50 µM – 500 µM) on RAECs. 
A and B), NO production as measured by DAF-2/DA fluorescence; C and D), % DHR fluorescence 
cells; E and F), % Propidium iodide fluorescence cells. All values are expressed as a percentage of the 










5.3.2 Effect of Epac modulation in healthy and FFA-treated RAECs: Dose-
response of drugs 
 
For a dose-response of drugs on the RAECs, the P7 generation were treated with 
FFAs (500 µM PA + 500 µM OA) and different dosages of Epac activator (CPT: [2 µM, 
5 µM, 10 µM]) and/or Epac inhibitor (ESI-09: [1 µM, 5 µM, 10 µM]) for 24 hours. The 
production of NO, oxidative stress and cell viability were measured using the 
appropriate fluorescent probes.  
 
5.3.2 (a) NO production  
 
Figure 5.10 A represents NO production as measured by DAF-2/DA fluorescence 
intensity in RAECs treated with CPT [2 µM] and ESI-09 [1 µM]. Epac activation with 
CPT [2 µM] significantly increased NO production compared to control (CPT [2 µM]: 
129.3 ± 5.8% vs. Control: 100%, P<0.1). Epac inhibition with ESI-09 [1 µM] 
significantly reversed the CPT [2 µM] effect on NO production (CPT [2 µM]: 129.3 ± 
5.8% vs. CPT [2 µM] + ESI-09 [1 µM]: 102.7 ± 5%, P<0.01). RAECs treated with FFA 
had a significant reduction in NO production compared to nontreated cells (FFA: 60.3 
± 1.2% vs. Ethanol (vehicle): 101.7 ± 2.7%, P<0.0001).  
However, neither Epac activation nor inhibition had a significant effect on FFA-treated 
cells (Figure 5.10 A, B, C). 
 
Figure 5.10 B represents NO production as measured by DAF-2/DA fluorescence 
intensity in RAECs treated with CPT [5µM] and ESI-09 [5µM]. The [5 µM] CPT 
concentration also increased NO production in RAECs compared to control (CPT [5 
µM]: 124.7 ± 1.2% vs. control: 100%, P<0.01). However, inhibition with [5 µM] ESI-09 
did not affect NO production.  
  
Figure 5.10 C represents NO production as measured by DAF-2/DA fluorescence 
intensity in RAECs treated with CPT [10µM] and ESI-09 [10µM]. CPT [10 µM] 
increased NO production when compared to control RAECs (CPT [10 µM]: 131 ± 7% 
vs. control: 100%, P<0.01) while the co-treatment with ESI-09 [10 µM] reversed the 
CPT [10 µM] effect on NO production (CPT [10µM]: 131 ± 7% vs. CPT [10 µM] + ESI-








Figure 5. 10 Effect of Epac modulation in healthy and FFA-treated (500µM PA + 500µM OA) cells.  
Intracellular NO production as measured by DAF-2/DA fluorescence after24hr of treatment with A) CPT, 
2 μM and ESI-09, 1 μM; B) CPT 5μM and ESI-09, 5 μM; C) CPT, 10 µM and ESI-09, 10 µM. All values 









5.3.2 (b) ROS production  
 
Figure 5.11A represents ROS production as measured by DHR fluorescence intensity 
in RAECs treated with CPT [2µM] and ESI-09 [1µM]. The RAECs treatment with FFAs 
showed no significant differences in ROS production when compared to ethanol 
(vehicle). RAECs co-treated with CPT [2 µM] and ESI-09 [1 µM] had an increased 
percentage DHR fluorescence intensity compared to DMSO (vehicle) (CPT [2 µM] + 
ESI-09: [1 µM]: 99.3 ± 1.1%  vs. DMSO: 96 ± 2.5%, P<0.05).  
However, neither Epac activation nor inhibition had a significant effect on FFA-treated 
cells (Figure 5.11 A, B, C). 
 
Figure 5.11B represents ROS production as measured by DHR fluorescence intensity 
in RAECs treated with CPT [5µM] and ESI-09 [5µM]. Epac activation with CPT [5 µM] 
reduced the percentage DHR fluorescence intensity compared to control (CPT [5 µM]: 
87.67 ± 1.5% vs. control: 100%, P<0.001). Furthermore, co-treatment of CPT [5 µM] 
with ESI-09 [5 µM] reversed the effects of CPT [5 µM] on ROS production (CPT [5 µM] 
+ ESI-09 [5 µM]: 93.7 ± 1.6% vs. CPT [5 µM]: 87.67 ± 1.5%, P<0.05). The RAECs 
treatment with FFAs showed no significant differences in ROS production when 
compared to ethanol (vehicle).  
 
Figure 5.11C represents ROS production as measured by DHR fluorescence intensity 
in RAECs treated with CPT [10 µM] and ESI-09 [10 µM]. CPT [10 µM] reduced the 
percentage DHR fluorescence intensity compared to control (CPT [10 µM]: 85.67 ± 
2.6% vs. control: 100%, P<0.05). The RAECs treatment with FFAs showed no 
















Figure 5. 11 Effect of Epac modulation in healthy and FFA-treated (500µM PA + 500µM OA) 
cells. 
ROS production as measured by % DHR fluorescence after 24hr of treatment with: A) CPT, 2 μM and 
ESI-09, 1 μM; B) CPT, 5 μM and ESI-09, 5 μM; C) CPT, 10 µM and ESI-09, 10 µM. All values are 









5.3.2 (c) Cell viability  
 
Figure 5.12A represents cell viability as measured by PI fluorescence intensity in 
RAECs treated with CPT [2 µM] and ESI-09 [1 µM]. RAECs treated with FFA had a 
significant decrease in PI fluorescence intensity compared to non-treated cells (FFA: 
69.33 ± 1.455 vs. Ethanol: 101.7 ± 5.21%, P<0.001). Epac activation with CPT [2 µM] 
had no effect on cell viability. 
Furthermore, neither Epac activation nor inhibition had a significant effect on FFA-
treated cells (Figure 5.12 A, B, C). 
 
 
Figure 5.12B represents cell viability as measured by PI fluorescence intensity in  
RAECs treated with CPT [5 µM] and ESI-09 [5 µM]. Epac activation with CPT [5µM] 
had no effect cell viability. Epac inhibition with ESI-09 showed a significant reduction 
in PI fluorescence intensity compared to DMSO (vehicle control) (ESI-09: 88 ± 2.31% 
vs. DMSO: 106 ± 0.57%, P<0.05; ESI-09 + CPT: 85.33 ± 5.21% vs. DMSO: 106 ± 
0.57%, P<0.01).  
 
Figure 5.12C represents cell viability as measured by PI fluorescence intensity in 
RAECs treated with CPT [10 µM] and ESI-09 [10 µM]. Epac activation with CPT [10 
µM] had no effect cell viability. Epac inhibition with ESI-09 showed a significant 
reduction in PI fluorescence intensity compared to DMSO (vehicle control) (ESI-09: 
86.67 ± 2.0% vs. DMSO: 106 ± 0.57%, P<0.01; ESI-09 + CPT: 89.33 ± 3.48% vs. 




















Figure 5. 12 Effect of Epac modulation in healthy and FFA-treated (500µM PA + 500µM OA) 
cells.  
Cell viability as measured by PI fluorescence intensity after 24hr of treatment with: A) CPT, 2 μM and 
ESI-09, 1 μM; B) CPT, 5 μM and ESI-09, 5 μM; C) CPT, 10 µM and ESI-09, 10 µM. All values are 









5.4 Discussion  
 
In this study we aimed to establish an in vitro model of FFAs induced endothelial 
dysfunction and to explore the role of the cAMP-Epac pathway in this model. To 
achieve the aim, RAECs were treated with saturated fatty acids, palmitic acid (PA) and 
monounsaturated fatty acid, oleic acid (OA) to induce endothelial dysfunction. In 
addition, the cells were treated with an Epac agonist, CPT and Epac antagonist, ESI-
09, respectively. We have demonstrated that Epac activation with CPT improved NO 
production/availability and reduced intracellular ROS in normal RAECs. However, 
CPT did not reverse the detrimental effects on FFAs on RAECs.  
 
5.4.1. FFAs induced endothelial dysfunction  
 
In this study, we used palmitic acid (PA) with an aim to establish a model of endothelial 
dysfunction. Previous studies have shown that PA causes oxidative stress and 
inflammation, and leads to insulin resistance and impairment of endothelial function  
(Batumalaie et al., 2016; Chen et al., 2019; Lee et al., 2014; Li et al., 2018). 
Furthermore, the unsaturated FFAs OA and linoleic acid inhibit Ca2+ mediated- NO 
production/release in endothelial cells demonstrating their role in the development of 
endothelial dysfunction (Kuroda et al., 2001). In the present study, endothelial function 
was assessed by investigating NO production, ROS production and cell viability in 
RAECs treated with different concentrations of FFAs. PA (50 µM - 500 µM) did not 
induce endothelial dysfunction after 24hours treatment. It has been reported that 
elevation in OA leads to an increase in mitochondrial ROS and a reduced nitric oxide 
synthase (eNOS) activity in endothelial cells (Gremmels et al., 2015). Therefore, we 
combined PA and OA, and a reduction (not significant, n = 2 per group) in NO 
availability was noticed from the concentration of (PA 100µM + OA 100 µM to PA 
500µM + OA 500µM). However, with an increased n-value (n = 3), FFAs significantly 
reduced NO production at the concentration of (PA 500 µM + OA 500 µM)(Figure 
5.10). The ROS production and cell viability did not change, we therefore, decided to 






5.4.2 The role cAMP-Epac pathway on FFA-induced endothelial dysfunction 
 
The present study showed that the chronic exposure of RAECs to FFAs for 24 hours 
had a detrimental effect on NO production (Figure 5.10A, B and C). These findings 
suggest that elevated FFAs have an inhibitory role on NO production in endothelial 
cells. In a study by Steinberg and co-workers (Steinberg et al., 1997), it was shown 
that high concentrations of circulating FFAs were closely associated with an 
impairment of endothelium-dependent vasodilation while endothelium-independent 
vasodilation was not affected. These findings confirmed the detrimental role of FFAs 
on endothelial NO production. Furthermore, Van Vickle and colleagues (Van Vickle, 
2005) demonstrated a reduction in eNOS protein expression in porcine aortic 
endothelial when exposed to PA and stearic acid which may affect NO availability. 
Inhibitory effects of FFAs on eNOS activity and eNOS mRNA expression were also 
observed in RAECs was suggested to be through oxidative stress and inflammation 
(Yu et al., 2008). Surprisingly, there were no significant changes in ROS 
production/oxidative stress between FFA-treated and control RAECs (Figure 5.11A, 
B, C). Therefore, we can speculate that the FFAs were not effective enough to produce 
ROS in this pilot study. Furthermore, this model needs to be optimized and the use of 
bovine serum albumin bind the FFAs could be beneficial to carry FFAs into the cell.  
 
We found that Epac activation with different concentrations of a selective agonist CPT 
[2 µM, 5 µM and 10 µM] significantly increased DAF-2/DA fluorescence (indicative of 
NO production) in non-FFA-treated RAECs as compared to untreated cells. This effect 
was abolished by the Epac inhibitor, ESI-09 [1 µM and 10 µM] (Figure 5.10A, B and 
C). These findings suggest that Epac activation may increase eNOS activity, which 
resulted in an increased endothelium-dependent NO bioavailability. Other studies 
suggested that both Epac and PKA play a dual role in eNOS activity and NO release 
in human umbilical vein endothelial cells (HUVEC) (García-Morales et al., 2017, 
2014).  
 
Oxidative stress reduces NO release and lessens endothelium-dependent 
vasodilatation (Pierini and Bryan, 2015). Furthermore, increased intracellular ROS is 
closely associated with the development of endothelial dysfunction and 





increased NO production observed in RAECs treated with CPT was associated with a 
decrease in intracellular ROS (Figure 511B and C). This effect was abolished with co-
treatment with ESI-09 [5 µM] (Figure 5.11B). In other cell types, Epac has been 
demonstrated to be involved in mitochondrial ROS production (Remans et al., 2006, 
2004). For example, Epac2-Rap1 inhibition with (ESI-05) in cardiomyocytes lead to an 
increased mitochondrial ROS production and CaMKII activation (Yang et al., 2016). 
Another study demonstrated that pharmacological activation of Epac with CPT 
reduced ROS production and prevented apoptosis in tubular epithelium after exposure 
to I/R injury (Stokman et al., 2014). Furthermore, hyperglycaemia downregulates Rap1 
expression and activation which leads to renal tubular cells injury via a mechanism 
that includes an overproduction of mitochondrial ROS (Xiao et al., 2014). In another 
study, it was demonstrated that the Epac-Rap pathway is essential in preventing and 
restoring barrier function after an inflammatory cytokine-induced retinal vascular 
permeability (Ramos et al., 2018). Furthermore, Epac1 is considered to be a 
therapeutic target for vascular endothelial cells due to its ability to attenuate 
proinflammatory cytokines (Barker et al., 2017). Therefore, we have demonstrated in 
this study that a selective Epac activation with CPT in RAECs plays a significant role 
in the reduction of intracellular ROS and the increase in NO availability. 
 
Furthermore, FFA-induced ROS production is associated with an increased monocyte 
expression of CD11b and adhesion of monocyte to endothelial cells, this is a critical 
mechanism in early development of atherosclerosis (Mestas and Ley, 2008; Zhang et 
al., 2006). However, in our study, there were no significant changes in ROS production 
among the groups treated with FFAs and CPT.  
  
In conclusion, Epac activation with CPT improved NO production/availability and 
reduced intracellular ROS in normal RAECs. However, CPT did not reverse the 












Conclusions, limitations and future directions 
 
 
6.1 Summary of the findings  
 
The first aim of the study was to elucidate the role of Epac in myocardial ischaemia-
reperfusion injury of ex vivo hearts of a rat model of normal body weight. We 
demonstrated that Epac activation with CPT  pre- or post- ischaemia protects the 
hearts against I/R injury. Furthermore, pharmacological inhibition of the RISK pathway 
suggested partial involvement of ERK1/2 and PKB in CPT-induced cardioprotection 
(reduced infarct size). The cardioprotective mechanism is not clear, as the western 
blot data indicated that CPT/Epac stimulation could not activate ERK 1/2 or PKB (RISK 
pathway). However, co-treatment with CPT and ESI-09 reduced the phosphorylation 
of both ERK1/2 and PKB compared to untreated hearts. Therefore even though CPT’s 
effect on the RISK pathway was inconclusive, Epac inhibition with 5 µM ESI-09 
negatively affected the RISK pathway. Suggesting that Epac-mediated 
cardioprotection partially involves the RISK pathway.  
 
The second aim of the study was to elucidate the role of Epac in myocardial ischaemia-
reperfusion injury of ex vivo hearts of a rat model of high-calorie diet-induced obesity 
and insulin resistance. We have demonstrated that male Wister rats fed with a HC diet 
for 16 weeks developed characteristics of the metabolic syndrome including increased 
body weight gain compared to control diet animals, increased IP, elevated non-fasting 
glucose levels, increased HOMA-IR and glucose intolerance. However, the hearts 
from the HC group did not present with altered cardiac function at stabilization nor post 
I/R. The HC diet also had no detrimental effect on infarct size. In addition, co-treatment 
of CPT with the RISK pathway inhibitors suggested that CPT-mediated protection, 
based on post ischaemic recovery of cardiac function and infarct size was partially 
mediated by PKB and ERK1/2 in the CD group, but mainly by PKB in the HC group. 
However, we found no association between infarct size data and the protein 





pathway need to be investigated e.g. connexins (Schulz et al., 2007) or the survivor 
activating factor enhancement (SAFE) pathway (Lecour, 2009). Interestingly, CPT 
activated CaMKII in the HC group but not eNOS and therefore this needs further 
elucidation. Epac inhibitor (ESI-09, 5 µM) was detrimental to cardiac function and this 
was associated with decreased phosphorylated ERK1/2 in both diets, decreased 
phosphorylated GSK-3b in CD, increased phosphorylated AMPK in both diets, 
increased PARP cleavage in CD and increased autophagy (phosphorylated ULK-1) in 
CD.  
 
The third aim was to investigate the role of Epac signalling in ex vivo thoracic aortas 
of a rat model of high-calorie diet-induced obesity and insulin resistance. The HC diet 
did not exert detrimental effects on vascular function. CPT treated aortas had a 
significant improvement in ACh-induced vasorelaxation and Epac inhibition with ESI-
09 abolished the CPT vasorelaxant effect. Most importantly, CPT directly induced 
vasorelaxation in a dose-dependent manner in both HC and CD group and this effect 
was NOS-dependent, as it was abolished by L-NAME (NOS inhibitor). Interestingly, 
ESI-09 also increased the phosphorylation of the stress kinase AMPK. However, the 
western blot data did not give conclusive results which limited our conclusion on the 
mechanism through which Epac induce vasorelaxation.  
 
The fourth aim was to investigate the role of Epac signalling in palmitic and oleic acid-
induced endothelial dysfunction in RAECs. We have demonstrated that Epac 
activation with CPT improved NO production/availability and reduced intracellular 
ROS in normal RAECs. However, CPT did not reverse the detrimental effects on FFAs 





























The novelty of this study lies in the role of Epac in the cardiovascular system (heart 
and vascular tissues) of diet-induced obese rats and isolated cells treated with FFA, 
and the possible mechanisms involved. In this regard, acute Epac activation with CPT 
(2 µM) at reperfusion is cardioprotective against I/R injury in ex vivo isolated hearts of 
diet-induced obese rats. Furthermore, direct Epac stimulation improves the 
endothelium-dependent vascular reactivity of diet-induced obese rats. To our 
knowledge, this is the first such observation. Previous studies have pointed towards 
the effects of Epac prior to I/R injury. However, Epac’s cardioprotective mechanisms 
still need further elucidation and therefore we propose the following mechanisms. The 
first speculated mechanism is that Epac-mediated cardioprotection partially involves 
the RISK pathway (ERK1/2 and PKB) as demonstrated by the infarct size data. 
Furthermore, inhibition of Epac with ESI-09 reduced phosphorylated ERK1/2 in both 
diets suggesting an impaired ERK signalling. Unfortunately, the PKB Western blot 
data was inconclusive and need to be repeated in future work. The second speculated 
mechanism is the possibility that Epac’s vasorelaxant effects are mediated via NOS 
but this also needs verification since the western blots could not give a clear answer. 
Interestingly, Epac activation with CPT significantly increased NO production and 
reduced intracellular ROS in normal RAECs which further supports its role NOS 
activity. 
 
Collectively, enhancing Epac signalling post-I/R injury reduces myocardial infarction 
in ex vivo isolated hearts, partially via the RISK pathway. These effects were 
attenuated by both Epac and the RISK pathway inhibitors. Furthermore, enhanced 
Epac signalling improved the vasculature responsiveness in ex vivo rat aortas and the 
presence of Epac and NOS inhibitors abolished the effect. In addition, Epac activation 
increased NO production and reduced ROS generation in RAECs. Thus, suggests that 
Epac signalling may be considered as a potential future therapeutic target in the 






6.3 Limitations  
 
a) The HC diet was not associated with altered cardiac function at stabilization nor 
post I/R and could not induce endothelial dysfunction. This suggests that the 
diet programme used in the study was not sufficiently harmful to induce overt 
and measurable markers of injury in the hearts and aortas. Despite this, several 
significant observations were made showing that the diet was able to exert 
partial effects, which allowed to draw some meaningful conclusions.  
 
b) Having one control (DMSO vehicle control) was a limiting factor since one of 
our drugs was dissolved in distilled water. However, DMSO is regarded as a 
safe solvent in low concentrations (Sanmartín-Suárez et al., 2011). 
 
c) Epac-mediated cardioprotective effects could be either Epac1 or Epac2. We 
did not study the role of the individual isoforms in this study, only the overall 
effect of Epac.  
 
d) The Epac inhibitor ESI-09 was detrimental to hearts with the result that we could 
not measure the cardiac function.  
 
e) The n-value in western blot experiments was low due to the large number of 
treatment groups and limited number of wells per gel. Furthermore, the Western 
blot data was not (always?) conclusive. 
 
f) Another challenge was to establish a working model of FFA-induced endothelial 
dysfunction in the cultured endothelial cells. PA alone did not induce endothelial 
dysfunction and the combination of PA and OA was potentially excessively 
detrimental to the RAECs compared to the vehicle control. As a result, Epac 
activation with CPT could not reverse the adverse effects of FFAs. 
 
g) Another limitation of this study was the cell viability assay (PI). The assay 
includes a washing step before measuring the fluorescence. The dead 
endothelial cells detached from the plate surfaces and will be lost during the 





was significantly lower because the necrotic cells are washed away. Therefore, 
the results in figure 5.12A, B and C may not be a true representation of cell 
viability.  
 
6.4 Future studies and contribution  
 
Our findings indicate the complexity of Epac-mediated cardioprotection and therefore 
emphasizes the importance of future mechanistic studies of Epac in the cardiovascular 
system. Such studies should include: 
 
a) The use of an in vivo animal model in which overt obesity/insulin resistance/ 
cardiomyopathy/ endothelial dysfunction has been induced to evaluate the role 
of Epac.  
 
b) Mechanistic studies to further elucidate the role of Epac on the RISK pathway 
 
c) Alternative cardioprotective pathways such connexins and SAFE pathway 
should also be investigated. 
 
d) We also demonstrated the detrimental effects of the Epac inhibitor ESI-09, 
which was associated with an increased stress kinase AMPK in both hearts and 
aortas, and therefore this needs further investigation. 
 
e) We demonstrated that Epac activation with CPT reduced autophagy (ULK1 
Ser555) and co-treatment ESI-09 abolished the effect in CD group but not HC 
group. Therefore, this suggests that an association exists between Epac and 
autophagy and this needs further investigation.   
 
f) Optimization of the FFA-induced endothelial dysfunction model in cultured 
endothelial cells, and the protocol which should include binding of PA and OA 
to bovine serum albumin. This will be beneficial to the study since our 






g) Additional assays (like MTT and flow cytometry) to measure apoptosis and cell 
viability in RAECs could be beneficial to the study.  
 


































Supplementary data  
 
 
Table A. 1 Characteristics of the Diet Models: Weekely food consumption, 
water intake and non-fasting blood glucose. 
Parameter            CD            HC Unit  n  n 
      
Food consumption      
Week 1-10 g 17.62±0.36 40 23.41±0.52*** 40 
Week 11-16 g 17.76±0.44 20 21.10±0.92*** 20 
Week 1-16 g 18.00±0.54 20 22.30±1.27*** 20 
Water intake       
Week 1-10 mL 29.09±0.90 40 19.85±0.64*** 40 
Week 11-16 mL 29.76±0.88 20 20.25±0.76*** 20 
Week 1-16 mL 29.74±0.74 20 19.55±0.58*** 20 
 
Non-fasting blood glucose       
Week 16 mM 6.88±0.11 63 7.78±0.14*** 65 
        































Figure A. 1 Oral glucose tolerance test, fasting blood insulin concentrations and HOMA-IR of 
male Wistar rats at 16 weeks of feeding high calorie diet (HC).  
(A), Oral glucose tolerance test; (B), fasting blood insulin concentrations; (C), Homeostatic model for 































Figure A. 2 (A), Effect of CPT on Rap1 Activation and expression (B), nPC = non-Preconditioning; 
IPC = Ischaemic Preconditioning; BPC = Beta-Preconditioning; CPT-PC = Epac agonist 




















Figure A. 3 Ischaemic hearts post-treated with agonist (8-CPT-2’-O-Me-cAMP) CPT, novel 
selective Epac1 antagonist ESI-09 and untreated ischaemic hearts  
(A) Infarct sizes expressed as % (IFS/AR) Infarct size /Area at risk, (B) Total work 
expressed as % recovery. Data are means ± SEM. *p < 0.05 vs. control; ‡P < 0.05 vs. 






































Figure A. 4 Cardiac function of male Wistar rats of normal weight (Langendorff “balloon 
model”). 
The hearts were treated with an Epac inhibitor ESI-09 [5µM] and monitored for 50 minutes. (A), Rate 
Pressure Product (RPP = LVDP × heart rate); (B), Heart rate; (C), Left ventricular developed pressure 
(LVDP = systolic pressure − end-diastolic pressure); (D), Coronary flow; (E), Peak systolic pressure 
(PSP); (F), Temperature; (G), Heart wet weight/dry weight. Data are means ± SEM. *p < 0.05; 


























Figure A. 5 Western blot normalization. 
(A) Specific protein signal enhanced with a ECL (Chemi Hi Sensitivity), (B) Stain-free 
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